<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<!-- Created by: EDGAR Online, Inc. EDGAR Filing HTML Converter, Version: 4.63, http://www.edgar-online.com -->
<TITLE> GENVEC INC (Form: 10-K, Received: 03/09/2016 12:02:58) </TITLE>
<META NAME="TABLES" CONTENT="FIS_FORM **FIS_PART_I **FIS_BUSINESS **FIS_NAME_AND_TITLE **FIS_RISK_FACTORS **FIS_UNRESOLVED_STAFF_COMMENTS **FIS_PROPERTIES **FIS_LEGAL_PROCEEDINGS **FIS_MINE_SAFETY_DISCLOSURE **FIS_PART_II **FIS_MARKET **FIS_FINANCIAL_DATA **FIS_MANAGEMENTS_DISCUSSION **FIS_RESULTS_OF_OPERATIONS **FIS_LIQUIDITY_CAPITAL **FIS_MARKET_RISK **FIS_FINANCIAL_STATEMENTS **FIS_ACCOUNTING_CHANGES **FIS_CONTROL_AND_PROCEDURES **FIS_OTHER_INFORMATION **FIS_PART_III **FIS_DIRECTORS_AND_OFFICERS **FIS_NAME_AND_TITLE_2 **FIS_COMPENSATION **FIS_COMPENSATION_TABLE **FIS_OPTIONS_AGGREGATE **FIS_SECURITY_OWNERS **FIS_BENEFICIAL_OWNERS **FIS_OFFICER_TRANSACTIONS **FIS_ACCOUNTANT_FEES **FIS_PART_IV **FIS_EXHIBITS **FIS_EXHIBIT_INDEX **FIS_SIGNATURES **FIS_AUDITORS_OPINION **FIS_BALANCE_SHEET **FIS_INCOME_STATEMENT **FIS_STOCKHOLDERS_EQUITY **FIS_CASH_FLOW **FIS_NOTES_TO_FINANCIAL_STATEMENT FIS_EXHIBIT_10 FIS_EXHIBIT_10_2 FIS_EXHIBIT_10_3 FIS_EXHIBIT_10_4 FIS_EXHIBIT_23 **FIS_EXPERTS_CONSENT FIS_EXHIBIT_24 **FIS_POWER_OF_ATTORNEY FIS_EXHIBIT_31 **FIS_CERTIFICATION FIS_EXHIBIT_31_2 **FIS_CERTIFICATION_2 FIS_EXHIBIT_32 **FIS_CERTIFICATION_3 FIS_EXHIBIT_32_2 **FIS_CERTIFICATION_4 ">
<META NAME="DETECTED PAGES" CONTENT="133">
<STYLE TYPE="text/css">
<!--
	body          { background-color: white; color: black }
	.eolNewPage   { page-break-after: always; line-height: 0; height: 0; margin: 0; padding: 0 }
	.eolLeftAlign { text-align: left; margin-left: auto; margin-right: auto }
	.eolCenter    { text-align: center }
	a:link        { color: blue }
	a:active      { color: red }
	a:visited     { color: purple }
	
	@media print
	{
		@page           { margin: 0.25in }
		body            { font-size: 10pt }
		a               { text-decoration: none }
		thead           { display: table-header-group }
		tfoot           { display: table-footer-group }
		hr.eolPageBreak { display: none }
		.eolPrint50pt   { font-size: 5pt }
		.eolPrint55pt   { font-size: 5.5pt }
		.eolPrint60pt   { font-size: 6pt }
		.eolPrint65pt   { font-size: 6.5pt }
		.eolPrint70pt   { font-size: 7pt }
		.eolPrint75pt   { font-size: 7.5pt }
		.eolPrint80pt   { font-size: 8pt }
		.eolPrint85pt   { font-size: 8.5pt }
		.eolPrint90pt   { font-size: 9pt }
		.eolPrint95pt   { font-size: 9.5pt }
	}
-->
</STYLE>
</HEAD>
<BODY>
<A NAME="eolPage1"></A>
<A NAME="FIS_TOP_OF_DOCUMENT"></A>

<A NAME="T1600102_10K_HTM"></A>
<EFX_FORM>
<A NAME="FIS_FORM"></A>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 2PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="MARGIN: 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 12PT">
	UNITED
	STATES
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 12PT">
	SECURITIES
	AND EXCHANGE COMMISSION
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 12PT">
	WASHINGTON,
	D.C. 20549
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 12PT">
	FORM
	10-K
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(Mark One)
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: WINGDINGS; FONT-WEIGHT: NORMAL">
	x
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	ANNUAL REPORT PURSUANT
	TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	For the
	fiscal year ended December 31, 2015
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	or
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: WINGDINGS; FONT-WEIGHT: NORMAL">
	&uml;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	TRANSITION REPORT PURSUANT
	TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
</FONT>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	ACT OF 1934
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	For the
	transition period from _______________to_______________.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	COMMISSION FILE NUMBER: 0-24469
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 25%; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; BORDER-BOTTOM: BLACK 2PX SOLID; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; FONT-SIZE: 12PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 16PT">
	GENVEC,
	INC.
<FONT STYLE="FONT-WEIGHT: NORMAL">
</FONT>
</FONT>
</TD>
<TD STYLE="WIDTH: 25%; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(Exact name of Registrant as specified in its charter)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; FONT-SIZE: 10PT; WIDTH: 49%">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;&nbsp;DELAWARE
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; WIDTH: 3%; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; WIDTH: 48%">
	23-2705690
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(State or other jurisdiction of incorporation or organization)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(I.R.S. Employer Identification Number)
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; WIDTH: 60%">
<FONT STYLE="FONT-SIZE: 10PT">
	910 CLOPPER ROAD, SUITE 220N, GAITHERSBURG, MD
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; WIDTH: 40%">
	20878
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(Address of principal executive offices)
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(Zip code)
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Registrant&rsquo;s
	telephone number, including area code:
</FONT>
<U>
	240-632-0740
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Securities
	registered pursuant to section 12(b) of the Act:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; WIDTH: 49%">
<FONT STYLE="FONT-SIZE: 10PT">
	Title of Each Class
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; WIDTH: 49%">
	Name of Each Exchange on Which Registered
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Common Stock, Par Value $0.001 Per Share
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	The NASDAQ Stock Market
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Securities
	registered pursuant to section (12g) of the Act: Preferred Share Purchase Rights
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Indicate
	by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
	Yes
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
	No
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Indicate
	by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Securities Exchange
	Act of 1934.
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
	Yes
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
	No
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Indicate
	by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
	Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports),
	and (2) has been subject to such filing requirements for the past 90 days.
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
	Yes
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
	No
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Indicate
	by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive
	Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during the
	preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). &nbsp;Yes&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Indicate
	by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (&sect;229.405 of this chapter) is not
	contained herein, and will not be contained, to the best of Registrant's knowledge, in definitive proxy or information statements
	incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Indicate
	by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
	reporting company. See definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; and &ldquo;smaller
	reporting company&rdquo; in Rule 12b-2 of the Exchange Act. (Check one):
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	Large accelerated filer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
</TD>
<TD STYLE="WIDTH: 50%; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 30.6PT; TEXT-ALIGN: JUSTIFY">
	Accelerated filer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0">
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Non-accelerated
	filer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(Do not
	check if a smaller reporting company)
</FONT>
</P>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 30.6PT; TEXT-ALIGN: JUSTIFY">
	Smaller reporting company&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Indicate
	by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934.
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
	Yes
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
	No
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	As of June 30, 2015 the aggregate market
	value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing sale price of such
	stock as reported by the NASDAQ Capital Market on such date, was $33,636,377. For purposes of this calculation, shares of common
	stock held by directors, officers, and stockholders whose ownership exceeds 10 percent of the common stock outstanding at June
	30, 2015 were excluded. Exclusion of such shares held by any person should not be construed to indicate that the person possesses
	the power, direct or indirect, to direct or cause the direction of the management or policies of the Registrant, or that the person
	is controlled by or under common control with the Registrant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	As of
	March 3, 2016 there were
<FONT STYLE="COLOR: BLACK; BACKGROUND-COLOR: WHITE">
	17,264,359
</FONT>
	shares of the Registrant&rsquo;s
	common stock, par value $0.001 per share, outstanding.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 2PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage2"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	TABLE OF CONTENTS
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; WIDTH: 10%">
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	PART
<BR>
	NO.
</P>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; WIDTH: 10%">
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	ITEM
<BR>
	NO.
</P>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; WIDTH: 70%">
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	DESCRIPTION
</P>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; WIDTH: 10%">
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	PAGE&nbsp;NO.
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	I
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_001">
	1
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_001">
	Business
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	4
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_002">
	1A
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_002">
	Risk Factors
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	24
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_003">
	1B
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_003">
	Unresolved Staff Comments
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	42
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_004">
	2
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_004">
	Properties
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	42
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_005">
	3
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_005">
	Legal Proceedings
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	42
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_006">
	4
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_006">
	Mine Safety Disclosures
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	42
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_007">
	II
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_031">
	5
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_031">
	Market for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
</A>
</FONT>
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	43
</FONT>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_008">
	6
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_008">
	Selected Financial Data
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	43
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_009">
	7
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_009">
	Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations
</A>
</FONT>
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	44
</FONT>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_010">
	7A
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_010">
	Quantitative and Qualitative Disclosures About Market Risk
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	51
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_011">
	8
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_011">
	Financial Statements and Supplementary Data
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	51
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_012">
	9
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_012">
	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
</A>
</FONT>
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	51
</FONT>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_013">
	9A
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_013">
	Controls and Procedures
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	51
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_014">
	9B
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_014">
	Other Information
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	52
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_015">
	III
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_016">
	10
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_016">
	Directors, Executive Officers, and Corporate Governance
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	53
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_017">
	11
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_017">
	Executive Compensation
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	57
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_018">
	12
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_018">
	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	64
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_019">
	13
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_019">
	Certain Relationships and Related Transactions, and Director Independence
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	67
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_020">
	14
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_020">
	Principal Accountant Fees and Services
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	68
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_021">
	IV
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_022">
	15
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_022">
	Exhibits and Financial Statement Schedules
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	70
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<A HREF="#T1600102_10K_HTM_A_023">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Signatures
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	75
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_024">
	Financial Statements
</A>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	F1 &ndash; F22
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 2; OPTIONS: NEWSECTION; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage3"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	This Annual Report includes forward-looking
	statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
	Act of 1934, as amended.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Forward-looking statements also may
	be included in other statements that we make. All statements that are not descriptions of historical facts are forward-looking
	statements and are based on management&rsquo;s estimates, assumptions and projections that are subject to risks and uncertainties.
	These statements can generally be identified by the use of forward-looking words like &ldquo;believe,&rdquo; &ldquo;expect,&rdquo;
	&ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;anticipate,&rdquo; or similar terminology.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Although we believe that the expectations
	reflected in our forward-looking statements are reasonable as of the date we make them, actual results could differ materially
	from those currently anticipated due to a number of factors, including risks relating to:
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	decisions we make with respect to the future and strategic direction of our Company;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.2IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.1IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our product candidates being in the early stages of development;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.2IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.1IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our ability to find collaborators and, if we find collaborators, to mutually agree on terms for
	our collaborations;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.2IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.1IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our reliance on collaborators;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.2IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.1IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the timing, amount, and availability of revenues from our government-funded vaccine programs;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.2IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.1IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	uncertainties with, and unexpected results and related analyses relating to, preclinical development
	and clinical trials of our product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.2IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.1IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the timing and content of future U.S. Food and Drug Administration (FDA) regulatory actions related
	to us, our product candidates, or our collaborators;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.2IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.1IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our financial condition, the sufficiency of our existing cash, cash equivalents, marketable securities,
	and cash generated from operations, and our ability to lower our operating costs;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.2IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.1IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the scope and validity of patent protection for our product candidates and our ability to commercialize
	technology and products without infringing the patent rights of others; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.2IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.1IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&bull;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our listing of our common
	stock on the NASDAQ Stock Market.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	These are only some of the factors
	that may affect the forward-looking statements contained in this Annual Report. Further information on the factors and risks that
	could affect our business, financial condition and results of operations is set forth in Item 1A (Risk Factors) and Item 7 (Management&rsquo;s
	Discussion and Analysis of Financial Condition and Results of Operations) in this Annual Report and is contained in our other filings
	with the Securities and Exchange Commission (SEC). The filings are available on our website at
<I>
	www.genvec.com
</I>
	or at the
	SEC&rsquo;s website,
<FONT STYLE="COLOR: BLACK">
<I>
	www.sec.gov
</I>
</FONT>
	.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	These forward-looking statements speak only as of the date
	of this Annual Report and we assume no duty to update our forward-looking statements, except as required by law. The forward-looking
	statements in this Annual Report are intended to be subject to protection afforded by the safe harbor for forward-looking statements
	contained in the Private Securities Litigation Reform Act of 1995.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 3; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage4"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_PART_I>
<A NAME="FIS_PART_I"></A>
<EFX_BUSINESS>
<A NAME="FIS_BUSINESS"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="T1600102_10K_HTM_A_001">
</A>
	ITEM 1. BUSINESS
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	OVERVIEW
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL; COLOR: BLACK">
	GenVec,
	Inc. (GenVec, we, our, or the Company) is a clinical-stage biopharmaceutical company with an entrepreneurial focus on leveraging
	its proprietary AdenoVerse&trade; gene delivery platform to develop a pipeline of cutting-edge therapeutics and vaccines. The Company
	is a pioneer in the design, testing and manufacture of adenoviral-based product candidates that can deliver on the promise of gene-based
	medicine. GenVec&rsquo;s lead product candidate, CGF166, is licensed to Novartis Institutes for BioMedical Research, Inc. (together
	with Novartis AG and its subsidiary corporations, including Novartis Pharma AG, Novartis) and is currently in a Phase 1/2 clinical
	study for the treatment of hearing loss and balance disorders. In addition to our internal and partnered pipeline, we also focus
	on opportunities to license our proprietary technology platform, including vectors and production cell lines, to potential collaborators
	in the biopharmaceutical industry for the development and manufacture of therapeutics and vaccines.
</FONT>
<FONT STYLE="FONT-WEIGHT: NORMAL; BACKGROUND-COLOR: YELLOW">
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	A key
	component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with
	prominent companies and organizations such as Novartis, Merial Limited, and the U.S. government, as well as promising young companies
	such as TheraBiologics, to support a portfolio of programs that addresses the prevention and treatment of a number of significant
	human and animal health concerns. GenVec&rsquo;s combination of internal and partnered development programs address therapeutic
	areas such as hearing loss and balance disorders and oncology, as well as vaccines against infectious diseases, including respiratory
	syncytial virus (RSV), herpes simplex virus (HSV), and malaria. In the area of animal health we are developing vaccines against
	foot-and-mouth disease (FMD).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Our AdenoVerse
	gene delivery technology has the important advantage of localizing protein delivery in the body. This is accomplished by using
	our adenovector platform to locally deliver genes to cells, which then direct production of the desired protein. This approach
	reduces side effects typically associated with systemic delivery of proteins. For therapeutics, the goal is for the protein produced
	to have a meaningful effect in treating the cause, manifestation, or progression of the disease. For vaccines, the goal is to induce
	an immune response against a target protein or antigen. This is accomplished by using an adenovector to deliver a gene that causes
	production of an antigen, which then stimulates the desired immune reaction by the body.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Our research
	and development activities yield product candidates that utilize our technology platform and represent potential commercial opportunities.
	For example, preclinical research in hearing loss and balance disorders indicates that the delivery of the atonal gene using GenVec&rsquo;s
	adenovector technology may have the potential to restore hearing and balance function. We are currently working with Novartis on
	the development of novel treatments for hearing loss and balance disorders that emerged from these research and development efforts.
	There are currently no effective therapeutic treatments available for patients who have lost all balance function, and hearing
	loss remains a major unmet medical problem.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We have
	multiple vaccine candidates that leverage our core adenovector technology including our vaccine candidates for the prevention or
	treatment of RSV and HSV. We also have a program to develop a vaccine for malaria, a program in which we are currently working
	in collaboration with the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the National Institute of Allergy and Infectious
	Diseases, National Institutes of Health. In the field of animal health, we are working with Merial Limited to commercialize vaccines
	for the prevention of a major animal health problem, FMD. Development efforts for this program were supported by the U.S. Department
	of Homeland Security (DHS) and performed in collaboration with the U.S. Department of Agriculture (USDA).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	As a
	biopharmaceutical company, our business and our ability to execute our strategy to achieve our corporate goals are subject to numerous
	risks and uncertainties. Material risks and uncertainties relating to our business and our industry are described in Item 1A of
	Part I of this Annual Report on Form 10-K. The description of our business in this Annual Report on Form 10-K should be read in
	conjunction with the information in Item 1A and the Financial Statements found in Item 8 of Part II of this Annual Report on Form
	10-K, which includes additional financial information, including information about our total assets, revenue, and measures of profit
	and loss.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 4; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage5"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	OUR STRATEGY
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Our primary
	objective is to leverage our proprietary technology through partnerships to develop and commercialize products that address significant
	unmet medical needs. We plan to achieve this objective through the following strategies:
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Working with Novartis to facilitate
	the development of first-in-class products for the treatment of hearing and balance disorders.
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;&nbsp;&nbsp;We
	believe that a significant commercial opportunity exists for hearing loss and balance disorders. We are committed to realizing
	the value of CGF166 by facilitating and supporting Novartis&rsquo; development program.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Entering into new collaborations for
	the development of product candidates utilizing our technology.
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;&nbsp;&nbsp; We are engaged
	in seeking strategic collaborations, partnerships and licensing arrangements to further develop and potentially commercialize therapeutic
	and vaccine product candidates that utilize our technology. We continue to seek corporate partnerships in the following programs
	and areas:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Vaccine against RSV, which is the most common viral cause of
	lower respiratory infections in infants and young children.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Vaccine against HSV, which is the virus responsible for most
	cases of genital herpes.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Other therapeutic and prophylactic applications of our human
	and non-human adenoviral vectors together with the related platform technology and packaging cell lines.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Exploring new applications of our
	technology to address the treatment and prevention of major unmet medical needs.
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;&nbsp;&nbsp;We
	intend to continue to enhance our core technologies and product pipeline through internal research as well as external collaborations,
	licensing arrangements and possible acquisitions. In the past we have received peer-reviewed external funding from the U.S. government
	and from nonprofit foundations to improve our technology platform for vaccine and gene delivery applications. We intend to further
	strengthen our technologies relating to vector performance, process development, formulation, and manufacturing through our existing
	and future relationships. We intend to explore the use of our AdenoVerse technology in the following areas:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Regenerative medicine;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Vaccines;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Therapeutic gene delivery;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Immunotherapy (including cellular immunotherapy);
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Nucleic acid therapeutics;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Gene editing;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Oncolytic viruses; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Cell therapy
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Minimizing our cash burn rate and
	reducing the need for additional equity financing.
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;&nbsp;&nbsp;We intend to further develop
	our product candidates and technology through strategic collaborations that provide external resources for development, as well
	as through selective, prudent deployment of our internal resources. We believe this strategy will allow us to advance our programs
	without the use of substantial additional capital and will insulate us from fluctuating capital raising conditions.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	HEARING AND BALANCE PROGRAM
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Overview.
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;&nbsp;&nbsp;In
	collaboration with Novartis, our hearing and balance disorders program is focused on the restoration of hearing and balance function
	through the regeneration of critical cells of the inner ear. Our lead product candidate, CGF166, emerged from research and development
	performed as part of the collaboration. In October&nbsp;2014, the first patient was treated in a Phase 1/2 proof-of-concept trial
	of CGF166 in patients with severe to profound hearing loss. In January 2016, we were notified by Novartis that enrollment was paused
	in the clinical study for CGF166. This pause was based on a review of data by the trial&rsquo;s Data Safety Monitoring Board in
	accordance with criteria in the trial protocol. Novartis will continue to collect safety and efficacy data on the nine patients
	currently enrolled in the study before determining whether to proceed with incremental patients.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 5; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage6"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Background.
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;&nbsp;&nbsp;Sensorineural
	hearing loss and vestibular dysfunction may result from destruction of inner ear sensory hair cells. Humans are born with approximately
	30,000 sensory hair cells, which are located in the cochlea, vestibular canals, utricle, and saccule of the ear. Sensory
	hair cells, located in the cochlea are critical for auditory function, while those located in the vestibular canals, utricle,
	and saccule provide the basis for vestibular function.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Sensory
	hair cells can be damaged or destroyed by pharmacological agents, infections, loud noises, or simply aging. Because these cells
	do not naturally regenerate, any damage to or destruction of them is permanent.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Patients
	whose sensory hair cells have been damaged or destroyed may experience hearing loss. According to the National Institute on Deafness
	and Other Communication Disorders (NIDCD), among adults aged 70 and older with hearing loss who could benefit from hearing aids,
	fewer than one in three (30%) has ever used them. Even fewer adults aged 20 to 69 (approximately 15%) who could benefit from wearing
	hearing aids have ever used them. Also according to the NIDCD, as of December 2012, approximately 324,200 patients worldwide have
	received cochlear implants &ndash; in the United States, roughly 58,000 devices have been implanted in adults and 38,000 in children.
	Although cochlear implants improve hearing, they require invasive surgery, do not discriminate pitch, and require ongoing maintenance
	and patient training.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Patients
	whose sensory hair cells have been damaged or destroyed may also experience more severe vestibular dysfunction, which may result
	in debilitating vertigo and nausea. There is currently no known therapy other than rehabilitation to facilitate the acquisition
	of environmental signals to compensate for vestibular dysfunction.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We believe
	that because there are no therapeutic options available to regenerate sensory hair cells to restore auditory or balance function,
	there is a significant and unmet medical need in the area of sensorineural hearing loss and vestibular dysfunction.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	GenVec&rsquo;s Solution.
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;&nbsp;&nbsp;During
	embryonic development, an atonal gene (Atoh1) induces the generation of sensory cells in the inner ear required for hearing and
	balance. In multiple animal models, we have demonstrated formation of new inner ear sensory hair cells and the restoration of hearing
	and balance function using our AdenoVerse technology to deliver the Atoh1 gene to the inner ear.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The lead
	product emerging from GenVec&rsquo;s hearing program is an advanced adenoviral vector engineered to deliver the human atonal gene
	under the control of a tissue specific promoter. Novartis has designated this product candidate as CGF166.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Collaboration with Novartis.
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;&nbsp;&nbsp;In
	January&nbsp;2010, we entered into a collaboration with Novartis to discover and develop novel treatments for hearing loss and
	balance disorders. Under the terms of the agreement, we licensed the world-wide rights to our preclinical hearing loss and balance
	disorders program to Novartis. We received a $5.0 million upfront payment and Novartis purchased $2.0 million of our common stock.
	If certain clinical, regulatory, and sales milestones are met, we are eligible, from the inception of the agreement, to receive
	up to an additional $206.6 million in milestone payments. From September 2010 through October 2014, we achieved four milestones
	resulting in aggregate payments from Novartis of $5.6 million. As of February&nbsp;29, 2016, milestones remaining available under
	the agreement include $21.0 million of additional clinical milestones, $45.0 million in regulatory milestones, and $135.0 million
	of sales-based milestones. Additionally, we are also entitled to royalties on future sales.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In September&nbsp;2010,
	we announced that we had achieved the first of the four milestones that have been achieved in the collaboration with Novartis.
	The first $300,000 milestone was triggered by the successful completion of certain preclinical development activities. In December&nbsp;2011,
	we announced that we had achieved the second milestone in the collaboration with Novartis. The second $300,000 milestone was triggered
	by the successful completion of certain preclinical development activities. In February&nbsp;2014, we announced that we had achieved
	the third milestone in the collaboration with Novartis. The $2.0 million milestone was triggered by the non-rejection by the FDA
	of the IND filed by Novartis for CGF166. In October&nbsp;2014, we announced that we had achieved the fourth milestone in the collaboration
	with Novartis. The $3.0 million milestone was triggered by the first patient treated in a clinical trial with CGF166.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 6; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage7"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In August&nbsp;2010,
	we entered into an additional agreement with Novartis for the supply of services relating to development materials in connection
	with our collaboration in hearing loss and balance disorders. Under this additional agreement, valued at $14.9 million, we agreed
	to manufacture clinical trial material for up to two lead product candidates. We recognized approximately $0.2 million and $0.3
	million in 2015 and 2014, respectively, for services performed under this agreement. As of December 31, 2015, we have recognized
	a total of $14.7 million under this agreement.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In December&nbsp;2013,
	the National Institutes of Health&rsquo;s Recombinant DNA Advisory Committee (RAC) unanimously approved the protocol for initiation
	of a Phase 1/2 study of CGF166. The protocol, &ldquo;A Three-part, Multicenter, Open Label, Single Dose Study to Assess the Safety,
	Tolerability, and Efficacy of Intralabyrinthine (IL) CGF166 in Patients with Severe Hearing Loss,&rdquo; was the subject of an
	in-depth review and public discussion at the RAC meeting. Novartis filed an investigational new drug application (IND) for CGF166
	in January&nbsp;2014, in February&nbsp;2014 the IND was deemed effective, and in October&nbsp;2014 the first patient was treated.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	CELL THERAPY PROGRAM
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In March
	2015, we announced a collaboration with TheraBiologics, Inc. to develop cancer therapeutics by leveraging GenVec&rsquo;s AdenoVerse
	gene delivery platform and TheraBiologics&rsquo; proprietary neural stem cell technology. We will contribute technology, know-how,
	vector construction, and technical and regulatory support to the program. TheraBiologics will be responsible for all other development
	costs. Depending on the manner of commercialization, we will be entitled to profit sharing and/or royalty and milestone payments
	for the products being developed under the collaboration.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	VACCINE PROGRAMS
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We have
	developed vaccine candidates using our AdenoVerse technology. We believe that our AdenoVerse vectors have superior properties to
	deliver antigens and stimulate an effective innate and adaptive immune response against pathogens of interest. Our vaccine candidates
	include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Many
	vectors used in developing vaccines are susceptible to pre-existing immunity that neutralizes and has the effect of preventing
	the vaccine from generating the desired immunological response; this is referred to as vector-specific immunity. Our most promising
	vectors for vaccine applications are derived from non-human primate adenovirus types, which we believe can circumvent neutralizing
	antibodies, or vector-specific immunity, in order to generate the desired immunologic response of the vaccine.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Respiratory Syncytial Virus (RSV).
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;&nbsp;&nbsp;We
	are seeking a partner to continue the development of our GV2311 vaccine against RSV, the single most important viral cause of lower
	respiratory infections in infants and young children.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	According
	to information published by the Centers for Disease Control and Prevention (CDC) in 2014, each year, on average, in the United
	States, RSV leads to 57,527 hospitalizations among children younger than 5 years old; 100,000 to 126,000 hospitalizations among
	children younger than 1 year old; 2.1 million outpatient visits among children younger than 5 years old; and 177,000 hospitalizations
	and 14,000 deaths among adults older than 65 years.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In September&nbsp;2012,
	data were presented on GenVec&rsquo;s RSV vaccine program at the International Respiratory Syncytial Virus Symposium, which took
	place in Santa Fe, New Mexico. Data presented at the conference demonstrated that GenVec&rsquo;s universal RSV vaccine candidate,
	GV2311, is highly immunogenic and produces durable and broad protection from a single intramuscular administration. Protection
	in cotton rat and mouse models was characterized by functional RSV neutralizing antibodies, and no disease potentiation was observed.
	GenVec&rsquo;s RSV vaccine candidate utilizes a proprietary adenovirus that is capable of generating a broad immune response while
	avoiding the problems of vector specific immunity that has hampered other vectored vaccines.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In March&nbsp;2012,
	data were presented on GenVec&rsquo;s RSV vaccine program at the &ldquo;Keystone Symposium on Viral Immunity and Host Gene Influence&rdquo;,
	which took place in Keystone, Colorado. Data presented at the conference demonstrated encouraging preclinical proof-of-principle
	findings generated in non-human primates. Specifically, the data showed GenVec&rsquo;s vaccine technology induced neutralizing
	antibody, and significant T-cell responses with a single administration. The immune responses were consistent with protective responses
	without disease potentiation and multiple administrations increased the neutralizing antibody responses.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 7; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage8"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In November&nbsp;2014,
	data exploring the immune responses generated by GV2311 were presented at the 9th International Respiratory Syncytial Virus (RSV)
	Symposium held in South Africa. In the experiments described in the presentation, RSV immunized mice had no detectable virus following
	low dose challenge, while breakthrough RSV replication in both lungs and noses was rapidly controlled upon high dose challenge.
	GV2311 immunization fully protected the lungs at both challenge doses with partial protection in noses. The studies also confirmed
	the major protective mechanism is through induction of antibodies against RSV, although antigen specific T cells contribute to
	viral clearance in the absence of antibody. GV2311 was previously shown to induce protective immunity to RSV in a dose-dependent
	manner in established animal models.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We are
	not engaging in significant development for RSV while we seek to partner this program.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Herpes Simplex Virus (HSV).
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;&nbsp;&nbsp;We
	are seeking a partner to continue the development of our GV2207 vaccines for the treatment of HSV including HSV type 2 (HSV-2),
	the virus responsible for most cases of genital herpes. According to the World Health Organization (WHO), an estimated 417 million
	people aged 14-49 (11%) worldwide have HSV-2 infections. According to the CDC, genital herpes is common in the United States &ndash;
	one of every six people aged 14-49 is infected. All HSV-2 infections are permanent and result in periodic virus shedding. The CDC
	notes that herpes infections are most contagious when symptoms are present, but can still be transmitted to others in the absence
	of symptoms. Of added concern, infection with HSV-2 increases the risk of acquiring and transmitting HIV infection. There is no
	approved vaccine for HSV-2 in the United States. Although antiviral regimens have become a standard of care, their inconvenience,
	cumulative cost and potential for drug resistance further underscore the need for safe, new approaches to reducing HSV-2 lesions,
	virus shedding, and transmission. Estimated costs of treating HSV in the United States alone are close to $1 billion, primarily
	for drugs and outpatient medical care.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In December&nbsp;2012,
	data were presented on GenVec&rsquo;s HSV vaccine program at the Keystone Symposia meeting on Immunological Mechanisms of Vaccination,
	which took place in Ottawa, Ontario. Data presented at the conference demonstrated that a single administration of our genetic
	vaccine was effective against HSV-2 in two industry-accepted HSV disease models. Specifically, immunization was shown to reduce
	viral shedding, and the recurrence and severity of lesions.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We are
	not engaging in significant development for HSV while we seek to partner this program.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Malaria.
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;&nbsp;&nbsp;We
	have worked with collaborators in recent years, including with the National Institute of Allergy and Infectious Diseases (NIAID),
	generating vaccine candidates for the prevention of malaria. According to the Malaria Fact Sheet available through the WHO, about
	3.2 billion people &ndash; almost half of the world&rsquo;s population &ndash; are at risk for malaria. Young children, pregnant
	women and non-immune travelers from malaria-free areas are particularly vulnerable to the disease. Despite advances in prevention
	and treatment, per WHO estimates, released in December 2015, there were 214 million cases of malaria in 2015 and 438,000 deaths.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In April&nbsp;2010,
	encouraging clinical and preclinical malaria vaccine data were presented at the Keystone Symposium &mdash; Malaria: New Approaches
	to Understanding Host-Parasite Interactions. Safety, tolerability, immunogenicity, and efficacy data from the Phase 1/2a malaria
	trial using GenVec technology were presented. Data indicate malaria vaccines given to malaria-na&iuml;ve adults were found to be
	safe and well-tolerated with minimal local or systemic reactions and no serious vaccine-related adverse reactions. Sterile protection,
	a complete absence of parasites in the blood, was seen in 4 out of 15 volunteers that had been inoculated with the vaccine and
	subsequently challenged with the malaria parasite.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In November&nbsp;2012,
	data were presented on GenVec&rsquo;s malaria vaccine program at the American Society of Tropical Medicine and Hygiene (ASTMH)
	61st Annual Meeting, which took take place in Atlanta, Georgia. Data presented at the conference highlighted GenVec&rsquo;s success
	in identifying novel antigens for use in its malarial vaccine development program. Using a proprietary screening technology, GenVec
	identified new antigens that are as protective as the gold standard, circumsporozoite protein, or CSP, in an industry-accepted
	mouse model of malaria. Recent data suggest that new antigens are needed and that CSP, used in vaccines being developed by others,
	may not be sufficient to generate a protective response in an adequate percentage of people. Data presented at the conference also
	highlighted GenVec&rsquo;s proprietary non-human primate adenoviral vectors that are capable of generating broad immune responses
	while avoiding the problems of vector-specific immunity which has limited the development of other adenoviruses as vectors for
	vaccines.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 8; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage9"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In March&nbsp;2012,
	we received a grant from the National Institute of Allergy and Infectious Diseases (NIAID) to support the Company&rsquo;s malaria
	vaccine program. This grant, valued at approximately $600,000, is being used to identify novel highly protective antigens for malaria
	vaccine development. Revenue recognized under this grant amounted to $0.1 million in both 2015 and 2014.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In September&nbsp;2012,
	we signed an agreement worth approximately $3.5 million with the U.S. Naval Medical Logistics Command to further support malaria
	vaccine development efforts at the NMRC. Under the terms of the agreement, GenVec was responsible for producing clinical supplies
	of its malaria vaccine, which utilizes its novel, proprietary technology. NMRC used this clinical material to assess the safety
	and efficacy of these next-generation vectored vaccines using the clinical challenge model developed by NMRC and the Walter Reed
	Army Institute of Research (WRAIR) malaria vaccine programs, which now are unified as the U.S. Military Malaria Vaccine Program
	(USMMVP). Under the agreement, GenVec retained the right to commercialize this novel technology. GenVec recognized $1.4 million
	in revenue under this contract in 2013. In July&nbsp;2013, we entered into a modification with the NMRC to terminate contractual
	obligations under this agreement. Through this arrangement, we demonstrated our ability to produce clinical supplies of a multi-antigen
	vaccine candidate for use in early stage clinical studies.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In April
	2015, we announced a research collaboration with the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the National Institute
	of Allergy and Infectious Diseases, National Institutes of Health. The collaboration will utilize GenVec's proprietary gorilla
	adenovirus vectors to deliver a number of novel antigens discovered at the LMIV in order to create and test a variety of malaria
	vaccine candidates. GenVec will construct vaccine candidates at its laboratories and provide them to LMIV's Vaccine Development
	Unit for preclinical testing. The purpose of this collaboration is to devise vaccines that block the transmission of the deadliest
	malaria-causing parasite, Plasmodium falciparum, by triggering the production of antibodies that are taken up by a mosquito when
	it bites a vaccinated individual. This approach, which is different from traditional vaccine approaches, is designed to launch
	an attack on the parasite while it is in its mosquito carrier and could potentially help stop the spread of the disease to subsequent
	bite victims.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	ANIMAL HEALTH PRODUCT DEVELOPMENT PROGRAM
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We are
	exploring applications of our technology to treat and prevent diseases that affect livestock and other animals. With our collaborators,
	we are developing vaccine and anti-viral candidates for the prevention and containment of foot-and-mouth disease (FMD) outbreaks.
	FMD is a highly contagious viral disease affecting cows and other animals with cloven hooves. Our novel FMD vaccine approach utilizes
	our proprietary adenovector technology and is manufactured on a proprietary GenVec cell line that is capable of producing antigens
	without the use of highly contagious FMD virus. Because the vaccine is produced without using killed virus materials, it can be
	produced cost effectively in the U.S. and around the world. While the United States has not had an outbreak of FMD since 1929,
	the highly contagious nature of FMD, and the grave economic consequences of an outbreak, has made developing a vaccine and anti-viral
	candidates a high priority of the U.S. government. Initial testing of a vaccine against FMD showed that inoculated cattle challenged
	with the virus causing FMD did not develop symptoms.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In June&nbsp;2012,
	the U.S. Department of Agriculture&rsquo;s Animal and Plant Health Inspection Service (APHIS) issued a conditional license for
	our FMD vaccine for use in cattle. APHIS issued the conditional license to Antelope Valley Bios, Inc., who manufactured the vaccine
	under a contract with GenVec. This is the first FMD vaccine licensed by the USDA Center for Veterinary Biologics. Under the conditional
	license, the product may be distributed as authorized by Federal emergency management officials within USDA, should the need for
	the product arise. APHIS issues conditional licenses in the event of an emergency situation, limited market or other special circumstance.
	In this case, the special circumstance was the need for an FMD vaccine that was capable of being manufactured in the U.S. that
	allowed for the differentiation between infected and vaccinated animals. The vaccine is available to agriculture officials in the
	event of an FMD emergency situation.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In December&nbsp;2010,
	we entered into a collaboration with Merial Limited to develop and commercialize our proprietary vaccine technology for use against
	FMD. Merial Limited is the leading FMD vaccine producer in the world, with leading positions in all key markets. Under the agreement,
	Merial Limited will be responsible for all costs related to the development and commercialization of FMD vaccines developed through
	the collaboration. If the program results in a commercial product, we will receive development milestones and royalties
	on sales. In May&nbsp;2011, we entered into a second agreement with Merial Limited. Under the agreement, Merial Limited has the
	right to evaluate GenVec technology for applications in other areas of animal health.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 9; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage10"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In February&nbsp;2010,
	we signed a contract with the U.S. Department of Homeland Security (DHS) to continue the development of adenovector-based vaccines
	against FMD. This agreement covered the use of our adenovector technology to develop additional FMD-serotype candidate vaccines
	and explore methods to increase the potency and simplify the production process of adenovector-based FMD vaccines. This agreement
	was completed in February&nbsp;2015.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	TECHNOLOGY PLATFORM
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	GenVec
	is a pioneer in the gene therapy field, with experience progressing therapeutics and vaccines from the research stage to the product
	candidate stage and into clinical development. Our AdenoVerse technology can be used to deliver genes precisely to target cells
	in order to elicit the desired biological response, as exemplified by the delivery of CGF166 to the inner ear in our hearing loss
	and balance disorder program. In addition, our technology can be used to deliver one or more antigens to elicit immune responses
	to the target disease. We believe we are also a leader in adenovector design and testing, with experience in scale-up and manufacture.
	Our technology platform includes a broad array of proprietary adenovirus vectors for gene delivery for therapeutics and vaccines,
	as well as proven scale-up and production methodologies and proprietary manufacturing cell lines.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	GenVec&rsquo;s
	highly potent AdenoVerse vectors include human and non-human low-seroprevalence serotypes, such as our monkey and gorilla adenovectors,
	and are designed for superior performance by providing what we believe is the ability to avoid the pre-existing immunity issues
	that can hamper gene delivery using some other adenovector constructs.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	When
	compared to standard vaccine approaches our gorilla adenovectors provide what we believe are other distinct advantages for molecular
	vaccines, including the induction of both durable high-level antibody and T cell responses. Our gorilla adenovectors have been
	shown to induce increased antigen-specific immune responses on repeat administration. We believe that our technology platform can
	be used to develop product candidates that address a variety of disease challenges.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Our manufacturing
	cell lines have been used to produce therapeutics and vaccines in accordance with the FDA&rsquo;s current Good Manufacturing Practices
	(cGMP) with high yields for numerous clinical studies. Our track record includes the successful design and manufacture of novel
	adenovectors containing single or multiple genes for the production of therapeutic proteins or antigens that we have been able
	to scale up for clinical manufacturing. Therapeutics and vaccines designed by GenVec and produced using our high-yield cell lines
	have been tested in over 3,000 study subjects in clinical trials conducted in the U.S., Europe, Africa and the Middle East.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Adenovirus Vector Technology.
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;&nbsp;&nbsp;We
	utilize a collection of differentiated, proprietary technologies to create product candidates with what we believe are superior
	attributes. Our product candidates are developed with our proprietary adenovector technology, which uses modified adenoviruses
	to deliver genes to cells. Adenoviruses are naturally occurring viruses that reproduce in certain tissues and can cause ailments
	such as mild respiratory infections. We design our vectors so they cannot replicate or cause diseases. This limits toxicity, including
	unwanted effects on target cells and the surrounding tissues. Our product candidates consist of adenovectors that contain one or
	more inserted gene(s). We have multiple proprietary adenovectors to suit different applications in therapeutic and vaccine products.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	When
	administered to tissues, our vectors enter target cells, leading the cells to produce the protein encoded by the inserted gene.
	The vector is then naturally eliminated from cells and tissues.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We believe
	adenovectors are desirable gene delivery vehicles because they efficiently deliver genes, can be readily modified, and are generally
	well tolerated.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We believe
	our differentiated gene delivery technology enables us to:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Improve the efficiency of discovering new therapies and vaccines;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 10; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage11"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Rapidly construct and screen product candidates;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Identify novel antigens in a quick, and cost-effective manner;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Minimize interference from antibodies to adenoviruses;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Put genes or antigens rapidly into vectors to evaluate function
	and usefulness in therapy;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Deliver our product candidates to specific organs or cell types
	to avoid systemic exposure;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Achieve efficient delivery of gene to, and stimulate protein
	expressions in, target cells;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Control the amount and duration of therapeutic protein production
	to allow flexibility in treating different diseases; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Scale our manufacturing process for commercial production.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We believe
	our adenovector technology is a preferred approach for therapeutic and vaccine products:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	For local delivery and expression of therapeutic genes;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	For cell type specific delivery and expression;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	For rational vaccine design;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	For high level antibody and cellular based vaccine responses;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	For vaccine production without exposure to contagious pathogens;
	and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	For the manufacture of new products that cannot be produced using
	standard technologies.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Local Delivery and Expression of Genes.
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;&nbsp;&nbsp;To
	achieve local production of proteins, we can administer our product candidates directly to the site of disease using standard medical
	devices such as syringes. Direct administration of our product candidates into diseased tissue allows us to increase effectiveness
	by achieving high concentrations of the protein at disease sites while improving safety by avoiding systemic exposure throughout
	the body.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Control of Gene Expression.
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;&nbsp;&nbsp;Our
	technology also allows us to modify the location, duration, and rate of therapeutic gene expression. We alter gene expression
	by inserting a sequence of DNA, called a promoter, into our vectors adjacent to the target gene. We tailor our technology to the
	therapeutic or vaccine product need. For some diseases, long-term expression of the therapeutic gene is required to achieve a
	clinical benefit while high level antigen expression from our molecular vaccines is preferred. Moreover, our adenovector
	technology allows multiple antigens or therapeutic genes to be efficiently expressed for therapeutic benefit. We have also shown
	that local production of therapeutic proteins by regulating expression via insertion of a specific proprietary promoter that either
	limits expression to specific cell types or can regulate expression after specific treatments can be preferred.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	New Adenovector Platforms.
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;&nbsp;&nbsp;We
	have generated vectors based on different types of adenovirus. These vectors have the potential to avoid neutralizing antibodies,
	and for vaccine applications can improve vaccine potency and generate desired immune responses to combat against an infectious
	agent or illicit desired therapeutic responses to treat an underlying infection.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Emerging applications.&nbsp;
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The
	AdenoVerse platform offers numerous advantages that could be beneficial for a variety of emerging therapeutic approaches such as
	gene editing, cell therapy, immunotherapy, regenerative medicine, and others. The flexibility of the AdenoVerse platform allows
	for the customized design of vectors capable of addressing the unique needs and limitations of each of these different applications.
	GenVec&rsquo;s expertise in vector construction can be leveraged to construct vectors with specific performance characteristics
	necessary for the successful delivery and expression of the genetic material applicable in these emerging fields, and we intend
	to further explore these opportunities.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 11; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage12"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Proprietary Cell Lines.
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;&nbsp;&nbsp;GenVec&rsquo;s
	established and proven ORF6 and M2A cell lines are used to produce all of our proprietary adenovectors. Our cell lines perform
	excellently in serum-free, animal protein-free suspension culture and efficiently complement for the growth of even the most complex
	human-origin and nonhuman-origin adenovector constructs. These include vectors bearing the genes for multiple antigens, vectors
	bearing targeted expression cassettes, and vectors containing inserts that encode for proteins which interfere with the host cell
	metabolism and therefore pose challenges for scale-up and manufacture. Our cell lines produce high-concentration, stable adenovector
	lots that meet the rigorous manufacturing standards of our corporate and governmental collaborators as well as regulatory agencies.
	In August&nbsp;2009, we received a Phase 2 SBIR grant, valued at $2.5 million, from the NIAID to support the development of our
	cell line and vector production technology. Revenue recognized under this grant amounted to $2.3 million through December&nbsp;31,
	2013. Work under this grant was completed in 2013.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	RESEARCH AND DEVELOPMENT
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL; COLOR: BLACK">
	As
	a biopharmaceutical company developing biologic products, and to support the activities discussed above, we have significant research
	and development expenditures each year. Our research and development expenses were $2.6 million and $2.3 million for the years
	ended December&nbsp;31, 2015 and 2014, respectively. These expenses were divided between our research and development programs
	in the following manner:
</FONT>
<FONT STYLE="FONT-WEIGHT: NORMAL; BACKGROUND-COLOR: YELLOW">
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_2"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	Years ended December 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-STYLE: ITALIC">
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<B>
<I>
	(in millions)
</I>
</B>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="WIDTH: 70%">
	Vaccines
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1.0
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1.1
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Hearing Loss and Balance Disorders
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.1
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX">
	Other Programs
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; TEXT-ALIGN: RIGHT">
	0.6
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; TEXT-ALIGN: RIGHT">
	0.1
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 4PX">
<B>
	Total
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<B>
	$
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<B>
	2.6
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<B>
	$
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<B>
	2.3
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	INTELLECTUAL PROPERTY
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We endeavor
	to protect and enhance our proprietary technology, inventions, and improvements that are commercially important to the development
	and sustainability of our business. We generally seek patent protection for our technology and product candidates in the U.S. and
	abroad as well as maintain and defend our patent rights whether developed internally or licensed from third parties. We also rely
	on trade secrets relating to our proprietary technology platform and on know-how, continuing technology innovation, and in-licensing
	of opportunities to strengthen, develop and maintain our proprietary position in the field of gene therapy that may be important
	for the development and sustainability of our business.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Our commercial
	success may depend in part on our ability to obtain and maintain patent and other proprietary protection for commercially important
	technology, inventions and know-how related to our business; defend and enforce our patents; preserve the confidentiality of our
	trade secrets; and operate without infringing the valid enforceable patents and proprietary rights of third parties.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Patent Rights and Licenses.&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We
	and our licensors have patents and continue to seek patent protection for technologies that relate to our product candidates, as
	well as technologies that may prove useful for future product candidates. Our proprietary intellectual property, including patent
	and non-patent intellectual property, is generally directed to, for example, matters such as the composition of our adenovector-based
	product candidates, our proprietary technologies and processes related to our product development candidates, certain genes and
	methods of transferring genetic material into cells, and our processes to manufacture and test our adenovector-based product candidates.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	As of
	December&nbsp;31, 2015, we hold or have licenses to 160 issued, allowed or pending patents worldwide, 39 of which are issued or
	allowed in the U.S. These patents and patent applications pertain to, among other things: the composition of matter of our vectors;
	genes that encode therapeutic proteins; expression control elements that regulate the production of the therapeutic proteins by
	such genes and targeting technology for enhanced target cell selectivity of our product candidates; cell lines used to manufacture
	our product candidates; methods of constructing, producing (including purification, quality control, and assay techniques), storing
	and shipping our product candidates; methods of administering our product candidates; and methods of treating disease using our
	product candidates.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 12; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage13"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Hearing Loss Program.
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;&nbsp;&nbsp;We
	have licensed the Atoh1 gene from the Baylor College of Medicine. This license is worldwide and is exclusive for gene therapy applications.
	We licensed our rights to this gene to Novartis as part of our worldwide collaboration with Novartis to develop treatments for
	hearing loss and balance disorders. Patents or patent application covering our product candidate are directed to composition of
	matter for the Atoh1 gene therapy vectors, as well as, compositions and methods of using the candidates emerging from this program.
	Issued patents that cover the product candidate begin to expire in 2024 and if patents are issued from the pending applications
	and if the appropriate maintenance, renewal, annuity or other governmental fees are paid for issued patents, we expect coverage
	to expire in 2034 (worldwide, excluding possible patent term extensions).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Proprietary Vectors.
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;&nbsp;&nbsp;We
	have issued patents and patent applications covering our proprietary AdenoVerse technology platform. We have filed patent applications
	that cover the composition of matter of our new GC Vectors, including those based on adenovirus isolated from mountain gorilla
	that if issued from the pending patent applications and if the appropriate maintenance, renewal annuity, or other governmental
	fees are paid are projected to expire in 2033 (excluding possible patent term extensions). Issued patents that cover the composition
	and use of our proprietary technology platform began to expire in 2015 and extend through 2033 if appropriate maintenance, renewal,
	annuity, or other governmental fees are paid.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Over
	this last year we have announced progress on the intellectual property front that we believe will help secure our interests to
	fully explore the potential of some of our newer adenovirus vectors.&nbsp; In January 2016 a U.S.&nbsp;patent that provides broad
	protection for our gene delivery vectors derived from mountain gorillas was issued.&nbsp; Based on the preclinical data we have
	seen to date, we believe these gorilla vectors have a strong potential in the molecular vaccines space as well as other applications.&nbsp;
	In addition, we were notified U.S. and European patents were issued in 2015 that cover our monkey adenovirus vector technology.&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In May&nbsp;1998,
	we entered into an Amended and Restated Exclusive License Agreement (Cornell Agreement) with the Cornell Research Foundation (Cornell),
	which was subsequently amended. Pursuant to the Cornell agreement we license certain proteins, genes, gene vectors, and similar
	biological materials that relate to our adenovector platform. We are obligated to pay Cornell a yearly maintenance fee of $50,000
	(creditable against any royalty payable in that year). No royalty payments have been made to date, and prior to commercialization
	of a licensed product, we have no royalty obligations to Cornell. The Cornell agreement may be terminated by Cornell or by us in
	the event of an uncured material breach by the other party or by us for any reason with prior written notice. The Cornell agreement
	continues in full force until the expiration of all patents or applications covered thereby, unless otherwise terminated. The latest
	expiring patent under the Cornell agreement expires in 2020.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Licenses to Genes.
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;&nbsp;&nbsp;To
	create our product candidates, we combine our vectors with genes intended to produce proteins with therapeutic potential. We have
	secured licenses to applicable genes for this purpose. We often seek to obtain exclusivity, consistent with our business needs,
	when securing such licenses. In return for the rights we receive under our gene licenses, we typically are required to pay royalties
	based on any commercial sales of the applicable product during a specified time period, as well as provide additional compensation,
	including up-front license fees and product development-related milestone payments.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Any of
	our licenses may be terminated by the licensor if we are in material breach of a term or condition of the particular license agreement,
	or if we become insolvent. In addition, some of our licenses require us to achieve specific milestones.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Production, Purification, Quality
	Assessment and Formulation Technology.
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;&nbsp;&nbsp;We hold issued patents expiring beginning
	in 2019 and have pending patent applications pertaining to the production, purification, quality assessment, and formulation of
	our product candidates, and if patents are issued from the pending applications and if the appropriate maintenance, renewal, annuity,
	or other governmental fees are paid for issued patents, we expect coverage to expire in 2033 (worldwide, excluding possible patent
	term extensions). In particular, we hold issued patents covering the process for manufacturing our product candidates, the purification
	of our product candidates applicable to both research and commercial scales, methods of assessing and confirming the quality and
	purity of our product candidates for clinical testing and commercialization, and product formulations that improve the stability
	of product candidates and allow our product candidates to be conveniently stored, shipped, and used. We are aware, however, of
	issued patents and pending patent applications of third parties relating to these and other aspects of production, purification,
	quality assessment, and formulation technology. It could be alleged that our production, purification, quality assessment, and
	formulation technology conflict with such existing or future patents.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 13; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage14"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We anticipate
	that we, and our current and future licensors, will continue to seek to improve existing technologies, develop new technologies
	and, when appropriate, secure patent protection for such improvements and new technologies.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Certain
	patents pertaining to our product candidates may be eligible for Patent Term Extension under 35 U.S.C. &sect;156. The term of any
	patent that claims a human drug product (including human biological products), a method of using a drug product, or a method of
	manufacturing a drug product is eligible for an extension to restore that portion of the patent term that has been lost as a result
	of FDA review subject to certain limitations.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Trade Secrets.
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;&nbsp;&nbsp;To
	a more limited extent, we rely on trade secret protection and confidentiality agreements to protect our interests. It is our policy
	to require our employees, consultants, contractors, manufacturers, collaborators, and other advisors to execute confidentiality
	agreements upon the commencement of employment, consulting or collaborative relationships with us. We also require signed confidentiality
	agreements from any entity that is to receive confidential data. With respect to employees, consultants, and contractors, the agreements
	generally provide that all inventions made by the individual while rendering services to us shall be assigned to us as our property.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	MANUFACTURING AND SUPPLY
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="COLOR: BLACK">
	Technology
	for Production, Purification, Quality Assessment and Formulation.&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We believe
	our proprietary production technology and know-how facilitate the production, purification, quality assessment, and formulation
	of our product candidates. The structure of our vectors and the procedures for their production and purification enable us to minimize
	the presence of contaminants. We believe our proprietary positions provide a competitive advantage in the following areas:
</FONT>
</FONT>
<FONT STYLE="FONT-WEIGHT: NORMAL; BACKGROUND-COLOR: YELLOW">
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="COLOR: BLACK">
<I>
	Production and Scale-Up.
</I>
	&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We
	produce our adenovectors using cell lines grown in culture under standardized and controlled conditions. We have developed specialized
	proprietary cell lines for production of our vectors. We employ materials that are free of animal-derived components. We have designed
	our production processes to be scalable for commercial production and to reduce the potential for contamination.
</FONT>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
	&bull;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="COLOR: BLACK">
<I>
	Purification.
</I>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;&nbsp;&nbsp;We
	have proprietary methods for the purification of our vectors that we believe are scalable to commercial levels as well as suitable
	for small-scale use in discovery and testing of new product candidates.
</FONT>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
	&bull;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="COLOR: BLACK">
<I>
	Quality Assessment.
</I>
	&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We
	have established proprietary methods to assess and confirm the quality and purity of vectors for research purposes and clinical
	testing. We use advanced techniques to determine the physical characteristics of our product candidates as a means to establish
	product consistency and purity. We have an issued U.S. patent covering this technology. We believe these methods are also suitable
	for quality assessment of commercial production.
</FONT>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
	&bull;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="COLOR: BLACK">
<I>
	Formulation.
</I>
	&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We
	have developed a novel product formulation that improves the stability of our vectors and is covered by issued U.S. patents. Our
	formulation allows products to be stored, shipped, and used in a controlled manner that assures activity for the duration of the
	product shelf-life. For research purposes, our formulation enhances the ease and reproducibility of testing.
</FONT>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Manufacturing Strategy.
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;&nbsp;&nbsp;We
	have relied on third-party manufacturers or our collaborators for cGMP production for clinical trials in the past and intend to
	do so for any future manufacturing of product candidates. We have significant experience working with contract manufacturers and
	we have successfully transferred manufacturing processes to several collaborators and contract manufacturers. Our research and
	development facility is located in Gaithersburg, Maryland, where we have established laboratories and staff to support the non-cGMP
	production and characterization methods for our product candidates. Many of the production and assay technologies developed for
	our hearing restoration, our now discontinued TNFerade clinical study, and those developed under our now terminated HIV vaccine
	contract with the National Institutes of Health (NIH), are suitable for our other product development programs.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We currently
	have two suppliers for our clinical manufacturing components, one for human health and one for animal health candidates. We procure
	raw materials, including specialized components known as resins, for our product purification and testing methods from a limited
	number of suppliers. We also procure nutrients used to support the growth of microorganisms or other cells from Thermo Fischer
	Scientific Corporation.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 14; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage15"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	OUR COMPETITION
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Competition
	in the discovery and development of new methods for treating and preventing disease is intense. We face, and will continue to face,
	substantial competition from pharmaceutical and biotechnology companies, as well as academic and research institutions and government
	agencies both in the U.S. and abroad. We face competition from organizations pursuing the same or similar technologies used by
	us in our drug discovery efforts and from organizations that are competitive with our potential therapeutic and vaccine product
	candidates.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Many
	of our competitors, either alone or together with their collaborative partners, have substantially greater financial resources
	and larger research and development organizations. In addition, our experience in clinical trials, obtaining FDA and other regulatory
	approvals, manufacturing, and commercialization of products may be more limited. We also compete in recruiting and retaining highly
	qualified scientific personnel and consultants. Our ability to compete successfully depends on adequate funding and collaborators
	who can supplement our capabilities.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We are
	aware of products under development by our competitors that target the same prevention or treatment of disease. There are several
	development-stage and established entities, including major pharmaceutical and biotechnology companies that are actively engaged
	in infectious disease vaccine research and development. These include Sanofi S.A., Novartis, GlaxoSmithKline plc, MedImmune, Inc.,
	(a wholly owned subsidiary of AstraZeneca), Merck &amp; Co., Inc., Pfizer Inc., Crucell N.V. (part of the Janssen Pharmaceutical
	Companies of Johnson &amp; Johnson), Bavarian Nordic A/S, Okairos S.r.l. (acquired by GlaxoSmithKline in 2013), Intercell A.G.,
	Genocea BioSciences Inc., Vical Incorporated, Emergent Biosolutions Inc., and Novavax Inc. among others.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We believe
	our competitive success will be based on the efficacy and safety of our products, as well as our ability to create and maintain
	scientifically advanced technology, attract and retain skilled scientific and management personnel, obtain patents or other protection
	for our products and technology, obtain regulatory approvals, and successfully commercialize our products either independently
	or through collaborators.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Hearing Loss and Balance Disorders.
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;&nbsp;&nbsp;The
	market for hearing loss treatments is dominated by devices such as hearing aids or cochlear implants, which are the current standard
	of care. There are no FDA-approved drug therapies. Several biotechnology and pharmaceutical companies have announced research programs
	into therapies for either the restoration of function or for the protection of hearing function. These therapies are in various
	stages of development.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	RSV Vaccine.
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;&nbsp;&nbsp;There
	are a number of companies pursuing the development of a RSV vaccine. These include but are not limited to MedImmune Inc.,
	Sanofi S.A., Bavarian Nordic A/S, Crucell N.V., Novavax Inc., AlphaVax Inc., NanoBio Corporation, and Okairos S.r.l.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	HSV Vaccine.
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;&nbsp;&nbsp;HSV
	vaccines are currently under development by Genocea BioSciences Inc., Sanofi S.A., Vical Incorporated, Coridon Pty Ltd. and Alphavax
	Inc.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	FMD Vaccine.
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;&nbsp;&nbsp;Vaccine
	manufacturers include Merial Limited, Intervet Inc., a subsidiary of Merck &amp; Co. Inc., Bayer AG, Indian Immunological Ltd.
	and other local vaccine producers around the world, including government producers as well as those pursuing the development of
	new vaccines.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Malaria Vaccine.&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-WEIGHT: NORMAL">
	There
	are currently no vaccines approved for the prevention of malaria. Companies developing malaria vaccines include GlaxoSmithKline
	plc, Sanofi S.A., Crucell N.V., Genocea BioSciences Inc., Sanaria, and Okairos S.r.l.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	GOVERNMENT REGULATION
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Regulation of Biologic Products.
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;&nbsp;&nbsp;The
	research, development, testing, manufacture, quality, safety, effectiveness, labeling, packaging, storage, approval, distribution,
	marketing, record keeping, advertising and promotion, and import and export of any biologic products developed by us or our collaborators
	are subject to regulation by federal, state, local, and foreign governmental authorities. In the U.S., new drugs are subject to
	extensive regulation under the Federal Food, Drug, and Cosmetic Act, and biologic products, such as therapeutic products and vaccines,
	are subject to regulation both under provisions of that Act and under the Public Health Service Act. The process of obtaining FDA
	approval for a new product is costly and time-consuming, and the outcome is not guaranteed. If approved, drug products are subject
	to ongoing regulation, and compliance with appropriate federal, state, local, and foreign statutes and regulations will require
	the expenditure of substantial time and financial resources.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 15; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage16"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<I>
	Biologic Product Candidates for Human
	Health
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The steps required before our proposed
	investigational biologic products may be marketed in the U.S. (other than for veterinary biologics, including our FMD vaccine product
	candidate, which are discussed below), include:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Performance of preclinical (animal and laboratory) tests;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Submission to the FDA of an Investigational New Drug application
	(IND), which must become effective before human clinical trials may commence;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Performance of adequate and well-controlled human clinical trials
	to establish the safety and efficacy in the intended target population for each indication for which approval is sought;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Performance of a consistent and reproducible manufacturing process
	intended for commercial use;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Submission to the FDA of a Biologics License Application (BLA);
	and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	FDA approval of the BLA before any commercial sale or shipment.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Preclinical
	studies may take several years to complete. The results of these studies, together with manufacturing information and analytical
	data, are submitted to the FDA as part of an IND. The FDA must review the IND prior to the commencement of human clinical trials.
	Unless the FDA raises concerns (such as concerns that human research subjects will be exposed to unreasonable risks), the IND will
	become effective 30 days following its receipt by the FDA, and the clinical trials covered by the IND may commence.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Clinical
	trials typically are conducted in three sequential but often overlapping phases. In Phase 1, a drug is typically studied in a small
	number of healthy volunteers or patients to test the drug for safety or adverse effects, dosage tolerance, absorption, metabolism,
	excretion and clinical pharmacology. Phase 2 involves clinical trials in the targeted patient population to determine the effectiveness
	of the drug for specific, targeted indications, to determine dosage tolerance and optimal dosage, and to gather additional safety
	data. Phase 3 clinical trials are commonly referred to as pivotal, or registrational, studies and are conducted to further evaluate
	dosage, to provide substantial evidence of clinical efficacy and to further test for safety in an expanded and diverse patient
	population. Each phase may take several years to complete.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The conduct
	of the clinical trials is subject to extensive regulation, including compliance with good clinical practice regulations and guidelines,
	obtaining informed patient consent, sponsor monitoring, auditing of the clinical, laboratory and product manufacturing sites, and
	review and approval of each study by an independent institutional review board (IRB) for each site proposing to conduct the clinical
	trial. The FDA, the IRB, a Data Safety Monitoring Board (DSMB) or Data Monitoring Committee (DMC), or the sponsor may, at its discretion,
	suspend or terminate a clinical trial at any time on various grounds, including a finding that the subjects or patients are being
	exposed to an unacceptable health risk.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In addition
	to the regulations discussed above, there are a number of additional standards that apply to clinical trials involving the use
	of gene therapy. The FDA has issued various guidance documents regarding gene therapies, which outline additional factors the FDA
	will consider at each of the above stages of development and relate to, among other things: the proper preclinical assessment of
	gene therapies; the chemical, manufacturing and control information that should be included in an IND; the proper design of tests
	to measure product potency in support of an IND or BLA; and measures to observe potential delayed adverse effects in subjects who
	have been exposed to investigational gene therapies when the risk of such effects is high. Further, the FDA usually recommends
	that sponsors observe subjects for potential gene therapy-related delayed adverse events for a 15-year period, including a minimum
	of five years of annual examinations followed by 10 years of annual queries, either in person or by questionnaire.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Promising
	data in early-stage clinical trials do not necessarily assure success in later-stage clinical trials. The FDA may request that
	additional clinical trials be conducted as a condition to product approval. Additionally, new government requirements may be established
	that could delay or prevent regulatory approval of products under development.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 16; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage17"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	After
	the completion of the required clinical trials, if we believe the data indicate the biologic product is safe and effective, we
	would prepare a BLA and submit it to the FDA. This process takes substantial time and effort. The FDA may refuse to file the BLA
	and request additional information, in which case, the application must be resubmitted with the supplemental information. Once
	a BLA is deemed filed by the FDA, there is no guarantee the FDA will approve the BLA. The FDA has substantial discretion in the
	approval process and may disagree with our interpretation of the preclinical or clinical data and request additional data and information,
	which could significantly delay, limit, or even prevent regulatory approval.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	As part
	of this review, the FDA may refer the BLA to an appropriate advisory committee, typically a panel of physicians, for review, evaluation,
	and an approval recommendation. Although the FDA is not bound by the opinion of the advisory committee, advisory committee discussions
	may further delay, limit, or prevent approval. The FDA also may conclude that as part of the BLA, the sponsor must develop a risk
	evaluation and mitigation strategy (REMS) to ensure that the benefits of the drug outweigh the risks. A REMS may have different
	components, including a package insert directed to patients, a plan for communication with healthcare providers, restrictions on
	a drug&rsquo;s distribution, or a medication guide to provide better information to consumers about the drug&rsquo;s risks and
	benefits.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	If its
	evaluations of the BLA are favorable and the agency concludes the standards for approval have been met, the FDA will issue an approval
	letter. If the FDA believes the BLA is deficient in some way that precludes approval, it will issue a Complete Response Letter
	that generally identifies the deficiencies, which can be minor, such as requiring labeling changes, or major, such as requiring
	additional preclinical or clinical studies. The Complete Response Letter may also include recommended actions the applicant might
	take to place the BLA in a condition for approval. If a Complete Response Letter is issued, the applicant may either resubmit the
	BLA, addressing all of the deficiencies identified in the letter, or withdraw the BLA. If the deficiencies have been addressed
	to the FDA&rsquo;s satisfaction, the FDA may issue an approval letter. Even if the requested information and data are submitted,
	however, the FDA may ultimately decide the BLA does not satisfy the criteria for approval. Prior to granting approval, the FDA
	generally conducts an inspection of the facilities, including third-party contract facilities that will be involved in the manufacture,
	production, packaging, testing, and control of the drug substance and finished drug product for compliance with current Good Manufacturing
	Practices (cGMP). The FDA will not approve the BLA unless cGMP compliance is satisfactory. In addition, each manufacturing establishment
	must be registered with the FDA and is subject to periodic FDA inspection. In order to supply products for use either inside or
	outside the U.S., including for investigation in clinical trials, domestic and foreign manufacturing establishments, including
	third-party facilities, must comply with cGMP regulations and are subject to periodic inspection by the corresponding regulatory
	agencies in their home country, often under reciprocal agreements with the FDA or by the FDA.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	After
	a biologic product is approved, it is subject to significant ongoing regulation and must comply with requirements relating to manufacturing,
	labeling, packaging, adverse event reporting, storage, advertising, promotion, distribution, and recordkeeping. As a condition
	of BLA approval, the FDA may require post-approval testing (referred to as Phase 4 clinical trials) and surveillance to monitor
	the product&rsquo;s safety or efficacy. In addition, the holder of an approved BLA is required to keep extensive records; to report
	certain adverse reactions, production deviations, and other problems to the FDA; to provide updated safety and efficacy information,
	and to comply with requirements concerning advertising and promotional labeling for their products. Generally, a company can promote
	a product only for those claims relating to safety and efficacy that are consistent with the labeling approved by the FDA and supported
	by substantial evidence. Failure to comply with the regulatory requirements of the FDA and other applicable U.S. and foreign regulatory
	authorities could result in administrative or judicially imposed sanctions or other setbacks, including warning letters, restrictions
	on the product, product recalls, suspension or withdrawal of approval, seizures, injunctions, civil fines, and criminal sanctions.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	If the
	FDA becomes aware of new safety information, it may require post-approval studies or clinical trials to investigate known serious
	risks or signals of serious risks or in response to the occurrence of unexpected serious risks identified following approval. If
	a post-approval study is required, periodic status reports must be submitted to the FDA. Failure to conduct such post-approval
	studies in a timely manner may result in substantial civil fines. In addition, newly discovered or developed safety or efficacy
	data may require changes to an approved product&rsquo;s distribution or labeling, including the addition of new warnings, contraindications
	or a REMS, or suspended marketing or withdrawal of the product.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 17; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage18"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	A biologic
	product is also subject to regulatory approval in other countries in which it is intended to be marketed. No such product can be
	marketed in a country until the regulatory authorities of that country have approved an appropriate license application. FDA approval
	does not assure approval by other regulatory authorities. In many countries, the government is involved in the pricing of the product.
	In such cases, a pricing review period often begins after market approval is granted.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	On March&nbsp;23,
	2010, the Biologics Price Competition and Innovation Act of 2009 (BPCIA) was signed into law. It creates an abbreviated approval
	pathway for biologic products that are &ldquo;biosimilar&rdquo; to a previously approved biologic product, which is called the
	&ldquo;reference product.&rdquo; This abbreviated approval pathway is intended to permit a biosimilar product to come to market
	more quickly and less expensively than if a full BLA were submitted, by relying to some extent on the FDA&rsquo;s previous review
	and approval of the reference product. If a proposed biosimilar product meets the statutory standards for approval (which include
	demonstrating that it is highly similar to the reference product and there are no clinically meaningful differences in safety,
	purity or potency between the products), the proposed biosimilar product may be approved on the basis of an application that is
	different from the standard BLA. In addition, a biosimilar product may be approved as interchangeable with the reference product
	if the proposed product application meets standards intended to ensure that the biosimilar product can be expected to produce the
	same clinical result as the reference product.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL; COLOR: BLACK">
	The
	BPCIA provides exclusivity periods during which a product approved under a BLA cannot be relied on as a reference product. No biosimilar
	application may be submitted to the FDA for a period of four years after the reference product was approved, and no biosimilar
	application may be approved until 12 years after the reference product&rsquo;s approval. If pediatric studies with the reference
	product are performed and accepted by the FDA, the 12-year exclusivity period will be extended for an additional six months. Additionally,
	the first biosimilar product approved as interchangeable with a reference product will be granted an exclusivity period of varying
	length, depending on the factual circumstances. Because the BPCIA is a relatively new law, we anticipate that its contours will
	be defined as the statute is implemented over a period of years. Some issues may be resolved through regulation or agency guidance,
	but other interpretations may develop on an ad hoc basis as the FDA confronts them in the context of specific applications.
</FONT>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The FDA has to date issued various guidance documents and other materials indicating the agency&rsquo;s thinking regarding a number
	of issues implicated by the BPCIA. Additionally, the FDA&rsquo;s approval in 2015 of the first biosimilar application helps define
	the agency&rsquo;s approach to certain issues. Much is still to be determined, however.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<I>
	Biologic Product Candidates for Animal
	Health
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Our FMD
	vaccine product candidate is subject to a separate regulatory regime. In the U.S., governmental regulation of animal health products
	is primarily provided by two agencies: the Animal and Plant Health Inspection Service (APHIS) within the Department of Agriculture
	(USDA) and the FDA. Vaccines for animals are considered veterinary biologics and are regulated by the Center for Veterinary Biologics
	of the USDA under the auspices of the Virus-Serum-Toxin Act. The USDA licensing process involves the submission of several data
	packages. These packages include information on how the product will be manufactured, information on the efficacy and safety of
	the product in laboratory and target animal studies, and information on performance of the product in field conditions. The USDA
	may issue one of two types of licenses: a full license or a conditional license. Conditional licenses are used to meet an emergency
	condition, limited market, local situation or other special circumstance and do not permit the general commercialization of the
	product. Conditionally licensed products are required to be pure and safe, and have a reasonable expectation of efficacy. Conditional
	licenses are effective for a finite time period and distribution of conditionally licensed products in each state is limited to
	authorized recipients designated by proper state officials. Conditional licenses may be renewed if the applicant demonstrates a
	good-faith effort toward obtaining full licensure.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In June&nbsp;2012,
	APHIS issued a conditional license for our FMD vaccine for use in cattle. The conditional license was issued because of the need
	for an FMD vaccine that is capable of being manufactured in the United States that allows for the differentiation between infected
	and vaccinated animals. The vaccine is available to agriculture officials in the event of an FMD emergency situation. The conditional
	license was renewed in 2014 and is effective until 2016. We expect to seek a further renewal in 2016 when the current license expires.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 18; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage19"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Reimbursement of Biologic Products.
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;&nbsp;&nbsp;If
	and when our products reach commercialization, insurance companies, health maintenance organizations, other third-party payers,
	and federal and state governments will be the primary payers for our products. The largest payer in this group will probably be
	the Centers for Medicare and Medicaid Services (CMS), the federal agency that administers the Medicare and Medicaid programs. Under
	Medicare, there are different reimbursement methodologies for certain drugs and biological products that depend on the site of
	service. These methodologies generally use average sales price (ASP) information. Manufacturers, including us, if and when we or
	our collaborators commercialize our products in the U.S., are required to provide ASP information to CMS on a quarterly basis if
	we participate in the Medicaid program. If a manufacturer is found to have made a misrepresentation in the reporting of ASP, the
	statute provides for civil monetary penalties of up to $10,000 for each misrepresentation for each day in which the misrepresentation
	was applied. Additional civil monetary penalties apply for reporting false information or reporting required information late.
	ASP is used to compute Medicare payment rates, updated quarterly based on this ASP information. Until enough ASP data are available
	to calculate a payment rate, reimbursement is wholesale acquisition cost plus 6%. There also is a mechanism for comparison of the
	ASP for a product to the widely available market price and the Medicaid Average Manufacturer Price (AMP) for the product. When
	the ASP for a product exceeds the product&rsquo;s AMP by a specified percentage, the product&rsquo;s ASP may be disregarded and
	an AMP-based reimbursement rate may be applied instead, which could cause further decreases in Medicare payment rates.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	For covered
	physician-administered drugs and biological products furnished in a physician&rsquo;s office, if the physician purchases the drug
	or biological product, CMS will reimburse the physician based upon that drug or biological product&rsquo;s ASP plus 6%. The ASP
	is determined by CMS based upon information reported by manufacturers. Medicare also has several reimbursement methodologies for
	drugs and biological products administered in hospital outpatient departments. New drugs and biologicals whose cost is &ldquo;not
	insignificant&rdquo; in relation to payment for related procedures are granted &ldquo;pass-through status&rdquo; and are reimbursed
	at ASP plus 6% for the first two to three years of payment under the Medicare hospital outpatient prospective payment system. For
	many other drugs and biological products that do not qualify for pass-through status but have an average cost per day greater than
	$100, the current Medicare payment to a hospital outpatient department is ASP plus 6%. Drugs and biological products with an average
	cost per day equal to or less than $100 are not separately reimbursed; payment for these products is included in payment for the
	associated procedure. Payment levels for drugs without pass-through status and the $100 threshold are subject to change through
	regulation each calendar year.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In addition,
	Congress may change Medicare reimbursement amounts or methods by statute. For example, beginning April&nbsp;1, 2013, Medicare payments
	for all items and services, including drugs and biologicals, have been reduced by 2% under the sequestration (i.e. automatic spending
	reductions) required by the Budget Control Act of 2011 (BCA), as amended by the American Taxpayer Relief Act of 2012 (ATRA). Subsequent
	legislation extended the 2% reduction, on average, to 2025, unless Congress modifies the sequestration in the future. In addition,
	Congress or CMS could change ASP-based reimbursement amounts through statute or regulation for the physician office or hospital
	outpatient settings, respectively. Health reform legislation enacted in March of 2010, the Patient Protection and Affordable Care
	Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, PPACA), also requires CMS to test new
	payment methodologies that would bundle payment for physician and hospital services and supplies, including drugs and biological
	products, for an episode of care. Changes to the calculation of ASP or Medicare reimbursement methodologies could affect reimbursement
	for our products and could negatively impact our results of operations, if and when we begin to commercialize products that could
	be reimbursed by the Medicare program.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Effective
	January&nbsp;1, 2006, an expanded prescription drug benefit for all Medicare beneficiaries (known as Medicare Part D) commenced
	to provide Medicare beneficiaries with drug coverage for self-administered drugs and biological products and other drugs and biological
	products not covered by Medicare, including many vaccines. This voluntary benefit is being implemented through private plans under
	contractual arrangements with the federal government. Currently, these plans negotiate directly with pharmaceutical manufacturers
	for rebates on drugs dispensed to Medicare Part D beneficiaries. Like pharmaceutical coverage through private health insurance,
	Medicare Part D plans establish formularies and use other utilization management tools when determining the drugs and biological
	products that are offered by each plan. These formularies can change on an annual basis, subject to federal governmental review.
	These plans may also require beneficiaries to provide out-of-pocket payments for such products. Effective January&nbsp;1, 2008,
	private Medicare Part D plans pay physicians one payment that includes both the administration cost and the cost of the vaccine
	for those vaccines that are not already covered by law under a different component of the Medicare program. PPACA requires manufacturers
	to pay rebates of 50% on all drugs dispensed to beneficiaries, other than low-income beneficiaries, in the Medicare Part D coverage
	gap, often referred to as the &ldquo;donut hole.&rdquo; It is possible that future health reform legislation would require the
	government to negotiate Medicare Part D rebates directly, which could result in much higher rebate amounts than those currently
	negotiated with the plans. In addition, although certain treatments are currently included in CMS&rsquo;s protected classes of
	drugs for purposes of Medicare Part D formularies, which generally ensures inclusion on plan formularies, it is possible that future
	regulatory or legislative changes could change that status.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 19; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage20"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Federal
	law requires pharmaceutical manufacturers to pay rebates on covered outpatient drugs reimbursed by the Medicaid program as a condition
	of having federal funds being made available to pay for those drugs under Medicaid and Medicare Part B. Rebate amounts for a product
	are determined by a statutory formula that is based on prices defined by statute: AMP, which must be calculated for all products
	that are covered outpatient drugs under the Medicaid program, and best price, which must be calculated only for those covered outpatient
	drugs that are innovator products, such as biological products and products approved under new drug applications. A pharmaceutical
	manufacturer is required to report AMP and best price for each of its covered outpatient drugs to the government on a regular basis.
	AMP is reported quarterly and monthly, and best price is reported quarterly.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Various
	states have adopted mechanisms under Medicaid that seek to control drug reimbursement, including by disfavoring certain higher
	priced drugs and by seeking supplemental rebates from manufacturers. PPACA and subsequent legislation made significant changes
	to the Medicaid drug rebate program, including changing the definition of AMP, increasing the minimum rebate percentage, changing
	the rebate calculation for new formulations of existing products, capping the rebate amount for innovator products at 100% of AMP,
	and expanding rebate liability from fee-for-service Medicaid utilization to include the utilization of Medicaid managed care organizations
	as well. We expect, if and when we or our collaborators commercialize our products in the U.S., a significant portion of our revenue
	and the revenue of our collaborators from sales of our products will be obtained through government payers, including Medicare,
	Medicaid and Department of Defense (DoD) programs, and any failure to qualify for reimbursement for our products under those programs
	would have a material adverse effect on future revenues from sales of our products.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	A pharmaceutical
	manufacturer must also participate in the 340B drug pricing program in order for federal funds to be available to pay for the pharmaceutical
	manufacturer&rsquo;s drugs under Medicaid and Medicare Part B. Under this program, the participating pharmaceutical manufacturer
	agrees to charge statutorily-defined covered entities no more than the 340B discounted ceiling price for the pharmaceutical manufacturer&rsquo;s
	covered outpatient drugs. The formula for determining the discounted purchase price is defined by statute and is based on the AMP
	and rebate amount for a particular product as calculated under the Medicaid drug rebate program, discussed above. PPACA also obligates
	the Secretary of the Department of Health and Human Services to create regulations and processes to improve the integrity of the
	340B drug pricing program and to ensure the agreement that manufacturers must sign to participate in the program obligates manufacturers
	to offer the ceiling price to covered entities if the manufacturer makes the drug available to any other purchaser at any price
	and report to the government the ceiling prices for its drugs. In addition, legislation may be introduced that, if passed, could
	further expand the 340B drug pricing program to include additional covered entities or could require participating manufacturers
	to agree to provide 340B discounted pricing on drugs used in the inpatient setting. To the extent that PPACA and subsequent legislation,
	as discussed above, causes the statutory and regulatory definitions of AMP and the Medicaid rebate amount to change, these changes
	also impact the 340B discounted ceiling price.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In order
	to be eligible to have our products paid for with federal funds under the Medicaid and Medicare Part B programs and purchased by
	certain federal agencies and grantees, we anticipate that we will participate in the Department of Veterans Affairs (VA) Federal
	Supply Schedule (FSS) pricing program, established by Section 603 of the Veterans Health Care Act of 1992. Under this program,
	we will be obligated to make our products available for procurement on an FSS contract and charge prices to four federal agencies
	&mdash; VA, DoD, Public Health Service and Coast Guard &mdash; that are no higher than the statutory Federal Ceiling Price (FCP).
	The FCP is based on the non-federal average manufacturer price (Non-FAMP), which we will be required to calculate and report to
	the VA on a quarterly and annual basis.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	To the
	extent our other products become available in the retail pharmacy setting if and when they are commercialized, we would be subject
	to Section 703 of the National Defense Authorization Act for Fiscal Year 2008. DoD has established a program under which it seeks
	FCP-based rebates from drug manufacturers on TRICARE retail utilization of covered drugs. Under this authority, DoD asserts an
	entitlement to rebates on TRICARE Retail Pharmacy utilization from January&nbsp;28, 2008 forward, unless DoD grants a waiver or
	compromise of amounts due. Rebates are computed by subtracting the applicable FCP from the corresponding annual Non-FAMP. DoD has
	asserted the right to apply offsets and/or proceed under the Debt Collection Act in the event that a company does not pay rebates
	or request a waiver of rebate liability in a timely fashion. Companies that want their covered drugs to be eligible for favorable
	positioning on DoD&rsquo;s Uniform Formulary must enter into a Section 703 Agreement with TMA under which the company agrees to
	pay the quarterly rebates.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 20; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage21"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	If and
	when we begin commercializing our products, we expect to experience pricing pressures in the United States in connection with the
	sale of these products due to the trend toward managed healthcare, the increasing influence of health maintenance organizations
	and additional legislative proposals. We are unable to predict what additional legislation, regulations or policies, if any, relating
	to the healthcare industry or third-party coverage and reimbursement may be enacted in the future or what effect such legislation,
	regulations or policies would have on our business. Any cost containment measures, including those listed above, or other healthcare
	system reforms that are adopted could have a material adverse effect on our ability to operate profitably.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In addition
	to the changes discussed above, PPACA substantially changes the way healthcare is financed by both governmental and private insurers
	and significantly impacts the pharmaceutical industry in other ways as well. PPACA contains a number of provisions that are expected
	to impact our business and operations, in some cases in ways we cannot currently predict. Changes that may affect our business
	if and when our products are commercialized in the U.S. include those governing expanded enrollment in federal and private healthcare
	programs, new Medicare reimbursement methods and rates, increased rebates and taxes on pharmaceutical products, and revised fraud
	and abuse and enforcement requirements. These changes will impact existing government healthcare programs and will result in the
	development of new programs.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The effects
	of reforms under PPACA will be shaped significantly by implementing regulations that have yet to be finalized, by difficulties
	in implementation of the new insurance marketplaces, and by state government decisions. On February 1, 2016, CMS issued a final
	regulation to implement the changes to the Medicaid drug rebate program under PPACA. This regulation becomes effective on April&nbsp;1,
	2016. Many states chose not to expand their Medicaid programs by raising the income limit to 133% of the federal poverty level,
	as permitted by PPACA. It is unclear whether these states will choose to expand their programs in the future and whether there
	will be more uninsured patients than anticipated when Congress passed PPACA. For each state that does not choose to expand its
	Medicaid program as permitted by PPACA, there will be fewer insured patients overall. In addition, problems with implementation
	of the websites and other administrative services to help people enroll in qualifying insurance coverage may have reduced the number
	of uninsured people who obtain coverage under PPACA. The reduction in the number of insured patients could impact our sales, business
	and financial condition following the commercialization, if successful, of our products in the U.S.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Other Laws and Regulations.&nbsp;&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Our business may be subject to healthcare
	fraud and abuse regulation and enforcement by both the federal government and the states in which we conduct our business, particularly
	once third-party reimbursement becomes available for one or more of our products. The healthcare fraud and abuse laws and regulations
	that may affect our ability to operate include but are not limited to:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL; COLOR: BLACK">
	The federal Anti-Kickback Law, which prohibits,
	among other things, knowingly or willingly offering, paying, soliciting or receiving remuneration, directly or indirectly, in cash
	or in kind, to induce or reward the purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order
	of any health care items or service for which payment may be made, in whole or in part, by federal healthcare programs such as
	Medicare and Medicaid. This statute has been interpreted to apply to arrangements between pharmaceutical companies on one hand
	and prescribers, purchasers and formulary managers on the other. Further, PPACA clarified that liability may be established under
	the federal Anti-Kickback Law without proving actual knowledge of the statute or specific intent to violate it. In addition, PPACA
	amended the Social Security Act to provide that the government may assert that a claim including items or services resulting from
	a violation of the federal Anti-Kickback Law constitutes a false or fraudulent claim for purposes of the federal civil False Claims
	Act. Although there are a number of statutory exemptions and regulatory safe harbors to the federal Anti-Kickback Law protecting
	certain common business arrangements and activities from prosecution or regulatory sanctions, the exemptions and safe harbors are
	drawn narrowly, and practices that involve remuneration to those who prescribe, purchase, or recommend pharmaceutical and biological
	products, including certain discounts, or engaging such individuals as speakers or consultants, may be subject to scrutiny if they
	do not fit squarely within an exemption or safe harbor. Our practices may not in all cases meet all of the criteria for safe harbor
	protection from anti-kickback liability. Moreover, there are no safe harbors for many common practices, such as educational and
	research grants or patient assistance programs.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 21; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage22"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL; COLOR: BLACK">
	The federal civil False Claims Act, which prohibits,
	among other things, individuals or entities from knowingly presenting, or causing to be presented, a false or fraudulent claim
	for payment of government funds or knowingly making, using or causing to be made or used, a false record or statement material
	to an obligation to pay money to the government or knowingly concealing or knowingly and improperly avoiding, decreasing or concealing
	an obligation to pay money to the federal government. Many healthcare companies have been investigated and have reached substantial
	financial settlements with the federal government under the civil False Claims Act for a variety of alleged improper activities
	including causing false claims to be submitted as a result of the marketing of their products for unapproved and thus non-reimbursable
	uses, inflating prices reported to private price publication services which are used to set drug payment rates under government
	healthcare programs, and other interactions with customers including those that may have affected their billing or coding practices
	and submission to the federal government. In addition, PPACA amended federal law to provide that the government may assert that
	a claim including items or services resulting from a violation of the federal Anti-Kickback Law constitutes a false or fraudulent
	claim for purposes of the federal civil False Claims Act. Pharmaceutical and other healthcare companies also are subject to other
	federal false claims laws, including, among others, federal criminal healthcare fraud and false statement statutes that extend
	to non-government health benefit programs.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL; COLOR: BLACK">
	The Health Insurance Portability and Accountability
	Act of 1996 (HIPAA), as amended by the Health Information Technology for Economic and Clinical Health Act, among other things,
	imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements
	in connection with the delivery of or payment for healthcare benefits, items or services, and also imposes obligations with respect
	to safeguarding the privacy, security and transmission of individually identifiable health information.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL; COLOR: BLACK">
	The federal Physician Payment Sunshine Act, being
	implemented as the Open Payments Program, which requires certain pharmaceutical and biological manufacturers to engage in extensive
	tracking of payments or transfers of value to physicians and teaching hospitals and public reporting of the payment data. Pharmaceutical
	and biological manufacturers with products for which payment is available under Medicare, Medicaid or the State Children&rsquo;s
	Health Insurance Program are required to have started tracking such payments on August&nbsp;1, 2013, and must submit a report on
	or before the 90th day of each calendar year disclosing reportable payments made in the previous calendar year.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL; COLOR: BLACK">
	Analogous state laws and regulations, such as state
	anti-kickback and false claims laws, which may apply to items or services reimbursed under Medicaid and other state programs or,
	in several states, regardless of the payer. Some state laws also require pharmaceutical companies to report expenses relating to
	the marketing and promotion of pharmaceutical products and to report gifts and payments to certain health care providers in those
	states. Some of these states also prohibit certain marketing-related activities including the provision of gifts, meals, or other
	items to certain health care providers. In addition, California, Connecticut, Nevada and Massachusetts require pharmaceutical companies
	to implement compliance programs or marketing codes of conduct.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL; COLOR: BLACK">
	The federal Foreign Corrupt Practices Act of 1997
	and similar anti-bribery laws in other jurisdictions generally prohibit companies and their intermediaries from providing money
	or anything of value to officials of foreign governments, foreign political parties or international organizations with the intent
	to obtain or retain business or seek a business advantage. Recently, there has been a substantial increase in anti-bribery law
	enforcement activity by U.S. regulators, with more frequent and aggressive investigations and enforcement proceedings by both the
	Department of Justice and the U.S. Securities and Exchange Commission. A determination that our operations or activities are not,
	or were not, in compliance with United States or foreign laws or regulations could result in the imposition of substantial fines,
	interruptions of business, loss of supplier, vendor or other third-party relationships, termination of necessary licenses and permits
	and other legal or equitable sanctions. Other internal or government investigations or legal or regulatory proceedings, including
	lawsuits brought by private litigants, may also follow.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 22; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage23"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	If our
	operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to
	us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from
	government-funded healthcare programs like Medicare and Medicaid, and the curtailment or restructuring of our operations, any of
	which could adversely affect our ability to operate our business and our financial results. Although compliance programs can mitigate
	the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Any action against
	us for violation of these laws or regulations, even if we successfully defend against it, could cause us to incur significant legal
	expenses and divert our management&rsquo;s attention from the operation of our business. Moreover, achieving and sustaining compliance
	with applicable federal and state privacy, security and fraud laws may prove costly.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Our business
	is also subject to regulation under various state and federal environmental laws, including the Occupational Safety and Health
	Act, the Resource Conservation and Recovery Act and the Toxic Substances Control Act. These and other laws govern our use, handling,
	and disposal of various biological, chemical and radioactive substances used in and wastes generated by our operations. We are
	not aware of any costs or liabilities in connection with any environmental laws that will have a material adverse effect on our
	business or financial condition.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_NAME_AND_TITLE>
<A NAME="FIS_NAME_AND_TITLE"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	EXECUTIVE OFFICERS OF THE REGISTRANT
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 95%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; WIDTH: 33%">
<FONT STYLE="FONT-SIZE: 10PT">
	Name
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 2PX; WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; WIDTH: 8%">
<FONT STYLE="FONT-SIZE: 10PT">
	Age
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 2PX; WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; WIDTH: 55%">
<FONT STYLE="FONT-SIZE: 10PT">
	Present Position with the Registrant
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-LEFT: 9PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Douglas J. Swirsky
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	46
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	President and Chief Executive Officer and Corporate Secretary
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-LEFT: 9PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Douglas E. Brough, Ph.D.
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	60
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Chief Scientific Officer
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-LEFT: 9PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Bryan T. Butman, Ph.D.
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	63
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Sr. Vice President, Development
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-LEFT: 9PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	James V. Lambert
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	51
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Sr. Director, Accounting and Finance, Corporate Controller, and Treasurer
</FONT>
</TD>
</TR>
</TABLE>
</EFX_NAME_AND_TITLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The Board
	of Directors appoints all executive officers annually. There is no family relationship between or among any of the executive officers
	or directors, or any arrangement or understandings pursuant to which the officers were appointed.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Douglas J. Swirsky
</I>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	has served as the President and Chief Executive Officer and as a director of the Company since September&nbsp;2013. He joined GenVec
	in 2006 as Chief Financial Officer, Treasurer, and Corporate Secretary; and continues to serve as Corporate Secretary. Prior to
	joining GenVec, Mr. Swirsky was a Managing Director and the Head of Life Sciences Investment Banking at Stifel Nicolaus from 2005
	to 2006 and held investment banking positions at Legg Mason from 2002 until Stifel Financial&rsquo;s acquisition of the Legg Mason
	Capital Markets business in 2005. Mr. Swirsky, a Certified Public Accountant and a holder of a Chartered Financial Analyst&reg;
	designation, has also previously held investment banking positions at UBS, PaineWebber, and Morgan Stanley. His experience also
	includes positions in public accounting and consulting. Mr. Swirsky received his B.S. in Business Administration from Boston University
	and his M.B.A. from the Kellogg School of Management at Northwestern University. Mr. Swirsky is a member of the Board of Directors
	of Fibrocell Science, Inc. Within the past five years, Mr. Swirsky has also served on the board of PolyMedix, Inc.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Douglas E. Brough, Ph.D
</I>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	.
	joined GenVec in 1993 and since September&nbsp;2013 has served as Chief Scientific Officer. Dr. Brough previously held several
	positions at GenVec including Senior Vice President, Research, Vice President, Head of Research, Executive Director of Vector Sciences,
	Senior Director of Vector Sciences, Director of Vector Sciences, Director of Molecular Virology, Head Molecular Virology and Research
	Scientist. Prior to joining GenVec, Dr. Brough was a Research Fellow in the Department of Molecular Biology at the Lewis Thomas
	Laboratory, Princeton University. Dr. Brough received his B.S. in Biology from Purdue University, a M.S. in Microbiology and Biochemistry
	from Idaho State University, and his Ph.D. in Microbiology and Molecular Genetics from Rutgers, the State University of New Jersey
	and the Robert Wood Johnson Medical School. Dr. Brough performed post-doctoral research in molecular biology at Princeton University.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 23; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage24"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Bryan T. Butman, Ph.D.
</I>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	joined the Company in 1999 and now serves as Senior Vice President, Development. Dr. Butman previously served as GenVec&rsquo;s
	Vice President of Vector Operations (2005 to 2006), Vice President of Quality (2002 to 2005) and Director of Quality and Analytical
	Science (1999 to 2002). Prior to joining GenVec, Dr. Butman was Executive Director of Diagnostic Product Research and Development
	with INTRACEL Corporation, a biotechnology company. Dr. Butman has over 30 years of biotechnology product development experience
	including clinical gene therapy, human monoclonal antibody and clinical diagnostic products. Throughout his biotechnology career,
	Dr. Butman has developed successful products in the areas of oncology, cardiovascular disease, infectious disease, food safety
	and hematology. He has held senior positions within Warner Lambert, AKZO-Nobel, Organon Teknika, PerImmune and INTRACEL. Dr. Butman
	holds a Ph.D. in Cell Biology from Wayne State University.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	James V. Lambert
</I>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	joined GenVec in 2006 and since 2014 has served as Senior Director, Accounting and Finance, Corporate Controller and Treasurer.
	Mr. Lambert previously served as GenVec&rsquo;s Senior Director, Accounting and Finance (2010 to 2014), Director, Accounting and
	Finance (2008 to 2010), and Senior Controller (2006 to 2008). Prior to joining GenVec, from 1999 to 2006, Mr. Lambert was the Controller
	at Sigma Tau Pharmaceuticals, the North American distributor of pharmaceutical drugs, dietary supplements, and fine chemicals for
	an Italian company. Previously, he served as Controller for Stone Street Capital, Inc., Accounting Manager for OncorMed, Inc.,
	and in various positions with increasing levels of responsibility at Blue Cross Blue Shield of the National Capital Area. Mr. Lambert
	began his career as an analyst for E-Systems, Melpar Division. Mr. Lambert, a Certified Public Accountant, received a B.A. in Economics
	and a B.S. in Accounting from the University of Maryland.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	EMPLOYEES
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	As of
	February&nbsp;29, 2016, we had 15 full-time employees, 3 of whom hold Ph.D. degrees and 3 of whom hold other advanced degrees.
	Of our total workforce, 5 are engaged primarily in research and development activities and 10 are engaged primarily in business
	development, finance, marketing, and administration functions. None of our employees is represented by a labor union or covered
	by a collective bargaining agreement, and we consider our employee relations to be good.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	PRINCIPAL EXECUTIVE OFFICES
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We were
	incorporated in Delaware in 1992. Our principal executive offices are located at 910 Clopper Road, Suite 220N, Gaithersburg, Maryland
	20878. Our telephone number at that location is (240) 632-0740.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	AVAILABLE INFORMATION
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We maintain
	an internet website at
<I>
	www.genvec.com
</I>
	. Our electronic filings with the U.S. Securities and Exchange Commission (including
	our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and any amendments to these reports)
	are available free of charge through our website as soon as reasonably practicable after we electronically file them with or furnish
	them to the U.S. Securities and Exchange Commission. Our website also includes copies or links to selected published studies and
	posters of presentations, within the limits of copyright law and practicability, which contain additional information about clinical
	trials of our product candidates. Our website and the information we post on our website is expressly not incorporated by reference
	in this Annual Report on Form 10-K. In addition to visiting our website, you may read and copy public reports we file with the
	SEC at the SEC&rsquo;s Public Reference Room at 100 F Street, NE, Washington DC 20549, or at
<I>
	www.sec.gov
</I>
	. You may obtain
	information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330.
</FONT>
</P>
</EFX_BUSINESS>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_RISK_FACTORS>
<A NAME="FIS_RISK_FACTORS"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<A NAME="T1600102_10K_HTM_A_002">
</A>
	ITEM 1A. RISK FACTORS
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL; COLOR: BLACK">
	Investing
	in our securities involves a high degree of risk. In addition to the other information contained in this Annual Report on Form
	10-K, you should consider the following important factors that could affect our actual future results, including, but not limited
	to, our product development programs, contract revenues, expenses, net losses, and earnings per share.
</FONT>
<FONT STYLE="FONT-WEIGHT: NORMAL">
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<I>
	&nbsp;
</I>
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	We have a history of losses and
	anticipate future losses.
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We have
	incurred net losses in each year since our inception in December&nbsp;1992, including a net loss of&thinsp;$6.5 million for the
	year ended December&nbsp;31, 2015. As of December&nbsp;31, 2015, we had an accumulated deficit of approximately $284.8 million.
	We are unsure if or when we will become profitable. The size of our net losses will depend, in part, on our revenues and our expenses.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 24; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage25"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We have
	derived primary all of our revenues from payments from collaborations with corporations and government entities and expect to do
	so for the foreseeable future. It may be years, if ever, before we will recognize revenue from product candidate sales or royalties.
	While we have taken efforts to control costs throughout 2015, a large portion of our expenses are fixed, including expenses related
	to facilities, equipment and personnel, and our ability to continue to meaningfully reduce costs is limited. In addition, we expect
	to continue to spend significant amounts to fund research and development to advance our programs and to enhance our core technologies.
	As a result of our operating expenses, we will need to generate significant additional revenue to achieve profitability. Even if
	we do achieve profitability, it may not be sustainable.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
<I>
	We are a biopharmaceutical
	company deploying unproven technologies, and we may never be able to develop, obtain regulatory approval of, or market any of our
	product candidates.
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Gene-based
	products are new and rapidly evolving medical approaches, which have not been shown to be effective on a widespread basis. Only
	a limited number of gene-based products have been successfully developed and commercialized to date. In addition, no gene therapy
	product has received regulatory approval in the U.S. None of our product candidates has been approved for sale in the U.S. or
	elsewhere. Gene-based products may be susceptible to various risks, including undesirable and unintended side effects from genes
	or the delivery systems, unintended immune responses, inadequate therapeutic efficacy, or other characteristics that may prevent
	or limit their approval or commercial use. Successful products require significant development and investment, including a lengthy
	and uncertain period of testing to show their safety and effectiveness before their regulatory approval or commercialization.
	Other than our limited conditional approval with respect to our FMD vaccine, we have not proven our ability to develop,
	obtain regulatory approval of, or commercialize gene-based medicines or vaccines.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	If we or our collaborators fail
	to adequately show the safety and efficacy of our product candidates, we will not be able to obtain FDA approval of our product
	candidates.
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We face
	the risk of failure involved in developing therapies based on new technologies and the difficulties generally associated with drug
	development. CGF166 is the only product candidate that we and our collaborators currently have in clinical trials. Novartis initiated
	dosing in a Phase 1/2 clinical trial of CGF166 in October&nbsp;2014. On January 8, 2016, we were notified by Novartis that enrollment
	in the clinical trial had been paused, based on a review of data by the trial&rsquo;s Data Safety Monitoring Board (DSMB) in accordance
	with criteria in the trial protocol. Novartis will continue to collect safety and efficacy data on the nine patients currently
	enrolled in the trial before determining whether to proceed with incremental patients. We are awaiting further guidance from Novartis
	on the status of the trial&rsquo;s enrollment. There can be no certainty regarding when the enrollment may continue, or if it will
	continue.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Significant
	additional research and animal testing, referred to as preclinical testing, will need to be conducted before any of our other product
	candidates currently under active development can advance to clinical trials. It may take us many years to complete preclinical
	testing or trials, and we expect that doing so will be dependent on our ability to enter into collaborations. Drug development
	is an uncertain scientific and medical endeavor, and failure could occur at any stage of development. Acceptable results in early
	testing or trials might not be repeated later. Not all products in preclinical testing or early stage clinical trials will become
	approved products, and historically there is a high rate of attrition for product candidates in preclinical and clinical trials
	due to scientific feasibility, safety, efficacy, changing standards of medical care and other variables. Before an application
	can be filed with the FDA for product approval, we or our collaborators must show that a particular product candidate is safe and
	effective. Even with respect to product candidates that advance to clinical trials, we or our collaborators must demonstrate the
	safety and efficacy of those product candidates before FDA approval can be secured. The failure to adequately show the safety and
	effectiveness of our product candidates would prevent FDA approval of our products. Any one of our product candidates could fail
	at any time, as clinical development of drug candidates presents numerous unpredictable and significant risks and is very uncertain
	at all times prior to regulatory approval by the FDA or health authorities in other major markets.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 25; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage26"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Because regulatory approval must
	be obtained to market our products, we cannot predict whether or when our products will be commercialized; failure to comply with
	applicable regulations can also harm our business and operations.
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Biologic
	products are subject to stringent regulation by a wide range of governmental authorities. We cannot predict whether we or our collaborators
	will obtain regulatory approval for any of our products. No one can market a biologic product in the U.S. until it has completed
	rigorous preclinical testing, clinical trials, and an extensive regulatory approval process implemented by the FDA. To date, the
	FDA has not approved a gene therapy product for sale in the U.S. Satisfaction of regulatory requirements typically takes many years,
	is dependent upon the type, complexity, and novelty of the product, and requires the expenditure of substantial resources. Of particular
	significance are the requirements covering research and development, testing, manufacturing, quality control, labeling, and promotion
	of drugs for human use.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Before
	commencing clinical trials, we or our collaborators must submit an IND application to the FDA and wait for the IND to become effective
	30 days following its receipt by the FDA. Even after an IND becomes effective, however, a clinical trial is subject to continuing
	oversight by an Institutional Review Board (IRB) and the FDA, and in some cases by a DSMB or Data Monitoring Committee (DMC).
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Clinical trials are also subject to:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Good clinical practices (GCP) regulations, which include a requirement
	for each subject&rsquo;s informed consent; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Potential suspension or termination by the company conducting
	the clinical trial, the IRB, or the FDA at any time if, among other reasons, it is believed that the subjects participating in
	these trials are being exposed to unacceptable health risks or if the FDA finds deficiencies in the IND or the conduct of the trials.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Delays
	or rejections in the regulatory approval process may be encountered because of additional government regulation from future legislation
	or administrative action or changes in FDA policy during the period of product development, clinical trials, or FDA regulatory
	review.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Failure
	to comply with applicable FDA or other regulatory requirements may result in criminal prosecution, civil penalties, recall or seizure
	of products, total or partial suspension of production, or injunction, as well as other regulatory action against our product candidates
	or us. If regulatory approval of a product is granted, this approval will be limited to those disease indications for which the
	product has been shown through clinical trials to be safe and effective. Even if approved, a product may not be approved for the
	indications that are necessary or desirable for successful commercialization, or the FDA may impose restrictions on distribution
	of the product that may materially impact our operations. The FDA also strictly regulates promotion and labeling after approval.
	Outside the U.S., the ability to market a product is also contingent upon receiving clearances from the appropriate regulatory
	authorities. This non-U.S. regulatory approval process includes risks similar to those associated with FDA clearance described
	above and is subject to the independent judgments, policies, priorities and decisions of the applicable regulatory authorities,
	which may differ from those of the FDA.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	We or our collaborators may experience
	delays in conducting our clinical trials.
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Clinical
	trials, including the Phase 1/2 clinical trial of CGF166, may be delayed or prematurely terminated by many factors, including:
	(i) limited number of, and competition for, suitable patients for the particular clinical trial; (ii) slower than expected rate
	of patient recruitment and enrollment; (iii) failure of patients to complete the trial; (iv) inability to obtain sufficient quantities
	of acceptable materials for use in clinical trials; (v) delay or failure in reaching agreement on contract terms with prospective
	study sites or other third-party vendors who are supporting our clinical trials; (vi) inability to reach agreement with the FDA
	on a trial design that we are able to execute; (vii) difficulty in adequately following up with patients after treatment; and (viii)
	changes in laws, regulations, regulatory policy or clinical practices. Our ability or the ability of our collaborators to enroll
	appropriate patients for any clinical trials for our product candidates also may be adversely affected by trials being conducted
	by our competitors for similar disease indications. The failure of any clinical trials to meet applicable regulatory standards,
	or the standards of the relevant reviewing bodies could cause such trials to be delayed, suspended or terminated, which could further
	delay the development of any of our product candidates. Any such delays increase our product development costs, with the possibility
	that we could be required to raise additional funds. Delays in one clinical trial also can adversely affect our ability and the
	ability of our collaborators to launch clinical trials for similar or different indications. Consequently, if such delays are significant
	they could negatively affect our financial results and the commercial prospects for our products.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 26; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	26
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage27"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Additionally,
	clinical trials may be suspended or terminated at any time by the FDA, an IRB, a DSMB or DMC, other regulatory authorities, or
	by us for a variety of reasons, including safety. In January 2016, Novartis paused enrollment in the clinical trial of CGF166,
	based on a review of data by the trial&rsquo;s DSMB in accordance with criteria in the trial protocol. Novartis will continue to
	collect safety and efficacy data on the nine patients currently enrolled in the trial before determining whether to proceed with
	incremental patients. We are awaiting further guidance from Novartis on the status of the trial&rsquo;s enrollment. There can be
	no certainty regarding when enrollment may continue, or if it will continue. Any failure or significant delay in completing clinical
	trials for our product candidates could harm our financial results and commercial prospects for our product candidates.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Any clinical
	trial may fail to produce results satisfactory to the FDA. Preclinical and clinical data can be interpreted in different ways,
	and the FDA may not agree with our interpretations, which could delay, limit or prevent regulatory approval. Negative or inconclusive
	results or adverse medical events during a clinical trial could cause a trial to be delayed or repeated or a program to be terminated.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	We do not currently have any late
	stage clinical trials in our therapeutic product or vaccine development programs and, therefore, we do not have any near-term prospects
	of generating revenues from the commercial sale of our therapeutic or vaccine products.
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We do
	not currently have any therapeutic products or vaccines in late stage clinical programs, and the one product of ours that has received
	some approval is our FMD vaccine, on which a conditional license was issued that was applicable in certain emergency or similar
	situations. Accordingly, we do not have any near-term prospects of generating revenues from the commercial sale of our product
	candidates in our therapeutic product or vaccine programs. In October&nbsp;2014 Novartis initiated dosing in a Phase 1/2 clinical
	trial of CGF166. In January 2016, Novartis paused enrollment in the clinical trial, based on a review of data by the trial&rsquo;s
	DSMB in accordance with criteria in the trial protocol. Novartis will continue to collect safety and efficacy data on the nine
	patients currently enrolled in the trial before determining whether to proceed with incremental patients. We are awaiting further
	guidance from Novartis on the status of the trial&rsquo;s enrollment. There can be no certainty regarding when the enrollment may
	continue, or if it will continue. If enrollment continues, there can be no assurance that CGF166 will successfully complete that
	trial, much less enter or successfully complete any other clinical trial. There also can be no assurance that any of our other
	therapeutic products or our vaccines will enter or successfully complete the clinical trials required for commercialization.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	In 2013, our Board of Directors
	adopted a new operating strategy, and we do not know if it will be successful.
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In 2013,
	our Board of Directors approved an operating strategy focused on working with leading companies and organizations such as Novartis and the U.S. government to leverage our proprietary gene-delivery technologies to address the prevention and treatment
	of significant health concerns. This strategy includes working with Novartis to facilitate the development of first-in-class products
	for the treatment of hearing and balance disorders, developing a sustainable revenue base by licensing rights to our proprietary
	vector and cell line technologies to additional companies and organizations, licensing our preclinical vaccine candidates for the
	prevention of RSV and the treatment of HSV-2 infection, and minimizing our cash burn by operating our business in a cost-efficient
	manner. This operating strategy was adopted after our Board of Directors approved and then determined to withdraw a Plan of Complete
	Liquidation and Dissolution of the Company (the Plan of Dissolution). This operating strategy may not be successful, and is largely
	dependent on the success of our collaboration agreement with Novartis, of which there can be no assurance, and our ability to enter
	into additional collaborations, which we have only been able to do to a limited extent. Furthermore, our ability to execute on
	our operating strategy may also be affected by our having approved and then withdrawn the Plan of Dissolution. For example, potential
	licensees or other collaborators may be reluctant to enter into arrangements with us on terms that are acceptable to us, or at
	all, because of any concerns regarding our long-term stability and plans raised by our adoption and then abandonment of the Plan
	of Dissolution. Accordingly, we may not be able to successfully execute our operating strategy.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<!-- FIELD: PAGE; SEQUENCE: 27; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	27
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage28"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	A central aspect of our business
	strategy is to enter into collaborations with other companies to develop, obtain regulatory approval of, and commercialize our
	potential products, and if we are unable to find collaborators or sustain existing relationships, we may not be able to generate
	revenue and advance our products.
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	A central
	aspect of our business strategy is to enter into collaborations to support the development of our products. Our lead program, in
	the field of regenerative medicine and licensed to Novartis, is for the development of novel treatments for hearing loss and balance
	disorders. In addition to this program, we intend to license rights to our proprietary vector and cell line technologies to additional
	companies and organizations and license our preclinical vaccine candidates for the prevention of RSV and the treatment of HSV-2
	infection. There can be no assurance that we will be able to enter into licensing and other collaboration agreements on terms that
	are acceptable to us, or at all. If we are not able to enter into and sustain license or other collaboration agreements, we would
	not be able to develop a sustainable revenue base, and we would need to raise additional funds for the development and commercialization
	of our product candidates and technologies and develop additional capabilities in testing, manufacturing, marketing and sales,
	among other areas. If we are not able to enter into successful collaborations or obtain additional funds through other means, we
	would have to delay, curtail or abandon the development and commercialization of certain product candidates and technologies.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	We intend to continue to seek support
	for our government funded contracts and collaborations for the development of new vaccines, but our existing agreements are subject
	to termination and uncertain future funding and there is no certainty that we will be able to enter into new agreements.
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In addition
	to corporate collaborations, we have historically entered into agreements with U.S. government agencies, such as the National Institute
	of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), the U.S. Department of Homeland Security
	(DHS), the U.S. Department of Agriculture (USDA) and the U.S. Naval Medical Research Center (NMRC) to support our vaccine research.
	These and similar agreements have historically accounted for a substantial portion of our revenues, and we intend to continue entering
	into these agreements in the future. Our business strategy is partially dependent on collaboration agreements with U.S. government
	agencies and on the ability of these government agencies to perform under these agreements, which performance depends on adequate
	continued funding of the agencies and their programs.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We have
	no control over the resources and funding government agencies may devote to any collaboration agreements with us, which may be
	subject to annual renewal and which generally may be terminated by the government agencies at any time. Any significant reductions
	in the funding of U.S. government agencies or in the funding areas targeted by our business could materially and adversely affect
	our business, results of operations, and financial condition. If we were to fail to satisfy our contractual obligations to deliver
	in the manner required by a collaboration agreement with a U.S. government agency, the applicable Federal Acquisition Regulations
	allow the agency to cancel the agreement in whole or in part, and we may be required to perform corrective actions, including but
	not limited to delivering to the government any uncompleted or partially completed work. The performance of these corrective actions
	could have a material adverse impact on our financial results in the period or periods affected. Government agencies may fail to
	perform their responsibilities under these agreements, which could materially impact our financial results.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In addition,
	our contract-related costs and fees, including allocated indirect costs, are subject to audits and adjustments by negotiation between
	us and the U.S. government. As part of the audit process, the government audit agency verifies that all charges made by a contractor
	against a contract are legitimate and appropriate. Audits may result in recalculation of contract revenues and non-reimbursement
	of some contract costs and fees. Any audits of our contract related costs and fees could result in material adjustments to our
	revenues. In addition, U.S. government contracts are conditioned upon the continuing availability of Congressional appropriations.
	Congress usually appropriates funds on a fiscal year basis even though contract performance may take several years. Consequently,
	at the outset of a major program, the contract is usually incrementally funded and additional funds are normally committed to the
	contract by the procuring agency as appropriations are made by Congress for future fiscal years. Any failure of such agencies to
	continue to fund such contracts could have a material adverse effect on our business, results of operations, and financial condition.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We apply
	for and have received funding from government agencies under Small Business Technology Transfer (STTR) and Small Business Innovation
	Research (SBIR) grants. Eligibility of public companies to receive such grants is based on size and ownership criteria that are
	under review by the Small Business Administration (SBA). As a result, our eligibility may change in the future and additional funding
	from this source may not be available.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 28; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	28
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage29"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	We depend, and anticipate depending
	further, on corporate collaborators for the development of our product candidates.
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	When
	we sign a collaboration agreement, license agreement or similar agreement with a collaborator to develop a product candidate, we
	will generally expect the collaborator to further the development of the product candidate, which could include the design and
	conduct of clinical trials, the preparation and filing of documents necessary to obtain regulatory approval, and the manufacturing,
	sale, marketing and other commercialization of the product if it obtains regulatory approval. We may also grant the collaborator
	certain rights. For example, under the terms of our collaboration agreement with Novartis, we granted Novartis certain exclusive,
	worldwide rights in specified intellectual property related to our atonal gene program and atonal adenovectors, as well as non-exclusive,
	world-wide rights to certain other intellectual property related to our hearing loss and balance disorders program and our adenovector
	platform related to the atonal gene. Novartis has the right to develop and commercialize any products related to the licensed intellectual
	property. Our dependence on a corporate collaborator, such as Novartis, subjects us to a number of risks, including that:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We may not be able to control the amount and timing of resources
	that the collaborator devotes to the development or commercialization of product candidates or to their marketing and distribution;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The collaborator may not be successful in its efforts to obtain
	regulatory approvals in a timely manner, or at all;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The collaborator may not properly maintain or defend our intellectual
	property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate
	our proprietary information or expose us to potential litigation;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The collaborator may delay clinical trials, provide insufficient
	funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials
	or require a new formulation of a product candidate for clinical testing;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Changes in the collaborator&rsquo;s business strategy may also
	adversely affect its willingness or ability to complete its obligations under any arrangement;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Our agreement with the collaborator may fail to provide us with
	significant protection, or may not be effectively enforced, if a collaborator fails to perform;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The collaboration may be terminated or allowed to expire, which
	would delay the development and may increase the cost of developing our product candidates;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The collaborator could have the ability to unilaterally terminate
	agreements, or have extension or renewal rights, in instances that we believe are not commercially reasonable or consistent with
	our current business strategy; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The collaborator may not be able to pay us as expected.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Given these risks, the success of our current
	and future collaborations is highly unpredictable and can have a substantial negative or positive impact on our business. If our
	collaborations fail, our product development or commercialization of product candidates could be delayed or cancelled, which would
	negatively impact our business, results of operations and financial condition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Collaborations might produce conflicts
	that could delay or prevent the development or commercialization of our potential product candidates and negatively impact our
	business and financial condition.
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	An important
	part of our strategy involves conducting multiple product development programs. We may pursue opportunities in fields that conflict
	with those of our collaborators. In addition, disagreements with our collaborators could develop over rights to our intellectual
	property or rights to technology developed with our collaborators. The resolution of such conflicts and disagreements may affect
	ownership of intellectual property to which we believe we are entitled. In addition, any disagreement or conflict with our collaborators
	could reduce our ability to obtain future collaboration agreements and negatively impact our relationship with existing collaborators.
	Such a conflict or disagreement could also lead to delays or termination of collaborative research, development, regulatory approval,
	or commercialization of various products or could require or result in litigation or arbitration, which would be time consuming,
	expensive, lead to a diversion of management attention and resources and could have a significant negative impact on our business,
	financial condition, and results of operations.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 29; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	29
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage30"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Our collaboration agreements may
	prohibit us from conducting research in areas that may compete with our collaboration products, while our collaborators may not
	be limited to the same extent. This could negatively affect our ability to develop products and, ultimately, prevent us from achieving
	a continuing source of revenues.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We anticipate
	some of our corporate or academic collaborators will be conducting multiple product development efforts within each disease area
	that is the subject of their collaborations with us. In certain circumstances we have agreed not to conduct independently, or with
	any third party, certain research and development activities that are competitive with the research and development activities
	conducted under our collaborations. Therefore, our collaborations may limit the areas of research and development we may pursue
	alone or with others. Some of our collaborators, however, may develop, either alone or with others, products in related fields
	that are competitive with the products or potential products that are the subject of their collaborations with us. In addition,
	competing products, either developed by the collaborators or to which the collaborators have rights, may result in their withdrawing
	support for our product candidates.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Agreements with government agencies
	may lead to claims against us under the Federal False Claims Act, and these claims could result in substantial fines and other
	penalties.
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The biopharmaceutical
	industry is, and in recent years has been, under heightened scrutiny as the subject of government investigations and enforcement
	actions. Our agreements with U.S. government agencies or any arrangement that implicates the payment of government funds may be
	subject to substantial financial penalties under the Federal Civil Monetary Penalties Act and the federal False Claims Act.
	Under the False Claims Act&rsquo;s &ldquo;whistleblower&rdquo; provisions, private enforcement of fraud claims against businesses
	on behalf of the U.S. government has increased due in part to amendments to the False Claims Act that encourage private individuals
	to sue on behalf of the government. These whistleblower suits, known as qui tam actions, may be filed by private individuals, including
	present and former employees. The federal False Claims Act provides for treble damages and civil penalties of up to $11,000
	per false claim. If our operations are found to be in violation of any of these laws, or any other governmental regulations that
	apply to us, we may be subject to penalties, damages, fines, exclusion from federal healthcare programs like Medicare and Medicaid,
	and the curtailment or restructuring of our operations. Any penalties, damages, fines, exclusions, curtailment or restructuring
	of our operations could adversely affect our ability to operate our business and our financial results.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	If successful large-scale manufacturing
	of gene-based medicines is not possible, we or our collaborators may be unable to manufacture enough of our product candidates
	to achieve regulatory approval or market our products.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Few companies
	to date have demonstrated successful large-scale manufacturing of gene-based medicines, including those that have had significantly
	more resources than we do and it is anticipated that significant challenges will be faced in the scale-up of our manufacturing
	process for commercial production. There are a limited number of contract manufacturers qualified to perform large-scale manufacturing
	of gene-based medicines. We or our collaborators may be unable to manufacture commercial-scale quantities of gene-base medicines
	or receive appropriate government approvals on a timely basis or at all. Failure to successfully manufacture or obtain appropriate
	government approvals on a timely basis or at all would prevent us from achieving our business objectives.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	If regulatory approvals are not
	obtained for a manufacturing facility for our products, we may experience delays, be unable to meet demand, and may lose potential
	revenues.
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Completion
	of clinical trials for and commercialization of our product candidates require access to, or development of, facilities to manufacture
	a sufficient supply of our product candidates. We have limited experience manufacturing any of our gene-based products in the volumes
	that will be necessary to support large-scale clinical trials or commercial sales, and we expect that we will rely on our collaborators
	for manufacturing capabilities. Before we or our collaborators can begin commercial manufacturing of any of our product candidates,
	we or our collaborators must obtain regulatory approval of the manufacturing facility and process. Manufacturing of our proposed
	products must comply with the FDA&rsquo;s current Good Manufacturing Practices (cGMP) requirements and similar non-U.S. regulatory
	requirements. The cGMP requirements govern, among other things, personnel, buildings and facilities, equipment, control of components
	and drug product containers and closures, production and process controls, packaging and labeling controls, holding and distribution,
	laboratory controls and records and reports. Among other things, complying with cGMP and comparable non-U.S. regulatory requirements
	will require us to expend time, money and effort in production, record keeping, and quality control to ensure the product meets
	applicable specifications and other requirements. We or our collaborators must also pass a preapproval inspection before FDA approval.
	Significant capital will likely need to be expended on the development of manufacturing capacity for a product candidate even before
	we know if the FDA will approve the product for commercialization. Furthermore, if we or our collaborators materially fail to comply
	with these requirements, our product candidates likely would not be approved. If we or our collaborators fail to comply with these
	requirements after approval, we would be subject to possible regulatory action (including warning letters, restrictions on the
	product, product recalls, suspension or withdrawal of approval, seizures, injunctions, civil fines, and criminal sanctions), and
	we may be limited in the jurisdictions in which we are permitted to sell our products. The FDA and non-U.S. regulatory authorities
	generally have the authority to perform unannounced periodic inspections of manufacturing facilities to ensure compliance with
	cGMP and non-U.S. regulatory requirements.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 30; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	30
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage31"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	We rely on a limited number of
	suppliers for some of our manufacturing materials. Any problems experienced by any of these suppliers could negatively impact our
	operations.
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We rely
	on third-party suppliers and vendors for some of the materials used in the manufacture of our product candidates. Some of these
	materials are available from only one supplier or vendor. For supply of early clinical trial materials, we rely on one supplier,
	Thermo Fischer Scientific Corporation, for its cell culture medium and another supplier, Lonza Walkersville, Inc., for custom
	buffers. The cell culture medium is used to grow the cells within which our product candidates are produced. We do not currently
	have supply agreements with any of our suppliers. Any significant problem experienced by one of our suppliers could result
	in a delay or interruption in the supply of materials to us until such supplier resolves the problem or an alternative source
	of supply is located. We have limited experience with alternative sources of raw materials. Any delay or interruption would likely
	lead to a delay or interruption of manufacturing operations, which could negatively affect our operations.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	We face substantial competition
	from other companies and research institutions that are developing products to treat the same diseases that our product candidates
	target, and we may not be able to compete successfully.
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We compete
	with pharmaceutical and biotechnology companies pursuing other forms of treatment for the health concerns our product candidates
	target. We may also face competition from companies that may develop competing technology internally or acquire it from the government,
	universities or other research institutions. As these companies develop their technologies, they may develop proprietary positions,
	which may prevent or limit our product commercialization efforts.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Some
	of our competitors are established companies with greater financial and other resources than ours. Our competitors may succeed
	in:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Identifying important genes or delivery mechanisms before we
	do;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Developing products or product candidates earlier than we do;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Forming collaborations before we do or precluding us from forming
	collaborations with others;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Obtaining approvals from the FDA or other regulatory agencies,
	for such products more rapidly than we do;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Developing and validating manufacturing processes more rapidly
	than we do;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Obtaining patent protection to other intellectual property rights
	that would limit or preclude our ability to use our technologies or develop products; or
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Developing products that are safer or more effective than those
	we develop or propose to develop.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	While
	we seek to expand our technological capabilities to remain competitive, research and development by others may render our technology
	or product candidates obsolete or noncompetitive or result in treatments or cures superior to any therapy developed by us.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 31; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	31
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage32"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In addition,
	with the March&nbsp;2010 enactment of the Biologics Price Competition and Innovation Act (BPCIA), our products, if approved, may
	subsequently face competition from biosimilar products that are approved via an abbreviated process on the basis of a showing that
	the product is highly similar to our approved product. The BPCIA provides periods of exclusivity during which abbreviated applications
	may not be submitted to, or approved by, the FDA, but the statute then allows approval by an abbreviated pathway and, if certain
	standards are met, a finding by the FDA that the biosimilar product is interchangeable with the reference product. A similar abbreviated
	approval process for biosimilars (but without the possibility of an interchangeability determination) is available in Europe. If
	competitors are able to obtain marketing approval for biosimilars under an abbreviated regulatory approval process in the U.S.
	or Europe, our products may become subject to additional competition with the attendant pricing pressure. We also could face or
	be forced to bring litigation with respect to the validity or scope of patents relating to our products.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	If we are unable to adequately
	protect our intellectual property rights, our competitors may be able to take advantage of our research and development efforts
	to compete with us.
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Our commercial
	success will depend, in part, on obtaining patent protection for our products and other technologies and successfully defending
	these patents against third party challenges. Our patent position, like that of other biotechnology firms, is highly uncertain
	and involves complex legal and factual questions. The laws, rules, and regulations affecting biotechnology patent protection in
	the U.S. and other countries are uncertain and are currently undergoing review and revision. Changes in, or different interpretations
	of, patent laws in the U.S. and other countries might allow others to use our discoveries or to develop and commercialize our products
	without any compensation to us.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Our ability
	to develop and protect a proprietary position based on biotechnological innovations and technologies involving genes and gene delivery
	systems, methods of use, production, formulations, and the like is particularly uncertain. The U.S. Patent and Trademark Office,
	as well as patent offices in other countries, have often required that patent applications concerning biotechnology-related inventions
	be limited or narrowed substantially. Our disclosures in our patent applications may not be sufficient to meet the statutory requirements
	for patentability in all cases. In addition, other companies or institutions possess issued patents and have filed and will file
	patent applications that cover or attempt to cover genes, vectors, cell lines, and methods of making and using gene therapy products
	that are the same as or similar to the subject matter of our patent applications. For example, although we have pending patent
	applications pertaining to particular adenovectors that cannot reproduce themselves and adenovectors modified to alter cell binding
	characteristics, we are aware of issued patents and pending patent applications of other companies and institutions relating to
	the same subject matter. Patents and patent applications of third parties may have priority over our issued patents and our pending
	or yet to be filed patent applications. Proceedings before the U.S. Patent and Trademark Office and other patent offices to determine
	who properly lays claim to inventions are costly and time consuming, and we may not win in any such proceedings.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The issued
	patents we already have or may obtain in the future may not provide commercially meaningful protection against competitors. Other
	companies or institutions may challenge our or our collaborators&rsquo; patents in the U.S. and in other countries. In the event
	a company, institution or researcher infringes upon our or our collaborators&rsquo; patent rights, enforcing these rights may be
	difficult, expensive and time consuming, with no guarantee that our or our collaborators&rsquo; patent rights will be upheld. Others
	may be able to design around these patents or develop unique products providing effects similar to our products. In addition, our
	competitors may legally challenge our patents, and they may be considered invalid. For example, we are also aware of issued patents
	and pending patent applications of third parties relating to aspects of production, purification, quality assessment, and formulation
	technology. It could be alleged that our production, purification, quality assessment, and formulation technology conflict with
	such existing or future patents.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Various
	components used in developing gene therapy products, such as particular genes, vectors, promoters, cell lines, and construction
	methods, used by others and by us, are available to the public. As a result, we are unable to obtain patent protection with respect
	to such components, and third parties can freely use such components. Third parties may develop products using such components
	that compete with our potential products. Also, with respect to some of our patentable inventions, we or our collaborators have
	decided not to pursue patent protection outside the U.S. Accordingly, our competitors could develop, and receive non-U.S. patent
	protection for, gene therapies or technologies for which we or our collaborators have or are seeking U.S. patent protection. Our
	competitors may be free to use these gene therapies or technologies outside the U.S. in the absence of patent protection.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We
	also rely to a limited extent on trade secrets to protect our technology. However, trade secrets are difficult to protect. While
	we have entered into confidentiality agreements with employees and collaborators, we may not be able to prevent the disclosure
	or use of our trade secrets. In addition, other companies or institutions may independently develop substantially equivalent information
	and techniques.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 32; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	32
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage33"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	If our technologies and potential
	products conflict with intellectual property rights of competitors, universities, or others, then we may be prevented from licensing
	those technologies, developing those product candidates or both.
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Other
	companies and institutions have issued patents and have filed or will file patent applications that may issue into patents that
	cover or attempt to cover genes, vectors, cell lines, and methods of making and using gene and gene-based therapy products used
	in or similar to our product candidates and technologies. We also are aware of other issued patents and pending patent applications
	that relate to various aspects of our manufacture of our product candidates and systems, and it could be alleged that our manufacture
	of these product candidates or licensure of those technologies conflicts with these patents. We have not conducted freedom-to-use
	patent searches on all aspects of our technologies, product candidates or potential product candidates, and we may be unaware of
	relevant patents and patent applications of third parties. In addition, the freedom-to-use patent searches that have been conducted
	may not have identified all relevant issued patents or pending patent applications that could issue into patents, particularly
	in view of the characterizations of the subject matter of issued patents and pending patent applications, as well as the fact that
	pending patent applications can be maintained in secrecy for a period of time and, in some circumstances, until issuance as patents.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	An issued
	patent gives rise to a rebuttable presumption of validity under U.S. law and under the laws of some other countries. The holder
	of a patent to which we or our collaborators do not hold a license could bring legal actions against our collaborators or us for
	damages or to stop us or our collaborators from using the affected technology, which could limit or preclude our ability to license
	our technologies or to develop and commercialize our product candidates. If any of our potential products are found to infringe
	a patent of a competitor or third party, we or our collaborators may be required to pay damages and to either obtain a license
	in order to continue to develop and commercialize the potential products or, at the discretion of the competitor or third party,
	to stop development and commercialization of the potential products. Similarly, if any of our out-licensed technologies are found
	to infringe a patent of a competitor or third party, we or our collaborators may be required to pay damages and to either obtain
	a license in order to continue to utilize the technologies or, at the discretion of the competitor or third party, to stop utilizing
	the technologies. Since we have concentrated our resources on licensing certain of our technologies and developing only a limited
	number of products, the inability to license one of our technologies or to market one of our products would disproportionately
	affect us as opposed to a competing company with many products in development.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We believe
	there will be significant litigation in our industry regarding intellectual property rights. Many of our competitors have expended
	and are continuing to expend significant amounts of time, money and management resources on intellectual property litigation. If
	we become involved in litigation, it could consume a substantial portion of our resources and could adversely affect our business,
	financial condition and results of operations, even if we ultimately are successful in such litigation.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	If we lose our rights to use intellectual
	property we license from others, or those rights are not enforceable, then our ability to develop and commercialize our product
	candidates will be harmed.
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We rely,
	in part, on licenses to use some technologies material to our business. For example, to create our product candidates we combine
	our adenovectors with genes intended to produce therapeutic proteins. In most instances we do not own the patents or patent applications
	that cover these genes and certain methods of use thereof which underlie these licenses. For these genes, we do not control the
	enforcement of the patents. We rely upon our licensors to properly prosecute and file those patent applications and defend and
	enforce any issued patents.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	While
	many of the licenses under which we have rights provide us with exclusive rights in specified fields, the scope of our rights under
	these and other licenses may be subject to dispute by our licensors or third parties. In addition, our rights to use these technologies
	and practice the inventions claimed in the licensed patents and patent applications are subject to our licensors abiding by the
	terms of those licenses and not terminating them. Any of our licenses may be terminated by the licensor if we are in breach of
	a term or condition of the license agreement or in certain other circumstances. In addition, some of our licenses are contingent
	upon our achievement of specific development milestones.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<!-- FIELD: PAGE; SEQUENCE: 33; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	33
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage34"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Legal proceedings to obtain, enforce,
	and defend patents, and litigation of third-party claims of intellectual property infringement could require us to spend money
	and could impair our operations.
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Our success
	will depend, in part, on our ability to obtain patent protection for our products and processes, both in the U.S. and in other
	countries. The patent positions of biotechnology and pharmaceutical companies, however, can be highly uncertain and can involve
	complex legal and factual questions. Therefore, it is difficult to predict the breadth of claims allowed in the biotechnology and
	pharmaceutical fields.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Protecting
	intellectual property rights can be expensive and time consuming. Litigation may be necessary to enforce patents issued to us or
	to determine the scope and validity of third party proprietary rights. Moreover, if a competitor were to file a patent application
	claiming technology also invented by us, we would have to participate in an interference proceeding before the U.S. Patent and
	Trademark Office to determine the priority of invention. We may be drawn into interferences with third parties or may have to provoke
	interferences ourselves to challenge third-party patent rights to allow us or our licensees to commercialize products based on
	our technologies. Litigation could result in substantial costs and diversion of management efforts regardless of the results of
	the litigation. An unfavorable result in litigation could subject us to significant liabilities to third parties, require disputed
	rights to be licensed, or require us to cease using some technologies.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Our products
	and processes may infringe, or be found to infringe, patents not owned or controlled by us. Patents held by others may require
	us to alter our products or processes, obtain licenses or stop activities. If relevant claims of third-party patents are upheld
	as valid and enforceable, we could be prevented from practicing the subject matter claimed in the patent. In addition, we may be
	required to obtain licenses, redesign our products or processes to avoid infringement or pay money damages. As a result, our business
	may suffer if we are not able to obtain licenses at all or on commercially reasonable terms to us or we are required to redesign
	our products or processes to avoid infringement.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	We are exposed to potential product
	liability claims.
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Our business
	exposes us to potential product liability risks inherent in the clinical testing and manufacturing and marketing of pharmaceutical
	products, and we may not be able to avoid significant product liability exposure. A product liability claim or recall could be
	detrimental to our business. Although we currently maintain product liability and clinical trial insurance, our present product
	liability and clinical trial insurance may be inadequate. Any successful product liability claim may prevent us from obtaining
	adequate product liability and clinical trial insurance in the future on commercially desirable or reasonable terms. In addition,
	product liability and clinical trial coverage may cease to be available in sufficient amounts or at an acceptable cost. An inability
	to obtain sufficient insurance coverage at an acceptable cost or otherwise to protect against potential product liability claims
	could prevent or inhibit the commercialization of our products. A successful product liability claim could have a material adverse
	effect on our reputation, business, financial condition and results of operations.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Adverse events in the field of
	gene therapy may negatively affect regulatory approval or public perception of our products or product candidates.
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Most
	of our product candidates under development could be broadly described as recombinant DNA therapies. A number of clinical trials
	are being conducted by other biotechnology and pharmaceutical companies involving related therapies, including compounds similar
	to or competitive with, our product candidates. The announcement of adverse results from these clinical trials, such as serious
	adverse events or unexpected side effects attributable to the treatment, or any response by the FDA or other similar regulatory
	authority to such clinical trials, may impede the timing of our clinical trials, delay or prevent us from obtaining regulatory
	approval, impede our ability to secure additional funding, or negatively influence public perception of our product candidates.
	As a result, these conditions could harm our business and results of operations and depress the value of our stock.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The commercial
	success of our product candidates will depend, in part, on public acceptance of the use of gene therapies for the prevention or
	treatment of significant health concerns. Public attitudes may be influenced by claims that gene therapy is unsafe, and gene therapy
	may not gain the acceptance of the public or the medical community. Negative public reaction to gene therapy could result in greater
	government regulation and stricter clinical trial oversight and commercial product labeling requirements of gene therapy products
	and could cause a decrease in the demand for any products we may develop.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 34; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	34
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage35"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Our
	product candidates involve new technologies and therapeutic approaches in the field of gene therapy, which is a new and evolving
	field. As discussed above, no gene therapy product has received regulatory approval in the U.S., and adverse events in this field
	may negatively affect public perception of our product candidates. Even if our product candidates attain regulatory approval, our
	success will depend upon the medical community, patients, and third-party payers accepting gene therapy products in general, and
	our product candidates in particular, as medically useful, cost-effective, and safe. In particular, our success will depend upon
	whether physicians who specialize in the diseases our product candidates target decide to prescribe treatments that involve the
	use of our product candidates in lieu of, or in addition to, existing treatments they are already familiar with and for which greater
	clinical data may be available. Even if the clinical safety and efficacy of our product candidates is established, physicians may
	elect not to recommend our products for a variety of reasons, including the reimbursement policies of government and third-party
	payers. Furthermore, third-party payers, such as health insurance plans, may be reluctant to authorize and pay for new forms of
	treatment they may deem expensive and less proven than existing treatments. Even if gene therapy products, and our product candidates
	in particular, are accepted by the medical community and third-party payers, the public in general, or patients in particular,
	may be uncomfortable with new therapies, including our product candidates, and it could take substantial time for them to accept
	gene therapy products as a viable treatment alternative, if ever. If gene therapy and our product candidates do not gain widespread
	acceptance, we may be unable to generate significant revenues, if any, which would adversely affect our results of operations.
	In addition, even if our product candidates achieve market acceptance, we may not be able to maintain that market acceptance over
	time if new products or technologies are introduced that are more favorably received than our product candidates or that render
	them obsolete.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	We use hazardous biological materials
	in our business; any liability or disputes relating to improper handling, storage or disposal of these materials could be time
	consuming and costly.
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Our research
	and development processes involve the use of hazardous biological materials. Such materials include human and animal cell lines
	and viruses, such as adenoviruses and animals infected with human viruses. Some of the biological material may be novel, including
	viruses with novel properties. We cannot eliminate the risk of accidental contamination or discharge or injury from these materials.
	Federal, state and local laws and regulations govern the use, manufacture, storage, handling and disposal of these materials. We
	could be subject to civil damages in the event of an improper or unauthorized release of, or exposure of individuals to, these
	hazardous materials. In addition, claimants may sue us for injury or contamination that results from our use or the use by third
	parties of these materials, and our liability may exceed our total assets.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Although
	we have general liability insurance, these policies contain exclusions from insurance against claims arising from pollution from
	chemical or radioactive materials. Our collaborators are working with these types of hazardous materials in connection with our
	collaborations. In the event of a lawsuit or investigation, we could be held responsible for any injury we or our collaborators
	cause to persons or property by exposure to, or release of, any hazardous materials. Although we believe we are currently in compliance
	with all applicable environmental and occupational health and safety regulations, compliance with environmental laws and regulations
	may be expensive and current or future environmental regulations may impair our research, development, or production efforts.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Our revenue is primarily derived
	from our collaboration agreements, which can result in significant fluctuation in our revenue from period to period, and our past
	revenue is therefore not necessarily indicative of our future revenue.
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Our
	revenue is primarily derived from our collaboration agreements with corporate partners, institutions, and governmental
	entities under which we may receive grants, milestone payments based on clinical progress, regulatory progress or net sales achievements,
	royalties, manufacturing revenue or payment for our development activities on behalf of third parties. We are particularly dependent
	on our agreement with Novartis, pursuant to which we are facilitating the development of first-in-class products for the treatment
	of hearing and balance disorders. On February&nbsp;11, 2014, Novartis informed us that the third milestone under our agreement
	had been achieved after Novartis filed an IND with the FDA for the clinical development of CGF166, the lead product candidate
	under our collaboration. The IND was deemed effective on February&nbsp;7, 2014, triggering a $2 million milestone payment to us.
	On October&nbsp;28, 2014, the fourth milestone under our agreement with Novartis was achieved after the first patient was dosed
	in the Phase 1/2 clinical trial of CGF166, triggering a $3 million milestone payment to us. Significant variations in the timing
	of receipt of cash payments and our recognition of revenue can result from the timing of clinical, regulatory or sales events
	which result in milestone payments and the timing and success of the commercial launch of new products by our collaboration partners.
	The amount of our revenue derived from collaboration agreements in any given period will depend on a number of unpredictable factors,
	including our ability to find and maintain suitable collaboration partners, the timing of the negotiation and conclusion of collaboration
	agreements with such partners, whether and when we or our collaboration partner achieve clinical, regulatory and sales milestones,
	whether the collaboration is exclusive or whether we can seek other partners, the timing of regulatory approvals in one or more
	major markets and the market introduction of new products or generic versions of the approved product, as well as other factors.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 35; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	35
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage36"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Changes in healthcare law and implementing
	regulations, including those based on recently enacted legislation, as well as changes in healthcare policy, may impact our business
	in ways that we cannot currently predict, and these changes could have a material adverse effect on our business and financial
	condition if we are able to commercialize our candidate products.
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Healthcare
	costs have risen significantly over the past decade. In March&nbsp;2010, President Obama signed the Patient Protection and Affordable
	Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, (collectively, PPACA). This law substantially
	changes the way health care is financed by both governmental and private insurers and significantly impacts the pharmaceutical
	industry. PPACA contains a number of provisions that are expected to impact our business and operations, in some cases in ways
	we cannot currently predict. Changes that may affect our business include those governing enrollment in federal and private healthcare
	programs, increased rebates and taxes on pharmaceutical products, and revised fraud and abuse and enforcement requirements. These
	changes will impact existing government healthcare programs and will result in the development of new programs.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We anticipate
	that if and when we or our collaborators commercialize our products in the U.S., a significant portion of our revenue and the revenue
	from our collaborators from sales of our products will be derived from government payers, including Medicare, Medicaid, and Department
	of Defense (DoD) programs. Reimbursement rates to purchasers of our drugs and our net revenues for sales of drugs used by these
	programs can be altered by legislation or regulation. PPACA and other federal law require rebates on certain drugs utilized under
	Medicare, Medicaid, and DoD programs and require discounts on certain drugs furnished to Medicare beneficiaries. For example, as
	part of PPACA&rsquo;s provisions closing a funding gap that currently exists in the Medicare Part D prescription drug program,
	(commonly known as the &ldquo;donut hole&rdquo;), once we or our collaborators participate in the Medicare program, we or our collaborators
	will be required to provide a 50% discount on branded prescription drugs dispensed to beneficiaries within this donut hole.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	PPACA
	also made changes to the Medicaid drug rebate program, discussed further herein, including changing the definition of AMP, expanding
	rebate liability from fee-for-service Medicaid utilization to include the utilization of Medicaid managed care organizations as
	well, and increasing the minimum rebate from 15.1% to 23.1% of the AMP for most innovator products and from 11% to 13% for non-innovator
	products. We expect that the increased minimum rebate of 23.1% will apply to our products following commercialization, if successful,
	in the U.S. Furthermore, PPACA requires pharmaceutical manufacturers of branded prescription drugs to pay a branded prescription
	drug fee to the federal government beginning in 2011. Each individual pharmaceutical manufacturer pays a prorated share of the
	branded prescription drug fee of&thinsp; $3.0 billion in 2015, based on the dollar value of its branded prescription drug sales
	to certain federal programs identified in the law. We expect that PPACA, as currently enacted or as it may be amended in the future,
	and other healthcare reform measures that may be adopted in the future could have an adverse effect on our industry generally and
	our ability to successfully commercialize our product candidates or could limit or eliminate our spending on development projects.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The effects
	of reforms under PPACA will be shaped significantly by implementing regulations that have yet to be finalized, by difficulties
	in implementation of the new insurance marketplaces and by state government decisions. On February 1, 2016, the Centers for Medicare
	and Medicaid Services (CMS), the federal agency that administers the Medicare and Medicaid programs, issued a final regulation
	to implement the changes to the Medicaid drug rebate program under PPACA. This regulation becomes effective on April 1, 2016. Many
	states have not chosen to expand their Medicaid programs by raising the income limit to 133% of the federal poverty level, as is
	permitted by PPACA. It is unclear whether these states will choose to expand their programs in the future and whether there will
	be more uninsured patients than anticipated when Congress passed PPACA. For each state that does not choose to expand its Medicaid
	program as permitted by PPACA, there will be fewer insured patients overall. In addition, problems with implementation of the websites
	and other administrative services to help people enroll in qualifying insurance coverage may have reduced the number of uninsured
	people who obtain coverage under PPACA. The reduction in the number of insured patients could impact the sales, business and financial
	condition following the commercialization, if successful, of our products in the U.S.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 36; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	36
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage37"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	PPACA
	also expanded the Public Health Service&rsquo;s 340B drug pricing discount program. A pharmaceutical manufacturer must participate
	in the 340B drug pricing program in order for federal funds to be available to pay for the pharmaceutical manufacturer&rsquo;s
	drugs under Medicaid and Medicare Part B. Under this program, the participating pharmaceutical manufacturer agrees to charge statutorily-defined
	covered entities no more than the 340B discounted ceiling price for the pharmaceutical manufacturer&rsquo;s covered outpatient
	drugs. PPACA obligates the Secretary of the Department of Health and Human Services to create regulations and processes to improve
	the integrity of the program and to ensure the agreement that manufacturers must sign to participate in the program obligates a
	manufacturer to offer the ceiling price to covered entities if the manufacturer makes the drug available to any other purchaser
	at any price and to report to the government the ceiling prices for its drugs. In addition, legislation may be introduced that,
	if passed, could further expand the 340B drug pricing program to include additional covered entities or could require participating
	manufacturers to agree to provide 340B discounted pricing on drugs used in the inpatient setting. To the extent that PPACA and
	subsequent legislation, as discussed above, causes the statutory and regulatory definitions of AMP and the Medicaid rebate amount
	to change, these changes also impact the 340B discounted ceiling price.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In addition
	to PPACA, there will continue to be proposals by legislators at both the federal and state levels, regulators and third-party payers
	to keep these costs down while expanding individual healthcare benefits. Certain of these changes could impose limitations on the
	prices we will be able to charge for any product candidates that are approved or the amounts of reimbursement available for these
	products from governmental agencies or third-party payers, or may increase the tax obligations on life sciences companies such
	as ours.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The healthcare
	industry, and thus our business, continues to be subject to extensive federal, state, local and foreign regulation. Some of the
	pertinent laws have not been definitively interpreted by the regulatory authorities or the courts, and their provisions are open
	to a variety of interpretations. In addition, these laws and their interpretations are subject to change. Applicable federal and
	state health care fraud and abuse laws and regulations may affect our ability to operate our business, particularly once third-party
	reimbursement becomes available for one or more of our products. These laws and regulations include, but are not limited to:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL; COLOR: BLACK">
	The federal Anti-Kickback Law, which prohibits,
	among other things, knowingly or willingly offering, paying, soliciting or receiving remuneration, directly or indirectly, in cash
	or in kind, to induce or reward the purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order
	of any health care items or service for which payment may be made, in whole or in part, by federal healthcare programs such as
	Medicare and Medicaid. This statute has been interpreted to apply to arrangements between pharmaceutical companies on one hand
	and prescribers, purchasers and formulary managers on the other. Further, PPACA clarified that liability may be established under
	the federal Anti-Kickback Law without proving actual knowledge of the statute or specific intent to violate it. In addition, PPACA
	amended the Social Security Act to provide that the government may assert that a claim including items or services resulting from
	a violation of the federal Anti-Kickback Law constitutes a false or fraudulent claim for purposes of the federal civil False Claims
	Act. Although there are a number of statutory exemptions and regulatory safe harbors to the federal Anti-Kickback Law protecting
	certain common business arrangements and activities from prosecution or regulatory sanctions, the exemptions and safe harbors are
	drawn narrowly, and practices that involve remuneration to those who prescribe, purchase, or recommend pharmaceutical and biological
	products, including certain discounts, or engaging such individuals as speakers or consultants, may be subject to scrutiny if they
	do not fit squarely within an exemption or safe harbor. Our practices may not in all cases meet all of the criteria for safe harbor
	protection from anti-kickback liability. Moreover, there are no safe harbors for many common practices, such as educational and
	research grants or patient assistance programs.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 37; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	37
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage38"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL; COLOR: BLACK">
	The federal civil False Claims Act, which prohibits,
	among other things, individuals or entities from knowingly presenting, or causing to be presented, a false or fraudulent claim
	for payment of government funds or knowingly making, using or causing to be made or used, a false record or statement material
	to an obligation to pay money to the government or knowingly concealing or knowingly and improperly avoiding, decreasing or concealing
	an obligation to pay money to the federal government. Many healthcare companies have been investigated and have reached substantial
	financial settlements with the federal government under the civil False Claims Act for a variety of alleged improper activities
	including causing false claims to be submitted as a result of the marketing of their products for unapproved and thus non-reimbursable
	uses, inflating prices reported to private price publication services which are used to set drug payment rates under government
	healthcare programs and other interactions with customers including those that may have affected their billing or coding practices
	and submission to the federal government. In addition, PPACA amended federal law to provide that the government may assert that
	a claim including items or services resulting from a violation of the federal Anti-Kickback Law constitutes a false or fraudulent
	claim for purposes of the federal civil False Claims Act. Pharmaceutical and other healthcare companies also are subject to other
	federal false claim laws, including, among others, federal criminal healthcare fraud and false statement statutes that extend to
	non-government health benefit programs.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL; COLOR: BLACK">
	The Health Insurance Portability and Accountability
	Act of 1996 (HIPAA), as amended by the Health Information Technology for Economic and Clinical Health Act, among other things,
	imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements
	in connection with the delivery of or payment for healthcare benefits, items or services, and also imposes obligations with respect
	to safeguarding the privacy, security and transmission of individually identifiable health information.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL; COLOR: BLACK">
	The federal Physician Payment Sunshine Act, being
	implemented as the Open Payments Program, which requires certain pharmaceutical and biological manufacturers to engage in extensive
	tracking of payments or transfers of value to physicians and teaching hospitals and public reporting of the payment data. Pharmaceutical
	and biological manufacturers with products for which payment is available under Medicare, Medicaid or the State Children&rsquo;s
	Health Insurance Program are required to have started tracking such payments on August&nbsp;1, 2013, and must submit a report on
	or before the 90th day of each calendar year disclosing reportable payments made in the previous calendar year.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL; COLOR: BLACK">
	Analogous state laws and regulations, such as state
	anti-kickback and false claims laws, which may apply to items or services reimbursed under Medicaid and other state programs or,
	in several states, regardless of the payer. Some state laws also require pharmaceutical companies to report expenses relating to
	the marketing and promotion of pharmaceutical products and to report gifts and payments to certain health care providers in those
	states. Some of these states also prohibit certain marketing-related activities including the provision of gifts, meals, or other
	items to certain health care providers. In addition, California, Connecticut, Nevada, and Massachusetts require pharmaceutical
	companies to implement compliance programs or marketing codes of conduct.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL; COLOR: BLACK">
	The federal Foreign Corrupt Practices Act of 1997
	and similar anti-bribery laws in other jurisdictions generally prohibit companies and their intermediaries from providing money
	or anything of value to officials of foreign governments, foreign political parties, or international organizations with the intent
	to obtain or retain business or seek a business advantage. Recently, there has been a substantial increase in anti-bribery law
	enforcement activity by U.S. regulators, with more frequent and aggressive investigations and enforcement proceedings by both the
	Department of Justice and the U.S. Securities and Exchange Commission. A determination that our operations or activities are not,
	or were not, in compliance with United States or foreign laws or regulations could result in the imposition of substantial fines,
	interruptions of business, loss of supplier, vendor or other third-party relationships, termination of necessary licenses and permits,
	and other legal or equitable sanctions. Other internal or government investigations or legal or regulatory proceedings, including
	lawsuits brought by private litigants, may also follow.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	If our operations are found to be in violation
	of any of the laws described above or any other governmental regulations that apply to us, we may be subject to significant civil,
	criminal and administrative penalties, damages, fines, imprisonment, exclusion from government-funded healthcare programs like
	Medicare and Medicaid, and the curtailment or restructuring of our operations, any of which could adversely affect our ability
	to operate our business and our financial results. Although compliance programs can mitigate the risk of investigation and prosecution
	for violations of these laws, the risks cannot be entirely eliminated. Any action against us for violation of these laws or regulations,
	even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&rsquo;s
	attention from the operation of our business. Moreover, achieving and sustaining compliance with applicable federal and state privacy,
	security and fraud laws may prove costly.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<!-- FIELD: PAGE; SEQUENCE: 38; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	38
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage39"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	If third party payers do not provide
	coverage or reimbursement for our products, those products will not be widely accepted, which would have a negative impact on our
	business, results of operations and financial conditions.
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Even
	if a product of ours receives regulatory approval, our success will depend, in part, on the extent to which coverage and reimbursement
	will be available from third party payers such as Medicare, Medicaid, other government health programs, private health insurers,
	managed care programs, and other organizations. Third party payers are increasingly challenging the price and cost-effectiveness
	of medical products and services, and this trend is expected to continue. Therefore, significant uncertainty exists as to the pricing
	approvals for, and the coverage or reimbursement status of, newly approved healthcare products. Additional federal or state health
	care legislation may be adopted in the future, any products that we seek to commercialize may not be considered cost-effective,
	and limitations on coverage and the amount of reimbursement for our products could be imposed. Adequate third-party insurance coverage
	may not be available for us to establish and maintain price levels that are sufficient for realization of an appropriate return
	on our investment in product development. Moreover, the existence or threat of cost control measures, including a reduction in
	reimbursement rates could cause potential corporate collaborators to be less willing or able to pursue research and development
	programs related to our product candidates. We cannot be certain that, if and when our products become commercialized, the pertinent
	reimbursement amounts or formulary status for our products will be sufficient to enable us to market and sell our products.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Our business involves animal testing
	and changes in laws, regulations, accepted clinical procedures, or social pressures could restrict our use of animals in testing
	and adversely affect our research and development efforts.
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Many
	of the research and development efforts we sponsor involve the use of laboratory animals. Changes in laws, regulations, or accepted
	clinical procedures may adversely affect these research and development efforts. Social pressures that would restrict the use of
	animals in testing or actions against us or our partners by groups or individuals opposed to testing using animals could also adversely
	affect these research and development efforts. In addition, preclinical animal studies conducted by us or third parties on our
	behalf may be subject to the FDA&rsquo;s Good Laboratory Practices (GLP) regulations and the USDA regulations for certain animal
	species. Failure to comply with applicable regulations could extend or delay clinical trials conducted for our drug candidates.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Our stock price could continue
	to be highly volatile and investors may not be able to resell their shares at or above the price they paid for them.
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The
	market price of our common stock, like that of many other life sciences companies, has been and is likely to continue to be highly
	volatile. For the period January 1 to February 29, 2016, the closing price of our stock price ranged from $0.38 to $1.82.
	The following factors, among others, could have a significant impact on the market price of our common stock:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Progress and results of our preclinical studies and future clinical
	trials or announcements regarding our plans for future studies or trials, or those of our competitors;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Evidence or lack of evidence of the safety or efficacy of our
	potential products or those of our competitors;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Announcement by us or our competitors of technological innovations
	or new products;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Developments concerning our patent or other proprietary rights
	or those of our competitors, including litigation and challenges to our proprietary rights;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Geopolitical developments, natural or man-made disease threats,
	or other events beyond our control;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	U.S. and foreign governmental regulatory actions;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Changes or announcements in reimbursement policies;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Period-to-period fluctuations in our operating results;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Market conditions for life science stocks in general;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Changes in the collective short interest in our stock;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Changes in estimates of our performance by securities analysts;
	and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Our cash balances, need for additional capital, and access to
	capital.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<!-- FIELD: PAGE; SEQUENCE: 39; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	39
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage40"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	We do not intend to pay dividends
	on our common stock for the foreseeable future.
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We do
	not anticipate that we will have any revenues for the foreseeable future and accordingly, we do not anticipate that we will pay
	any dividends for the foreseeable future. Accordingly, any return on an investment in our Company will be realized, if at all,
	only when you sell shares of our common stock.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	We are at risk of securities-related
	litigation due to our expected stock price volatility.
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In the
	past, stockholders have brought securities class action litigation against a company following a decline in the market price of
	its securities. This risk is especially acute for us because life science companies have experienced greater than average stock
	price volatility in recent years and, as a result, have been subject to, on average, a greater number of securities class action
	claims than companies in other industries. We may be the target of securities-related litigation in the future. Securities litigation
	could result in substantial costs, divert our management&rsquo;s attention and resources, and could seriously harm our business.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	We depend on our key technical
	and management personnel to advance our technology and implement our business strategy, and the loss of these personnel could impair
	the development of our products and business.
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We rely,
	and will continue to rely, on our key management and scientific staff, all of whom are employed at will. Our success depends upon
	the ability of our senior management to implement our business strategy. The loss of key personnel could have a material adverse
	effect on our business and results of operations. There is intense competition from other companies, research and academic institutions
	and other organizations for qualified personnel. We may not be able to continue to attract and retain the qualified personnel necessary
	for the development of our business. If we do not succeed in retaining and recruiting necessary personnel or developing this expertise,
	our business could suffer significantly. Furthermore, changes in our senior management may lead to instability for our Company
	which could cause our business to suffer significantly.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	We have implemented anti-takeover
	provisions that could discourage or prevent a takeover, even if an acquisition would be beneficial to our stockholders and may
	prevent attempts by our stockholders to replace or remove our current management.
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Provisions
	of our amended and restated certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more
	difficult for a third party to acquire us, even if doing so would be beneficial to our stockholders. In addition, these provisions
	may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult
	for stockholders to replace members of our Board of Directors. Because our Board of Directors is responsible for appointing the
	members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members
	of our management team. These provisions include:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Establishing a classified board of directors requiring that members
	of the board be elected in different years, which lengthens the time needed to elect a new majority of the board;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Authorizing the issuance of &ldquo;blank check&rdquo; preferred
	stock that could be issued by our Board of Directors to increase the number of outstanding shares or change the balance of voting
	control and thwart a takeover attempt;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Prohibiting cumulative voting in the election of directors, which
	would otherwise allow for less than a majority of stockholders to elect director candidates;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Limiting the ability of stockholders to call special meetings
	of the stockholders;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Prohibiting stockholder action by written consent and requiring
	all stockholder actions to be taken at a meeting of our stockholders; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 18.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9.35PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Establishing 90- to 120-day advance notice requirements for nominations
	for election to the Board of Directors and for proposing matters that can be acted upon by stockholders at stockholder meetings.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<!-- FIELD: PAGE; SEQUENCE: 40; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	40
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage41"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	We have adopted a stockholder rights
	plan that may discourage, delay, or prevent a merger or acquisition that is beneficial to our stockholders.
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In August&nbsp;2011,
	our Board of Directors adopted a stockholder rights plan that may have the effect of discouraging, delaying or preventing a merger
	or acquisition beneficial to our stockholders by diluting the ability of a potential acquirer to acquire us. Pursuant to the terms
	of our plan, when a person or group (except under certain circumstances) acquires 20 percent or more of our outstanding common
	stock or 10 business days after commencement or announcement of a tender or exchange offer for 20 percent or more of our outstanding
	common stock, the rights (except those rights held by the person or group who has acquired or announced an offer to acquire 20
	percent or more of our outstanding common stock) would generally become exercisable for shares of our common stock at a discount.
	Because the potential acquirer&rsquo;s rights would not become exercisable for our shares of common stock at a discount, the potential
	acquirer would suffer substantial dilution and may lose its ability to acquire us. In addition, the existence of the plan itself
	may deter a potential acquirer from acquiring us. As a result, either by operation of the plan or by its potential deterrent effect,
	mergers and acquisitions of us that our stockholders may consider in their best interests may not occur.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Our ability to utilize our net
	operating loss carryforwards may be limited.
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We have
	significant federal and state net operating loss carryforwards. However, our net operating loss carryforwards and certain other
	tax attributes may expire and not be used. Additionally, under Section 382 and Section 383 of the Internal Revenue Code of 1986,
	as amended, if a corporation undergoes an &ldquo;ownership change,&rdquo; which is generally defined as a greater than 50% change,
	by value, in its equity ownership over a three-year period, the corporation&rsquo;s ability to use its pre-change net operating
	loss carryforwards, as well as other pre-change tax attributes (e.g., research and experimentation tax credits), to offset its
	post-change income may be limited. We have previously experienced at least one ownership change and may experience ownership changes
	in the future as a result of subsequent shifts in our stock ownership or future equity offerings. As of December 31, 2015, we had
	federal net operating loss carryforwards of approximately $259.0 million that expire at various dates through 2035 that together
	with other tax attributes could expire unutilized or could be limited if we have experienced, or if in the future we experience,
	an ownership change.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	We may need to raise additional
	capital, and the issuance of debt or equity securities could adversely affect our common stockholders.
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We are
	unable to estimate the duration and completion costs of our research and development projects or when, if ever, and to what extent
	we will receive cash inflows from the commercialization and sale of a product. Our inability to complete our research and development
	projects in a timely manner or our failure to enter into collaborative agreements, when appropriate, could significantly increase
	our capital requirements and could adversely impact our liquidity. We may need to seek additional, external sources of financing
	from time to time in order to continue with our business strategy. Our inability to raise additional capital, or to do so on terms
	reasonably acceptable to us, would jeopardize the future success of our business.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We have
	historically raised capital through the issuance of equity securities. We have on file an effective shelf registration statement
	that allows us to raise up to $75.0 million from the sale of common or preferred stock or warrants for the purchase of common
	or preferred stock.
</FONT>
	Pursuant to General Instruction I.B.6 of Form S-3, however, in no event will we sell securities
	in a public primary offering pursuant to a registration statement on Form S-3 with a value exceeding more than one-third of our
	public float in any 12-month period so long as our public float remains below $75.0 million. We may also choose to issue either
	debt or equity securities in offerings not made pursuant to our shelf registration statement, which could include, among other
	things, offerings pursuant to registration statements on Form S-1 or pursuant to private offerings. The issuance of debt or
	equity securities could adversely affect the voting power of holders of our common stock. The issuance of debt or equity securities
	could also decrease the market price of our common stock or have terms and conditions that could discourage a takeover or other
	transaction that might involve a premium price for our shares or that our stockholders might believe to be in their best interests.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	We may not be able to raise additional
	capital on favorable terms, if at all.
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We may
	not be able to raise additional funds on acceptable terms, or at all through the issuance of equity or debt securities. If we are
	unable to secure sufficient capital to fund our research and development activities, we may not be able to continue operations,
	or we may have to enter into collaboration agreements that could require us to share commercial rights to our products to a greater
	extent or at earlier stages in the drug development process than is currently intended.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 41; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	41
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage42"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Our common stock is at risk for
	delisting from the NASDAQ Stock Market. &nbsp;If it is delisted, our stock price and the liquidity of our common stock would be
	impacted.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Our common
	stock is currently listed on the NASDAQ Capital Market of the NASDAQ Stock Market (NASDAQ). Continued listing of a security on
	NASDAQ is conditioned upon compliance with various continued listing standards. On January 11, 2016, the minimum bid price of our
	common stock on NASDAQ dropped below $1.00 per share.&nbsp; On February 24, 2016, we received notification from NASDAQ that the
	minimum bid price of our common stock had remained below $1.00 per share for 30 consecutive business days, and we therefore are
	not in compliance with the minimum bid price requirement for continued listing set forth in Marketplace Rule 5550(a)(2). The notification
	letter stated that we would be afforded 180 calendar days, or until August 22, 2016, to regain compliance with the minimum bid
	price requirement. &nbsp;To regain compliance, the closing bid price of our common stock must meet or exceed $1.00 per share for
	at least ten consecutive business days.&nbsp;&nbsp;NASDAQ may, in its discretion, require our common stock to maintain a bid price
	of at least $1.00 per share for a period in excess of ten consecutive business days, but generally no more than 20 consecutive
	business days, before determining we have demonstrated an ability to maintain long-term compliance.&nbsp;&nbsp;If we do not regain
	compliance by August 22, 2016, we may be afforded a second 180 calendar day grace period. To qualify, we would be required to meet
	the continued listing requirement for market value of publicly held shares ($1 million) and all other initial listing standards
	for the NASDAQ Capital Market, with the exception of the minimum bid price requirement. In addition, we would be required to provide
	written notice of our intention to cure the minimum bid price deficiency, and it must appear to NASDAQ that it is possible for
	us to cure the deficiency.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Delisting
	from NASDAQ could adversely affect our ability to raise additional financing through the public or private sale of equity securities,
	significantly affect the ability of investors to trade our securities and negatively affect the value and liquidity of our common
	stock. Delisting could also have other negative results, including the potential loss of confidence by employees, the loss of institutional
	investor interest, and fewer business development opportunities.
</FONT>
</P>
</EFX_RISK_FACTORS>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNRESOLVED_STAFF_COMMENTS>
<A NAME="FIS_UNRESOLVED_STAFF_COMMENTS"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<A NAME="T1600102_10K_HTM_A_003">
</A>
	ITEM 1B. UNRESOLVED STAFF COMMENTS
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	None.
</FONT>
</P>
</EFX_UNRESOLVED_STAFF_COMMENTS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<EFX_PROPERTIES>
<A NAME="FIS_PROPERTIES"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<A NAME="T1600102_10K_HTM_A_004">
</A>
	ITEM 2. PROPERTIES
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In December
	2013, we entered into a lease for 6,489 square feet for our corporate offices and research development laboratories at 910 Clopper
	Road, Suite 220N in Gaithersburg, Maryland. We relocated our operations to this location in January 2014. In December 2014 we
	amended this lease to include an additional 2,290 square feet located at 910 Clopper Road, Suite 260S in Gaithersburg, Maryland.
	In February 2015 we amended this lease to include an additional 733 square feet located at 910 Clopper Road, Suite 280S in Gaithersburg,
	Maryland. In July 2015 we amended this lease to include an additional 4,457 square feet located at 910 Clopper Road, Suite 215N
	in Gaithersburg, Maryland. This amendment we will be effective no earlier than July 1, 2016. As a result of this last amendment,
	the term of the lease expires on June 30, 2021. We have additional space within this facility that can be utilized to accommodate
	future growth, and we currently believe this facility is sufficient to meet our present nee
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	ds.
</FONT>
</FONT>
</P>
</EFX_PROPERTIES>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_LEGAL_PROCEEDINGS>
<A NAME="FIS_LEGAL_PROCEEDINGS"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="T1600102_10K_HTM_A_005">
</A>
	ITEM 3. LEGAL PROCEEDINGS
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	None.
</FONT>
</P>
</EFX_LEGAL_PROCEEDINGS>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_MINE_SAFETY_DISCLOSURE>
<A NAME="FIS_MINE_SAFETY_DISCLOSURE"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="T1600102_10K_HTM_A_006">
</A>
	ITEM 4. MINE SAFETY DISCLOSURES
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Not Applicable.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 42; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	42
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_MINE_SAFETY_DISCLOSURE>
</EFX_PART_I>
<A NAME="eolPage43"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<EFX_PART_II>
<A NAME="FIS_PART_II"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<A NAME="T1600102_10K_HTM_A_007">
</A>
	PART II
</B>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_MARKET>
<A NAME="FIS_MARKET"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
	ITEM&nbsp;5.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A NAME="T1600102_10K_HTM_A_031">
</A>
	MARKET FOR REGISTRANT&rsquo;S COMMON EQUITY, RELATED STOCKHOLDER
	MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Our common stock is currently traded on the NASDAQ Capital Market
	under the symbol &ldquo;GNVC&rdquo;. Set forth below is the range of quarterly high and low closing sale prices for our common
	stock for the two most recent years, as reported on the NASDAQ Capital Market:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_3"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	HIGH
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	LOW
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="WIDTH: 70%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	First Quarter 2015
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	4.31
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	2.16
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Second Quarter 2015
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	3.03
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1.85
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Third Quarter 2015
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	2.92
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	2.01
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Fourth Quarter 2015
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	2.37
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1.59
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	First Quarter 2014
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	4.15
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	2.33
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Second Quarter 2014
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	2.93
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	2.06
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Third Quarter 2014
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	2.67
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	2.00
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Fourth Quarter 2014
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	2.24
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1.68
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	As of
	February 29, 2016, there were approximately
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	75
</FONT>
	stockholders of record of our common
	stock, one of which is Cede &amp; Co., a nominee for Depository Trust Company (DTC), which is the single record holder for shares
	of common stock held by brokerage firms, banks, and other financial institutions as nominees for beneficial owners.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We have
	not paid any cash dividends since our inception and we do not anticipate paying any cash dividends in the foreseeable future. We
	did not repurchase any of our equity securities during the quarter ended December 31, 2015.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Unregistered Sales of Equity Securities and Use of Proceeds.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	None.
</FONT>
</P>
</EFX_MARKET>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_FINANCIAL_DATA>
<A NAME="FIS_FINANCIAL_DATA"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="T1600102_10K_HTM_A_008">
</A>
	ITEM 6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SELECTED FINANCIAL DATA
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The following
	tables set forth our selected financial data for each of the years in the five-year period ended December 31, 2015. The information
	below should be read in conjunction with our financial statements and notes thereto included elsewhere in this report and &ldquo;Management&rsquo;s
	Discussion and Analysis of Financial Condition and Results of Operations&rdquo; included elsewhere in this Annual Report on Form
	10-K. The historical results are not necessarily indicative of results to be expected for future periods.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_4"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
<B>
	SUMMARY STATEMENT OF OPERATIONS:
</B>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="18" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	YEARS ENDED DECEMBER 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	2013
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	2012
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	2011
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD COLSPAN="18" STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: ITALIC; TEXT-ALIGN: CENTER">
	(in thousands, except per share data)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: ITALIC">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="WIDTH: 45%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.125IN; PADDING-LEFT: 0.125IN">
	Revenues
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	885
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	6,041
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	3,682
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	9,353
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	17,744
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Operating expenses:
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	General and administrative
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	4,901
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	6,314
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	8,484
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	9,102
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	7,810
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT; PADDING-BOTTOM: 2PX">
	Research and development
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2PX SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PX SOLID">
	2,551
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2PX SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PX SOLID">
	2,264
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2PX SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PX SOLID">
	5,492
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2PX SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PX SOLID">
	14,348
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2PX SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PX SOLID">
	17,416
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; PADDING-LEFT: 0.25IN">
	Total operating expenses
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	7,452
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	8,578
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	13,976
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	23,450
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	25,226
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Operating loss
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(6,567
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(2,537
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(10,294
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(14,097
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(7,482
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX">
	Other income, net
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	22
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	22
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	275
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	42
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	41
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX">
	Net loss
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(6,545
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(2,515
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(10,019
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(14,055
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(7,441
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX">
	Basic and diluted net loss per share
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(0.39
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(0.16
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(0.77
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(1.09
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(0.58
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; TEXT-INDENT: -0.1IN; PADDING-LEFT: 0.1IN">
	Shares used in computation of basic and diluted net loss per share
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	16,778
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	15,827
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	12,948
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	12,940
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	12,921
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 43; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	43
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage44"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_5"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	SUMMARY BALANCE SHEET DATA:
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="18" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	AS OF DECEMBER 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	2013
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	2012
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	2011
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD COLSPAN="18" STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: ITALIC; TEXT-ALIGN: CENTER">
	(in thousands)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: ITALIC">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="WIDTH: 45%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Cash, cash equivalents, and investments
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	8,676
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	14,692
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	6,105
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	15,255
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	26,446
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Working capital
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	7,393
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	13,014
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	3,999
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	12,741
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	25,739
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Total assets
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	9,463
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	15,609
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	7,254
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	17,430
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	30,150
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Accumulated deficit
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(284,840
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(278,295
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(275,780
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(265,761
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(251,706
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Total stockholders' equity
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	7,680
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	13,298
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	4,610
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	13,743
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	26,538
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
</EFX_FINANCIAL_DATA>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_MANAGEMENTS_DISCUSSION>
<A NAME="FIS_MANAGEMENTS_DISCUSSION"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<A NAME="T1600102_10K_HTM_A_009">
</A>
	ITEM&nbsp;7.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL
	CONDITION AND RESULTS OF OPERATIONS
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The following
	discussion should be read in conjunction with the Financial Statements and Notes thereto appearing elsewhere in this Annual Report.
	See &ldquo;Item 1A: Risk Factors&rdquo; regarding certain factors known to GenVec that could cause reported financial information
	not to be necessarily indicative of future results, including discussions of the risks related to the development, regulatory approval,
	manufacture, and proprietary protection of our product candidates, and their market success relative to alternative products.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	OVERVIEW
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	GenVec,
	Inc. (GenVec, we, our, or the Company) is a clinical-stage biopharmaceutical company with an entrepreneurial focus on leveraging
	its proprietary AdenoVerse&trade; gene delivery platform to develop a pipeline of cutting-edge therapeutics and vaccines. The Company
	is a pioneer in the design, testing and manufacture of adenoviral-based product candidates that can deliver on the promise of gene-based
	medicine. GenVec&rsquo;s lead product candidate, CGF166, is licensed to Novartis Institutes for BioMedical Research, Inc. (together
	with Novartis AG and its subsidiary corporations, including Novartis Pharma AG, Novartis) and is currently in a Phase 1/2 clinical
	study for the treatment of hearing loss and balance disorders. In addition to our internal and partnered pipeline, we also focus
	on opportunities to license our proprietary technology platform, including vectors and production cell lines, to potential collaborators
	in the biopharmaceutical industry for the development and manufacture of therapeutics and vaccines.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	A key
	component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with
	prominent companies and organizations such as Novartis, Merial Limited, and the U.S. government, as well as promising young companies
	such as TheraBiologics, to support a portfolio of programs that address the prevention and treatment of a number of significant
	human and animal health concerns. GenVec&rsquo;s combination of internal and partnered development programs addresses therapeutic
	areas such as hearing loss and balance disorders and oncology, as well as vaccines against infectious diseases including respiratory
	syncytial virus (RSV), herpes simplex virus (HSV), and malaria. In the area of animal health we are developing vaccines against
	foot-and-mouth disease (FMD).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Our AdenoVerse
	gene delivery technology has the important advantage of localizing protein delivery in the body. This is accomplished by using
	our adenovector platform to locally deliver genes to cells, which then direct production of the desired protein. This approach
	reduces side effects typically associated with systemic delivery of proteins. For therapeutics, the goal is for the protein produced
	to have meaningful effect in treating the cause, manifestation, or progression of the disease. For vaccines, the goal is to induce
	an immune response against a target protein or antigen. This is accomplished by using an adenovector to deliver a gene that causes
	production of an antigen, which then stimulates the desired immune reaction by the body.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Our research
	and development activities yield product candidates that utilize our technology platform and represent potential commercial opportunities.
	For example, preclinical research in hearing loss and balance disorders indicates that the delivery of the atonal gene using GenVec&rsquo;s
	adenovector technology may have the potential to restore hearing and balance function. We are currently working with Novartis on
	the development of novel treatments for hearing loss and balance disorders that emerged from these research and development efforts.
	There are currently no effective therapeutic treatments available for patients who have lost all balance function, and hearing
	loss remains a major unmet medical problem.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 44; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	44
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage45"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL; COLOR: BLACK">
	We
	have multiple vaccine candidates that leverage our core adenovector technology including our preclinical vaccine candidates for
	the prevention or treatment of RSV and HSV. We also have a program to develop a vaccine for malaria, a program in which we are
	currently working in collaboration with
</FONT>
<FONT STYLE="FONT-WEIGHT: NORMAL; COLOR: BLACK">
	the Laboratory of Malaria Immunology
	and Vaccinology (LMIV) of the National Institute of Allergy and Infectious Diseases, National Institutes of Health. In the field
	of animal health, we are working with Merial Limited to commercialize vaccines for the prevention of a major animal health problem,
	FMD. Development efforts for this program were supported by the U.S. Department of Homeland Security (DHS) and performed in collaboration
	with the U.S. Department of Agriculture (USDA).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Our business
	strategy is focused on entering into collaborative arrangements with third parties to complete the development and commercialization
	of our product candidates. In the event that third parties take over the development for one or more of our product candidates,
	the estimated completion date would largely be under the control of that third party rather than us. We cannot forecast with any
	degree of certainty which proprietary products or indications, if any, will be subject to future collaborative arrangements, in
	whole or in part, or how such arrangements would affect our development plan or capital requirements. Our programs may also benefit
	from subsidies, grants, or government or agency-sponsored studies that could reduce our development costs.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	An element
	of our business strategy is to pursue, as resources permit, the research and development of a range of product candidates for a
	variety of indications. This is intended to allow us to diversify the risks associated with our research and development expenditures.
	To the extent we are unable to maintain a broad range of product candidates, our dependence on the success of one or a few product
	candidates would increase.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	On February
	24, 2016, we received notification from NASDAQ that the minimum bid price of our common stock had remained below $1.00 per share
	for 30 consecutive business days, and we therefore are not in compliance with the minimum bid price requirement for continued listing
	set forth in Marketplace Rule 5550(a)(2). Delisting of our common stock from NASDAQ as a result of non-compliance could adversely
	affect our ability to raise additional financing through the public or private sale of equity securities, significantly affect
	the ability of investors to trade our securities and negatively affect the value and liquidity of our common stock. Delisting could
	also have other negative results, including the potential loss of confidence by employees, the loss of institutional investor interest,
	and fewer business development opportunities.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Our research
	and development expenses were $2.6 million and $2.3 million for the years ended December&nbsp;31, 2015 and 2014, respectively.
	These expenses were divided between our research and development platforms in the following manner:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_6"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 95%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	Years ended December 31,
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: ITALIC; PADDING-BOTTOM: 2PX">
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<I>
	(in millions)
</I>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="WIDTH: 74%; FONT-WEIGHT: NORMAL">
	Vaccines
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1.0
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1.1
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Hearing Loss and Balance Disorders
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1.0
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1.1
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX">
	Other Programs
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	0.6
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	0.1
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 4PX">
<B>
	Total
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<B>
	$
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<B>
	2.6
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<B>
	$
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<B>
	2.3
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Hearing.
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;&nbsp;&nbsp;Through
	a collaboration with Novartis, our hearing loss and balance disorders program is focused on the restoration of hearing and balance
	function through the regeneration of critical cells of the inner ear. Since commencement of this development program, GenVec has
	incurred approximately $24 million in research and development costs, including an allocation of corporate general and administrative
	expenses, most of which have been funded under our agreement with Novartis. The decrease in research and development expenses in
	2015 was primarily due to the ongoing Phase 1/2 clinical study of our lead product candidate, CGF166.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 45; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	45
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage46"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Vaccines.
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;&nbsp;&nbsp;Our
	vaccine programs have been funded in part by our collaborations with both corporate and governmental entities. GenVec has worked
	on developing vaccine candidates against RSV, HSV, and other infectious diseases, as well as an animal health vaccine for FMD,
	and continues to work on vaccine candidates for malaria. Since the commencement of these vaccine development programs in 2002,
	GenVec has incurred approximately $121 million in research and development costs, including an allocation of corporate general
	and administrative expenses, most of which have been funded under our agreements with our various collaborators. We have a collaboration
	with Merial Limited to develop and commercialize vaccines for the prevention of a major animal health problem, FMD. Development
	efforts for this program were supported by the U.S. Department of Homeland Security and in collaboration with the U.S. Department
	of Agriculture. We also have a research collaboration with the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the National
	Institute of Allergy and Infectious Diseases, National Institutes of Health which will utilize GenVec's proprietary gorilla adenovirus
	vectors to deliver a number of novel antigens discovered at the LMIV in order to create and test a variety of malaria vaccine candidates.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	To date,
	none of our proprietary or collaborative programs has resulted in a commercial product; therefore, we have not received any revenues
	or royalties from the sale of products. We have funded our operations primarily through public and private placements of equity
	securities, payments received under collaborative programs with public and private entities, and debt financings.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Our
	revenue is primarily derived from our collaboration agreements with corporate partners, institutions, and government entities
	under which we may receive grants, milestone payments based on clinical progress, regulatory progress or net sales achievements,
	royalties, manufacturing revenue, or payment for our development activities on behalf of third parties. We are particularly dependent
	on our agreement with Novartis. The amount of our revenue derived from collaboration agreements in any given period will depend
	on a number of unpredictable factors, including, among other factors, whether and when we or our collaboration partner achieve
	clinical, regulatory and sales milestones.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We have
	incurred operating losses each year since inception and, as of December&nbsp;31, 2015, had an accumulated deficit of approximately
	$284.8 million. Our losses have resulted principally from costs incurred in research and development and from general and administrative
	activities. Research and development expenses consist primarily of salaries and related personnel costs, sponsored research costs,
	patent costs, technology access fees, clinical trial costs, and other expenses related to our product development and research
	programs. General and administrative expenses consist primarily of compensation and benefit expenses for executive, finance and
	other administrative personnel, facility costs, professional fees, business development costs, insurance premiums, and other general
	corporate expenditures.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Due
	to the inherent uncertainties in research and development and the nature of our business, including those discussed throughout
	this Annual Report on Form 10-K, we are unable to estimate the duration and completion costs of our research and development projects
	or when, if ever, and to what extent we will receive cash inflows from the commercialization and sale of a product. Our inability
	to complete our research and development projects in a timely manner or our failure to enter into collaborative agreements, when
	appropriate, could significantly increase our capital requirements and could adversely impact our liquidity. These uncertainties
	could force us to seek additional, external sources of financing from time to time in order to continue with our business strategy.
	Our inability to raise additional capital, or to do so on terms reasonably acceptable to us, would jeopardize the future success
	of our business. However, we believe our current cash and investments and committed and expected revenues from our strategic collaborations
	are expected to be sufficient to continue our current research, development and collaborative activities into the second quarter
	of 2017.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The preparation
	of financial statements in conformity with accounting principles generally accepted in the United States requires our management
	to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing
	basis, we evaluate our estimates using authoritative pronouncements, historical experience, and other assumptions as the basis
	for making estimates. Actual results could differ from those estimates. Significant accounting policies are more fully described
	in Note 2 &ldquo;Summary of Significant Accounting Policies&rdquo; in the Notes to Financial Statements included in this Annual
	Report on Form 10-K.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 46; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	46
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage47"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We have
	discussed the development, selection, and disclosure of critical accounting policies and estimates with the Audit Committee of
	our Board of Directors. While we base estimates and assumptions on our knowledge of current events and actions we may undertake
	in the future, actual results may ultimately differ from these estimates and assumptions.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We believe
	the following accounting policies to be critical because they require significant estimates or judgment on the part of management.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Revenue Recognition.
</I>
</B>
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL; COLOR: BLACK">
	Revenue
	is recognized when all four of the following criteria are met (i) a contract is executed, (ii) the contract price is fixed and
	determinable, (iii) delivery of the services or products has occurred, and (iv) collectability of the contract amounts is considered
	probable.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Our
	collaborative research and development agreements provide for upfront license fees, research payments, and/or substantive milestone
	payments. Upfront non-refundable fees associated with license and development agreements where we have continuing involvement
	in the agreement are recorded as deferred revenue and recognized over the estimated service period. If the estimated service period
	is subsequently modified, the period over which the upfront fee is recognized is modified accordingly on a prospective basis.
	Upfront non-refundable license and development fees for which no future performance obligations exist are recognized when
	collection is assured. Substantive milestone payments are considered performance payments and are recognized upon achievement
	of the milestone if all of the following criteria are met: (i)&nbsp;achievement of the milestone involves a degree of risk and
	was not reasonably assured at the inception of the arrangement; (ii) substantive effort is involved in achieving the milestone;
	and (iii) the amount of the milestone payment is reasonable in relation to all of the deliverables and payment terms within the
	arrangement. Determination of whether a milestone meets the aforementioned conditions involves the judgment of management.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Research
	and development revenue from cost-reimbursement and cost-plus fixed-fee agreements is recognized as earned based on the performance
	requirements of the contract. Revisions in revenues, cost, and billing factors, such as indirect rate estimates, are accounted
	for in the period of change. Reimbursable costs under such contracts are subject to audit and retroactive adjustment. Contract
	revenues and accounts receivable reported in the financial statements are recorded at the amount expected to be received. Contract
	revenues are adjusted to actual upon final audit and retroactive adjustment. Estimated contractual allowances are provided based
	on management&rsquo;s evaluation of current contract terms and past experience with disallowed costs and reimbursement levels.
	Payments received in advance of work performed are recorded as deferred revenue.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Research
	and development revenue from fixed-price best efforts arrangements is recognized as earned based on the performance requirements
	of the contract. Revenue under these arrangements is recognized when delivery to and acceptance by the customer has been received.
	During the period of performance, recoverable contract costs are accumulated on the balance sheet in other current assets, but
	no revenue or profit is recorded prior to customer acceptance of the contractually stated deliverables. Recoverable contract costs
	that are accumulated on the balance sheet include all direct costs associated with the arrangement and an allocation of indirect
	costs. Payments received in advance of customer acceptance are recorded as deferred revenue. Once customer acceptance has been
	received, revenue and recoverable contract costs are recognized. Over the course of the arrangement, we routinely evaluate whether
	revenue and profitability should be recognized in the current period. Any known or probable losses on projects are charged to operations
	in the period in which such losses are determined.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Stock Based Compensation
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We account
	for stock-based compensation based on the estimated grant date fair value of the stock using the Black-Scholes option-pricing model.
	The estimated grant date fair value is recognized in earnings over the requisite service period.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	RECENT ACCOUNTING PRONOUNCEMENTS
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	For a
	discussion of recently issued accounting pronouncements, refer to the section titled &ldquo;Recent Accounting Pronouncements&rdquo;
	within Note 2, &ldquo;Summary of Significant Accounting Policies&rdquo; in the Notes to Financial Statements included in this Annual
	Report on Form 10-K.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 47; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	47
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage48"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_RESULTS_OF_OPERATIONS>
<A NAME="FIS_RESULTS_OF_OPERATIONS"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	RESULTS OF OPERATIONS
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	YEARS ENDED DECEMBER 31, 2015 AND 2014
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	REVENUE
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	Revenue
</I>
	.
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;&nbsp;&nbsp;Revenue
	decreased 85% to $0.9 million in 2015 from $6.0 million in 2014.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL; COLOR: BLACK">
	Revenues
	for the 12-month period ended December&nbsp;31, 2015 were derived from the collaboration with Novartis to discover and develop
	novel treatments for hearing loss and balance disorders, from the Company&rsquo;s funded research and development programs
	with the Department of Homeland Security (DHS), National Institutes of Allergy and Infectious Diseases (NIAID) of the National
	Institutes of Health (NIH), and the U.S. Naval Medical Research Center (NMRC), each of which use GenVec&rsquo;s proprietary
	adenovector technology for the development of either vaccine candidates against foot-and-mouth disease (FMD) for livestock or
	vaccines against malaria and under other licensing agreements.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Our research
	collaboration and license agreement (the Agreement) with Novartis accounted for $0.2 million of revenue in each 2015 and 2014,
	respectively.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Since
	the inception of the Agreement, we have been eligible to receive up to an aggregate of $206.6 million in milestone payments if
	certain clinical, regulatory and sales milestones are met. To date, we have received a total of $5.6 million in milestone
	payments under the agreement. In September&nbsp;2010, we announced that we had achieved the first milestone in the collaboration
	with Novartis. The $300,000 milestone was triggered by the successful completion of certain preclinical development activities.
	In December&nbsp;2011, we announced that we had achieved the second milestone in the collaboration with Novartis. The $300,000
	milestone was triggered by the successful completion of certain preclinical development activities. In February&nbsp;2014, we
	announced that we had achieved the third milestone in the collaboration with Novartis. The $2.0 million milestone was triggered
	by the non-rejection of the Investigational New Drug application filed by Novartis for CGF166 with the U.S. Food and Drug Administration
	(FDA). In October&nbsp;2014, we announced that we had achieved the fourth milestone in the collaboration with Novartis. The $3.0
	million milestone was triggered by the first patient treated with CGF166 in a Phase 1/2 clinical trial sponsored by Novartis utilizing
	GenVec technology for the treatment of severe-to-profound bilateral hearing loss. As of February&nbsp;29, 2016, milestones remaining
	available under the Agreement include $21.0 million of additional clinical milestones, $45.0 million in regulatory milestones,
	and $135.0 million of sales-based milestones. Additionally, we are also entitled to royalties on future sales.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In August&nbsp;2010,
	the Company and Novartis entered into a development agreement related to the supply of clinical trial material in connection with
	activities under the Agreement, which accounted for $0.2 million and $0.3 million in revenue in 2015 and 2014, respectively.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In January
	2016, we were notified by Novartis that enrollment was paused in the clinical study for CGF166. This pause was based on a review
	of data by the trial&rsquo;s Data Safety Monitoring Board in accordance with criteria in the trial protocol. Novartis will continue
	to collect safety and efficacy data on the nine patients currently enrolled in the study before determining whether to proceed
	with incremental patients.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The
	decrease in revenue in 2015 primarily resulted from a decrease in revenue of&thinsp;$5.1 million generated by our hearing
	loss and balance disorders program versus the prior year as a result of our achievement of milestones totaling $5.0 million in
	revenue in 2014 and a $0.1 million reduction in revenues received for services performed in connection with this program in 2015.
	Our work under the contract with the DHS related to our animal health program was completed in February 2015; as a result we experienced
	reduced revenues of $0.2 million.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	OPERATING EXPENSES
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	General and administrative.
</I>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;&nbsp;&nbsp;General
	and administrative expenses decreased 22% to $4.9 million in 2015 from $6.3 million in 2014. General and administrative expenses
	were lower in 2015 primarily as a result of higher facility costs related to the relocation of our corporate offices in
	2014 and lower professional costs in 2015. The reduced costs were partially offset by an increase in personnel costs in 2015 as
	compared to 2014. General and administrative expenses include an increase of approximately $242,000 of stock-based compensation
	expense in 2015 as compared to the prior year.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 48; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	48
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage49"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Research and development.
</I>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;&nbsp;&nbsp;Research
	and development expenses increased 13% to $2.6 million in 2015 from $2.3 million in 2014. In 2015, we experienced higher research
	and development costs than in the prior year primarily as a result of increased personnel costs. Stock-based compensation
	expense included in research and development personnel costs increased approximately $133,000 in 2015 as compared to the prior
	year.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	OTHER INCOME (LOSS)
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Total
	other income was $22,000 in 2015 which is in line with total other income in 2014. In both 2015 and 2014, total other income consisted
	primarily of interest income.
</FONT>
</P>
</EFX_RESULTS_OF_OPERATIONS>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_LIQUIDITY_CAPITAL>
<A NAME="FIS_LIQUIDITY_CAPITAL"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	LIQUIDITY AND CAPITAL RESOURCES
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We have
	experienced significant losses since our inception. As of December&nbsp;31, 2015 we have an accumulated a deficit of $284.8 million.
	The process of developing and commercializing our product candidates requires significant research and development work and clinical
	trial work, as well as significant manufacturing and process development efforts. These activities, together with our general and
	administrative expenses, are expected to continue to result in significant operating losses for the foreseeable future.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	As of
	December&nbsp;31, 2015, cash, cash equivalents, and investments totaled $8.7 million as compared to $14.7 million at
	December&nbsp;31, 2014.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	For the
	12 months ended December&nbsp;31, 2015, we used net cash of $5.9 million for operating activities. This consisted of a net loss
	for the period of&thinsp;$6.5 million, which included approximately $0.1 million of non-cash depreciation and amortization, $0.9
	million of non-cash stock-based compensation expenses, $0.5 million used for the net change in current assets and liabilities,
	and $0.1 million provided by the net change in non-current assets. Net cash was used primarily for our internally funded research
	and development programs and general and administrative activities.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Net cash
	provided by investing activities during the 12 months ended December&nbsp;31, 2015 was $5.0 million, which included $5.1 million
	for the net proceeds of marketable securities and $0.1 million for the purchase of property and equipment.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Net
	cash used in financing activities during the 12 months ended December 31, 2015 was $24,000, which represents the costs of maintaining
	our ATM, described below, in 2015.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	As of
	December&nbsp;31, 2014, cash, cash equivalents, and short-term investments totaled $14.7 million as compared to $6.1 million at
	December&nbsp;31, 2013.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	For the
	12 months ended December&nbsp;31, 2014, we used net cash of&thinsp;$2.0 million for operating activities. This consisted of a net
	loss for the period of&thinsp;$2.5 million, which included approximately $0.2 million of non-cash depreciation and amortization,
	$0.5 million of non-cash stock-based compensation expenses, $0.1 million of loss on sale of long lived assets, $0.4 million used
	for the net change in current assets and liabilities, and $0.1 million provided by the net change in non-current assets. Net cash
	was used primarily for our internally funded research and development programs and general and administrative activities.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Net cash
	used in investing activities during the 12 months ended December&nbsp;31, 2014 was $5.9 million, which included $5.9 million for
	the net purchases of marketable securities and $44,000 for the purchase of property and equipment.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	There
	was $10.7 million of cash provided by financing activities during the 12 months ended December&nbsp;31, 2014 as a result of our
	&ldquo;at-the-market&rdquo; offering and Registered Direct Offerings that occurred in the first quarter of 2014 as described below.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 49; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	49
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage50"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	On February
	24, 2016, we received notification from NASDAQ that the minimum bid price of our common stock had remained below $1.00 per share
	for 30 consecutive business days, and we therefore are not in compliance with the minimum bid price requirement for continued listing
	set forth in Marketplace Rule 5550(a)(2). The notification letter stated that we would be afforded 180 calendar days, or until
	August 22, 2016, to regain compliance with the minimum bid price requirement. &nbsp;To regain compliance, the closing bid price
	of our common stock must meet or exceed $1.00 per share for at least ten consecutive business days.&nbsp;&nbsp;NASDAQ may, in its
	discretion, require our common stock to maintain a bid price of at least $1.00 per share for a period in excess of ten consecutive
	business days, but generally no more than 20 consecutive business days, before determining we have demonstrated an ability to maintain
	long-term compliance.&nbsp;&nbsp;If we do not regain compliance by August 22, 2016, we may be afforded a second 180 calendar day
	grace period. To qualify, we would be required to meet the continued listing requirement for market value of publicly held shares
	($1 million) and all other initial listing standards for the NASDAQ Capital Market, with the exception of the minimum bid price
	requirement. In addition, we would be required to provide written notice of our intention to cure the minimum bid price deficiency,
	and it must appear to NASDAQ that it is possible for us to cure the deficiency.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Delisting
	from NASDAQ could adversely affect our ability to raise additional financing through the public or private sale of equity securities,
	significantly affect the ability of investors to trade our securities and negatively affect the value and liquidity of our common
	stock. Delisting could also have other negative results, including the potential loss of confidence by employees, the loss of institutional
	investor interest, and fewer business development opportunities.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Historically
	we have entered into agreements with academic medical institutions and contract research organizations to perform research and
	development activities and with clinical sites for the treatment of patients under clinical protocols. Such contracts expire at
	various dates and have differing renewal and expiration clauses.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Since
	our initial public offering, we have raised capital by offering shares of our common stock and warrants to purchase shares of
	our common stock in a variety of offerings. On May&nbsp;29, 2014, 711,539 warrants with an exercise price of $8.58 issued in May&nbsp;2009
	expired. On February&nbsp;1, 2015, 420,000 warrants with an exercise price of $27.50 issued in February&nbsp;2010 expired. As
	a result, as of February&nbsp;29, 2016, we have no warrants outstanding. See Note 8 &ldquo;Stockholders&rsquo; Equity&rdquo;
	to our audited financial statements included in this Annual Report.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Effective
	September&nbsp;7, 2011, we entered into a Stockholder Rights Agreement between the Company and American Stock Transfer &amp; Trust
	Company, LLC, as rights agent. The Stockholder Rights Agreement was not adopted in response to any specific effort to acquire control
	of the Company. In connection with the adoption of the Stockholder Rights Agreement, the Company&rsquo;s Board of Directors declared
	a dividend of one preferred stock purchase right, or Right, for each outstanding share of common stock to stockholders of record
	as of the close of business on September&nbsp;7, 2011. Initially, the Rights will be represented by GenVec&rsquo;s common stock
	certificates or book entry notations, will not be traded separately from the common stock and will not be exercisable. In the event
	that any person acquires beneficial ownership of 20% or more of the outstanding shares of GenVec&rsquo;s common stock, or upon
	the occurrence of certain other events, each holder of a Right, other than the acquirer, would be entitled to receive, upon payment
	of the purchase price, which is initially set at $32 per Right, a number of shares of GenVec common stock having a value equal
	to two times such purchase price. The Company&rsquo;s Board of Directors is entitled to redeem the Rights at $0.001 per right at
	any time before a person or group has acquired 20% or more of the Company&rsquo;s common stock. The Rights will expire on September&nbsp;7,
	2021, subject to the Company&rsquo;s right to extend such date, unless earlier redeemed or exchanged by the Company or terminated.
	The Rights will at no time have any voting rights. The Company has authorized 30,000 shares of Series B Junior Participating Preferred
	Stock in connection with the adoption of the new Stockholder Rights Agreement. There was no Series B Junior Participating Preferred
	Stock issued or outstanding as of December&nbsp;31, 2015.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	On January&nbsp;23,
	2014, we filed a $75.0 million shelf registration statement on Form S-3 (the 2014 shelf registration statement), with the Securities
	and Exchange Commission. The 2014 shelf registration statement was declared effective February&nbsp;11, 2014 and allows us to obtain
	financing through the issuance of any combination of common stock, preferred stock or warrants. Pursuant to General Instruction
	I.B.6 of Form S-3, in no event will we sell securities in a public primary offering using Form S-3 with a value exceeding more
	than one-third of our public float in any 12-month period so long as our public float remains below $75.0 million.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	On February&nbsp;11,
	2014, we entered into an Equity Distribution Agreement (the EDA) with Roth Capital Partners, LLC (Roth Capital Partners), pursuant
	to which we may sell from time to time up to $10.0 million of shares of our common stock, par value $0.001 per share, through
	Roth Capital Partners (the ATM Offering). Sales of shares in the ATM Offering, if any, may be made by any method permitted by
	law deemed to be an &ldquo;at the market&rdquo; offering as defined in Rule 415 of the Securities Act of 1933, as amended, including
	without limitation directly on the NASDAQ Capital Market, or any other existing trading market for the shares or through a market
	maker, or, if agreed by the Company and Roth Capital Partners, by any other method permitted by law, including but not limited
	to in negotiated transactions. The ATM Offering is being made pursuant to the 2014 shelf registration statement. We have used
	and intend to continue using the net proceeds from the sale of shares in the ATM Offering, if any, for operating costs,
	working capital and general corporate purposes. At the time of the registered direct offering described immediately below, we
	suspended the ATM Offering. We will continue to evaluate the markets and look for opportunities to resume activity under the ATM
	Offering. As of March&nbsp;31, 2014, we had sold 721,677 shares in the ATM Offering for gross proceeds of approximately
	$2.6 million. We have not sold any shares under the ATM Offering since that date.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 50; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	50
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage51"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	On March&nbsp;18,
	2014, we sold 2,870,000 shares of our common stock, par value $0.001, in a registered direct offering pursuant to the 2014 shelf
	registration statement (the Registered Direct Offering), at a price of $3.15 per share, resulting in gross proceeds of approximately
	$9.0 million.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	As of
	December 31, 2015, pursuant to the Equity Distribution Agreement and the Registered Direct Offering we have sold 3,591,677 shares
	of our common stock since the 2014 shelf registration statement became effective on February 11, 2014 for gross proceeds of $11.6
	million; all of these sales were completed prior to March 31, 2014.&nbsp;&nbsp;These sales resulted in proceeds, net of issuance
	costs of approximately $10.6 million.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Our
	estimated future capital requirements are uncertain and could change materially as a result of many factors, including the progress
	of our research, development, clinical, manufacturing, and commercialization activities. We currently estimate we will use between
	$6 million and $7 million of cash during the four quarters ending December&nbsp;31, 2016. Our estimate includes approximately
	$0.3 million in contractual obligations. Based on this estimate we have sufficient resources to fund our operations into the
	second quarter of 2017.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	OFF-BALANCE SHEET OBLIGATIONS
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We had no off-balance sheet
	obligations other than in connection with our operating leases.
</FONT>
</P>
</EFX_LIQUIDITY_CAPITAL>
</EFX_MANAGEMENTS_DISCUSSION>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_MARKET_RISK>
<A NAME="FIS_MARKET_RISK"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
	ITEM&nbsp;7A.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A NAME="T1600102_10K_HTM_A_010">
</A>
	QUANTITATIVE AND QUALITATIVE DISCLOURES ABOUT MARKET RISK
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Not applicable.
</FONT>
</P>
</EFX_MARKET_RISK>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_FINANCIAL_STATEMENTS>
<A NAME="FIS_FINANCIAL_STATEMENTS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
	ITEM&nbsp;8.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A NAME="T1600102_10K_HTM_A_011">
</A>
	FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The response to this item
	is submitted in a separate section of this Annual Report. See &ldquo;Financial Statements&rdquo; beginning on Page F-1.
</FONT>
</P>
</EFX_FINANCIAL_STATEMENTS>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<EFX_ACCOUNTING_CHANGES>
<A NAME="FIS_ACCOUNTING_CHANGES"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
	ITEM&nbsp;9.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A NAME="T1600102_10K_HTM_A_012">
</A>
	CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING
	AND FINANCIAL DISCLOSURE
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Not applicable.
</FONT>
</P>
</EFX_ACCOUNTING_CHANGES>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<EFX_CONTROL_AND_PROCEDURES>
<A NAME="FIS_CONTROL_AND_PROCEDURES"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
	ITEM&nbsp;9A.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A NAME="T1600102_10K_HTM_A_013">
</A>
	CONTROLS AND PROCEDURES
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<I>
	Disclosure Controls and Procedures
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We
	have carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal
	financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules&nbsp;13a-15(e)
	and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;)) as of December&nbsp;31, 2015.
	Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of that
	period, these disclosure controls and procedures are effective at the reasonable assurance level in alerting them in a timely manner
	to material information required to be included in our periodic reports filed with the SEC.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<I>
	&nbsp;
</I>
</P>
<!-- FIELD: PAGE; SEQUENCE: 51; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	51
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage52"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<I>
	Changes in Internal Control
	over Financial Reporting
</I>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	There
	were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rules&nbsp;13a-15(e)
	and 15d-15(e) of the Exchange Act, that occurred during the quarter ended December&nbsp;31, 2015 that have materially affected,
	or are reasonably likely to materially affect, our internal control over financial reporting.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<I>
	Management&rsquo;s Annual Report
	on Internal Control over Financial Reporting
</I>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Our
	management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control
	over financial reporting is defined in Rules&nbsp;13a-15(f) and 15d-15(f) under the Exchange Act as a process designed by, or under
	the supervision of, a company&rsquo;s principal executive and principal financial officers and effected by a company&rsquo;s board
	of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and
	the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Our
	internal control over financial reporting includes those policies and procedures that:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Pertain to the maintenance of records that, in reasonable detail,
	accurately and fairly reflect the transactions and dispositions of our assets;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 27.35PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Provide reasonable assurance that transactions are recorded as
	necessary to permit preparation of financial statements in accordance with generally accepted accounting principles and that our
	receipts and expenditures are being made only in accordance with authorizations of our management and directors;&nbsp;and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 27.35PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Provide reasonable assurance regarding prevention or timely detection
	of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Because
	of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of
	any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes
	in conditions or the degree of compliance with the policies or procedures may deteriorate.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Our
	management assessed the effectiveness of our internal control over financial reporting as of December&nbsp;31, 2015. In making
	this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission
	(COSO) in Internal Control&nbsp;&mdash; Integrated Framework (2013). Based on this assessment, management concluded that, as of
	December&nbsp;31, 2015, our internal control over financial reporting is effective based on those criteria.
</FONT>
</P>
</EFX_CONTROL_AND_PROCEDURES>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<EFX_OTHER_INFORMATION>
<A NAME="FIS_OTHER_INFORMATION"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
	ITEM&nbsp;9B.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A NAME="T1600102_10K_HTM_A_014">
</A>
	OTHER INFORMATION
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	None.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 52; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	52
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_OTHER_INFORMATION>
</EFX_PART_II>
<A NAME="eolPage53"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_PART_III>
<A NAME="FIS_PART_III"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<A NAME="T1600102_10K_HTM_A_015">
</A>
	PART III
</B>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_DIRECTORS_AND_OFFICERS>
<A NAME="FIS_DIRECTORS_AND_OFFICERS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
	ITEM&nbsp;10.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A NAME="T1600102_10K_HTM_A_016">
</A>
	DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Directors
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The following table sets forth
	the director nominees for election at the Company&rsquo;s 2016 annual meeting of stockholders (the Annual Meeting), the directors
	of the Company currently in office, their ages and the positions currently held by each such person with the Company.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_NAME_AND_TITLE>
<A NAME="FIS_NAME_AND_TITLE_2"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: BOLD; WIDTH: 50%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Name
</B>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 2PX; WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; WIDTH: 8%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Age
</B>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX; WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: BOLD; WIDTH: 38%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Position
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Directors whose terms expire at the Annual Meeting
</I>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	William N. Kelley, M.D.
<SUP>
	(2) (3)
</SUP>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	76
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Director&nbsp;&nbsp;(nominee)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Quinterol J. Mallette, M.D.
<SUP>
	(1)
</SUP>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	41
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Director (nominee)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Directors whose terms expire in 2017
</I>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Stefan D. Loren, Ph.D.
<SUP>
	(1) (3)
</SUP>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	52
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Marc R. Schneebaum
<SUP>
	(1) (2)
</SUP>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	61
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Directors whose terms expire in 2018
</I>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Wayne T. Hockmeyer, Ph.D.
<SUP>
	(2) (3)
</SUP>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	71
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Chairman of the Board of Directors
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Douglas J. Swirsky
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	46
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Director, President and Chief Executive Officer
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Michael Richman
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	55
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_NAME_AND_TITLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
	(1)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Member of the Audit Committee.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
	(2)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Member of the Compensation Committee.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
	(3)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Member of the Nominating and Corporate Governance Committee.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The
	biographies of each of the directors below contains information regarding the experiences, qualifications, attributes, or skills
	that caused the Nominating and Corporate Governance Committee and the Board to determine that the person should serve as a director
	for the Company.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	Directors Whose Terms Expire in 2016
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	William N. Kelley, M.D.
</I>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	has served as a director of the Company since June&nbsp;2002. Dr. Kelley is the Chairman of the Nominating and Corporate Governance
	Committee and a member of the Compensation Committee. Dr. Kelley and his colleagues at the University of Michigan were the first
	to show proof of concept data for
<I>
	in vivo
</I>
	gene therapy as it is recognized today. From 1989 to 2000, Dr. Kelley served as
	Executive Vice President of the University of Pennsylvania with responsibilities as Chief Executive Officer for the Medical Center,
	Dean of the School of Medicine, and the Robert G. Dunlop Professor of Medicine and Biochemistry and Biophysics. He is currently
	Professor of Medicine at the School of Medicine of the University of Pennsylvania. In the national leadership arena, Dr. Kelley
	has served as President of the American Society for Clinical Investigation, President of the American College of Rheumatology,
	Chair of the American Board of Internal Medicine, and Chair of the Residency Review Committee for Internal Medicine. Dr. Kelley
	serves on the board of directors of Transenterix, Inc. Within the past five years, he served on the boards of directors of Merck
	&amp; Co. Inc., Beckman Coulter, Inc., and Advanced Biosurfaces,&nbsp;Inc.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 53; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	53
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage54"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Dr. Kelley
	brings a long history of involvement in experimental models of gene therapy to the Board. Dr.&nbsp;Kelley&rsquo;s many leadership
	roles, both as a leader in the field of gene therapy and as a senior management figure of an internationally renowned medical center,
	allow him to provide strong leadership to our Board.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Quinterol J. Mallette, M.D.
</I>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	has
	served as a director of the Company since October&nbsp;2014. Dr. Mallette is a member of the Audit Committee. Dr. Mallette is currently
	an industry consultant. From 2013 to May&nbsp;2015, Dr. Mallette served as Senior Analyst at SWK Holdings, Inc., a publicly-traded
	healthcare-focused specialty finance firm. From 2011 to 2013, Dr. Mallette was the Founder and President of Mallette Research Associates,
	a provider of in-depth, real-time equity research to brokerage houses. From 2009 to 2011, Dr.&nbsp;Mallette was the Founder and
	President of the Invictus Trading Group, Inc., a proprietary trading group with expertise in healthcare. Dr. Mallette began his
	career in 2001 at Lehman Brothers as an Equity Research Analyst in the Biotechnology space. Dr. Mallette left Lehman to fill the
	role of Senior Analyst for a healthcare-dedicated fund, before starting his own fund. Dr. Mallette holds B.S. degrees in Biomedical
	Engineering and Psychology from Duke University. He also received an MBA from the Fuqua School of Business at Duke University and
	a medical degree from the Duke University School of Medicine.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Dr. Mallette
	has significant experience in healthcare and biotechnology-focused finance and investment institutions and an educational background
	in medicine and business, bringing to the Board a deep understanding of the Company&rsquo;s industry and the capital markets.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	Directors Whose Terms Expire in 2017
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Stefan D. Loren, Ph.D.
</I>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	has served as a director of the Company since September&nbsp;2013. Dr. Loren is a member of the Audit Committee and the Nominating
	and Corporate Governance Committee. Since March&nbsp;2014, Dr. Loren has been the managing member of Loren Capital Strategy, LLC
	a start-up investment fund and strategy group. Dr. Loren was a Managing Director of Westwicke Partners, a healthcare-focused consulting
	firm, from 2008 through February&nbsp;2014. From 2007 to 2008, Dr. Loren was an Analyst with Perceptive Advisors, a healthcare-focused
	investment fund, and, prior to that, served as an analyst and portfolio manager for MTB Investment Advisors from 2005 to 2007.
	Prior to 2005, Dr. Loren was a Managing Director in the healthcare equity research group at Legg Mason, and before joining Legg
	Mason, a Research Chemist at the advanced technologies division of Abbott Laboratories and a Research Fellow at the Scripps Research
	Institute. Dr. Loren received his B.A. from the University of California, San Diego, and his Ph.D. from University of California,
	Berkeley. Currently, he is a director of Marina Biotech, Inc. and Cellectar Biosciences, Inc. Within the past five years, Dr. Loren
	has served on the boards of directors of Orchid Cellmark Inc. and Polymedix, Inc.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Dr. Loren
	has over 16 years of experience in financial markets and a decade of experience in research and development in the pharmaceutical
	and biotechnology industries. This unique combination makes Dr.&nbsp;Loren an important resource to our Board.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Marc R. Schneebaum
</I>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	has served as a director of the Company since April&nbsp;2007. Mr. Schneebaum is a member of the Compensation Committee and the
	Chairman of the Audit Committee. Mr. Schneebaum has served as the Chief Financial Officer and Senior Vice President of Synta Pharmaceuticals
	Corp. since December&nbsp;2014. He served as an industry consultant from 2013 to December&nbsp;2014. Mr. Schneebaum served as President,
	Chief Executive Officer and a director of Predictive BioSciences, Inc., a commercial stage cancer diagnostics company, from 2011
	to 2013. From 1997 to 2010, Mr. Schneebaum served as President, Chief Executive Officer, and a director of Sensors for Medicine
	and Science, Inc., an emerging medical technology company. From 1991 to 1997, he served as Senior Vice President, Finance, Business
	Development and Administration, and Chief Financial Officer of Genetic Therapy, Inc., a biotechnology company (acquired by Sandoz/Novartis).
	From 1987 to 1991, Mr. Schneebaum was a Vice President at Alex Brown &amp; Sons Incorporated, a leading investment banking firm
	(now part of Deutsche Bank), where he participated in a variety of finance and strategic assignments. Mr. Schneebaum began his
	career in the accounting and auditing group at KPMG LLP, advancing to Senior Manager in the management consulting group. Mr. Schneebaum,
	a Certified Public Accountant (inactive), received his degree in Business Administration from the University of Maryland. He has
	also served on the boards of the March of Dimes of Maryland and the Maryland Enterprise Investment Fund.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Mr.
	Schneebaum&rsquo;s financial acumen, his varied leadership roles in the medical technology and biotechnology fields and his experience
	in investment banking, accounting, and management consulting at leading institutions bring a level of knowledge to the Board that
	aids greatly in its deliberations.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 54; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	54
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage55"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	Directors Whose Terms Expire in 2018
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Wayne T. Hockmeyer, Ph.D.
</I>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	has served as a director of the Company since December&nbsp;2000. Dr. Hockmeyer is a member of the Nominating and Corporate Governance
	Committee, is the Chairman of the Compensation Committee, and was appointed Chairman of the Board in November&nbsp;2013. Dr. Hockmeyer
	founded MedImmune, Inc. (MedImmune) in April&nbsp;1988 as President and Chief Executive Officer and was elected a director of MedImmune
	in May&nbsp;1988. Dr. Hockmeyer became Chairman of the board of directors of MedImmune in May&nbsp;1993 and left his position as
	Chief Executive Officer in October&nbsp;2000. Dr.&nbsp;Hockmeyer is currently retired, having resigned from his positions as Chairman
	of the MedImmune board of directors and as President of MedImmune Ventures, Inc. following the acquisition of MedImmune by AstraZeneca
	Biopharmaceuticals, Inc. in June&nbsp;2007. Dr. Hockmeyer earned his bachelor&rsquo;s degree from Purdue University and his Ph.D.
	from the University of Florida in 1972. Currently, he is the Chairman of the Board of Baxalta, Inc. and Chairman of the Board of
	the Indian River Medical Center. Within the past five years, Dr. Hockmeyer served on the board of directors of Idenix Pharmaceuticals,
	Inc. and Baxter International Inc.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Dr. Hockmeyer&rsquo;s
	experience for the past two decades at the forefront of biotechnology development provides a valuable resource and knowledge base
	for our Board. Dr. Hockmeyer&rsquo;s experience in founding and managing MedImmune prior to its acquisition, both as its most senior
	executive and as Chairman of its board of directors, enables him to counsel the Board in a unique and beneficial manner.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Douglas J. Swirsky
</I>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	has served as the President and Chief Executive Officer and as a director of the Company since September&nbsp;2013. He joined the
	Company in 2006 as Chief Financial Officer, Corporate Secretary and Treasurer, and continues to serve as Corporate Secretary. Prior
	to joining the Company, Mr.&nbsp;Swirsky was a Managing Director and the Head of Life Sciences Investment Banking at Stifel Nicolaus
	from 2005 to 2006 and held investment banking positions at Legg Mason from 2002 until Stifel Financial&rsquo;s acquisition of the
	Legg Mason Capital Markets business in 2005. Mr. Swirsky, a Certified Public Accountant and holder of a Chartered Financial Analyst&reg;
	designation, has also previously held investment banking positions at UBS, PaineWebber, and Morgan Stanley. His experience also
	includes positions in public accounting and consulting. Mr. Swirsky received his undergraduate degree in Business Administration
	from Boston University and his M.B.A. from the Kellogg School of Management at Northwestern University. Mr. Swirsky is a member
	of the Board of Directors of Fibrocell Science, Inc. Within the past five years, Mr. Swirsky has also served on the board of PolyMedix,
	Inc.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Mr. Swirsky&rsquo;s
	background with, and institutional knowledge of, the Company together with his day-to-day leadership of our business gives the
	Board an invaluable executive with a Company-focused perspective.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="COLOR: BLACK">
<I>
	Michael
	Richman
</I>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	was appointed to the Board in April&nbsp;2015. Mr. Richman has served as
</FONT>
</FONT>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	President
	and CEO of NextCure, Inc. since December 2015. He served as
<FONT STYLE="COLOR: BLACK">
	an industry consultant from September 2015
	until December 2015. Mr. Richman served as President and Chief Executive Officer of Amplimmune, a member of the AstraZeneca Group,
	from 2013 until August&nbsp;2015. From 2008 until Amplimmune&rsquo;s acquisition by AstraZeneca in 2013, he was president and then
	president and chief executive officer of Amplimmune when it was a privately-held biologics company focused on cancer and autoimmune
	diseases. From 2002 through 2007, Mr. Richman was the Executive Vice President and Chief Operating Officer of MacroGenics, a clinical-stage
	biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment
	of cancer, autoimmune disorders and infectious diseases. Mr. Richman has more than 30 years of experience working in research,
	intellectual property and business development capacities in companies such as Chiron Corporation (now Novartis) and MedImmune,
	Inc. (prior to its acquisition by AstraZeneca), where he was Senior Vice President Corporate Development. While at MedImmune, Mr.&nbsp;Richman
	was responsible for all business development, licensing, intellectual property, legal affairs, project management and strategic
	planning functions, and he drove many significant transactions during his tenure there. Mr. Richman is a member of the board of
	directors of Opexa Therapeutics, Inc. and Pieris Pharmaceuticals, Inc.
	Mr. Richman obtained his B.S. in genetics/molecular biology at the University of California at Davis and his M.S.B.A. in international
	business at San Francisco State University.
</FONT>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Mr. Richman&rsquo;s
	extensive experience in the biotechnology and biopharmaceutical industries, including in various executive-level management roles,
	enable him to provide the Board with deep industry knowledge and insight into all aspects of the Company&rsquo;s business and operations.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 55; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	55
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage56"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Executive Officers
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	See &ldquo;Executive Officers
	of the Registrant&rdquo; in Part I of this Form 10-K.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Section 16(a) Beneficial Ownership
	Reporting Compliance
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Section
	16(a) of the Exchange Act requires the Company&rsquo;s executive officers, directors and persons who beneficially own more than
	10% of a registered class of the Company&rsquo;s equity securities to file with the SEC initial reports of ownership and reports
	of changes in ownership of common stock and other equity securities of the Company. Such executive officers, directors, and greater
	than 10% beneficial owners are required by SEC regulation to furnish the Company with copies of all Section 16(a) reports filed
	by such reporting persons.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Based
	solely on the Company&rsquo;s review of copies of such reports furnished to the Company and written representations that no other
	reports were required during the year ended December&nbsp;31, 2015, the Company believes that all Section 16(a) filing requirements
	applicable to the Company&rsquo;s executive officers, directors, and greater than 10% beneficial owners were complied with in a
	timely manner.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Code of Business Conduct and Ethics
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The Board
	has adopted the Code of Business Conduct and Ethics (the Code), which sets forth standards of expected conduct of the Chief Executive
	Officer, financial executives (including the principal financial officer and principal accounting officer), directors, executive
	officers, and all employees of the Company. The Code includes policies on employment, conflicts of interest and the treatment of
	confidential information and requires strict adherence to all laws and regulations applicable to the conduct of the Company&rsquo;s
	business. A copy of the Code can be found in the Investors &mdash; Corporate Governance section on the Company&rsquo;s website
	at
<I>
	www.genvec.com
</I>
	. The Company will disclose any amendment to the Code or waivers from the Code relating to the Company&rsquo;s
	directors, executive officers, principal executive financial and accounting officers, or persons performing similar functions on
	its website within five business days following the date of any such amendment or waiver.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Director Nomination Process
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	There
	have been no material changes to the process by which stockholders may submit nominees for election to the Board of Directors to
	the Nominating and Corporate Governance Committee since that process was described in the Company&rsquo;s Proxy Statement filed
	with the SEC on October 6, 2015.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Audit Committee &amp; Audit Committee
	Financial Expert
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The Board
	has established an Audit Committee in accordance with Section 3(a)(58)(A) of the Exchange Act. The Board has adopted, and annually
	reviews, a written charter outlining the practices followed by the Audit Committee. The Audit Committee&rsquo;s job is one of oversight
	as set forth in its charter. It is not the duty of the Audit Committee to prepare the Company&rsquo;s financial statements, to
	plan or conduct audits, or to determine that the Company&rsquo;s financial statements are complete and accurate and are in accordance
	with accepted accounting principles. The Company&rsquo;s management is responsible for the preparation, presentation, and integrity
	of the financial statements. Management is also responsible for maintaining appropriate accounting and financial reporting practices
	and policies as well as internal controls and procedures designed to provide reasonable assurance that the Company is in compliance
	with accounting standards and applicable laws and regulations. The Company&rsquo;s independent registered public accounting firm
	is responsible for planning and performing an independent audit of financial statements in accordance with the standards of the
	Public Company Accounting Oversight Board (United States) (PCAOB). The independent registered public accounting firm is responsible
	for expressing an opinion on the conformity of those audited financial statements with U.S. generally accepted accounting principles.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The members
	of the Audit Committee are Marc R. Schneebaum (Chairman), Stefan D. Loren, Ph.D. and Quinterol J. Mallette, M.D. Each member of
	the Audit Committee is independent as defined by NASDAQ listing standards. The Board has determined that at least one member of
	the Audit Committee, Marc R. Schneebaum, is an Audit Committee Financial Expert as defined in the SEC&rsquo;s rules and regulations.
	The Audit Committee is responsible for appointing, compensating, overseeing, and evaluating the selection of the Company&rsquo;s
	independent registered public accounting firm and is responsible for overseeing the following: management&rsquo;s preparation of
	the Company&rsquo;s financial statements and management&rsquo;s conduct of the accounting and financial reporting processes; management&rsquo;s
	maintenance of internal controls and procedures over financial reporting; the Company&rsquo;s compliance with applicable legal
	and regulatory requirements, including without limitation those requirements relating to financial controls and reporting; the
	independent auditor&rsquo;s qualifications and independence; and the performance of the independent auditors, including the annual
	independent audit of the Company&rsquo;s financial statements.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 56; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	56
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_DIRECTORS_AND_OFFICERS>
<A NAME="eolPage57"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_COMPENSATION>
<A NAME="FIS_COMPENSATION"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
	ITEM&nbsp;11.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A NAME="T1600102_10K_HTM_A_017">
</A>
	EXECUTIVE COMPENSATION
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_COMPENSATION_TABLE>
<A NAME="FIS_COMPENSATION_TABLE"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	EXECUTIVE COMPENSATION TABLES AND INFORMATION
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Summary Compensation Table
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The following table summarizes the total compensation paid or
	earned by each of the named executive officers for the year ended December 31, 2015:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT-STYLE: NORMAL; FONT-WEIGHT: NORMAL">
<TD STYLE="FONT-WEIGHT: NORMAL; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-STYLE: NORMAL">
<B>
	Name and Principal Position
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX; FONT-STYLE: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-STYLE: NORMAL">
<B>
	Year
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX; FONT-STYLE: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-STYLE: NORMAL">
<B>
	Salary
<BR>
	($)
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX; FONT-STYLE: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-STYLE: NORMAL">
<B>
	Option
</B>
<BR>
<B>
	Awards
</B>
<BR>
<B>
	($)
<SUP>
	(1)
</SUP>
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX; FONT-STYLE: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-STYLE: NORMAL">
<B>
	Non-Equity
</B>
<BR>
<B>
	Incentive Plan
</B>
<BR>
<B>
	Compensation
</B>
<BR>
<B>
	($)
<SUP>
	(2)
</SUP>
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX; FONT-STYLE: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-STYLE: NORMAL">
<B>
	All
	Other Compensation
</B>
<BR>
<B>
	($)
<SUP>
	(3)
</SUP>
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX; FONT-STYLE: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-STYLE: NORMAL">
<B>
	Total
<BR>
	($)
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="WIDTH: 32%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Douglas J. Swirsky,
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	2015
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	425,000
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	482,730
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	127,500
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	6,625
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1,041,855
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Chief Executive Officer
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	2014
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	375,000
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	232,899
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	140,625
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	6,500
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	755,024
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Douglas E. Brough,
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	2015
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	310,650
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	217,229
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	67,100
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	6,625
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	601,604
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Chief Scientific Officer
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	2014
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	310,650
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	155,266
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	75,000
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	6,500
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	547,416
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Bryan T. Butman,
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	2015
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	285,000
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	144,819
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	51,300
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	6,625
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	487,744
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Senior Vice President, Development
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	2014
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	278,060
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	124,213
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	62,564
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	6,500
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	471,337
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_COMPENSATION_TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(1)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Amounts represent the aggregate grant date fair value as computed in accordance with ASC
	Topic 718 using the assumptions set forth in Note 8 to the audited financial statements of the Company.
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(2)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Represents amounts earned under the Company's annual performance award plan for the respective
	year.
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(3)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Amounts shown include matching contributions under the Company's 401K Plan.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Narrative Disclosure to Summary Compensation Table
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The following section provides a description
	of the 2015 compensation information contained in the Summary Compensation Table above for the following individuals, whom we refer
	to as our named executive officers:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.1IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.13IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Douglas
	J. Swirsky, President, Chief Executive Officer, and Corporate Secretary
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.13IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Douglas
	E. Brough, Chief Scientific Officer
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.13IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Bryan
	T. Butman, Senior Vice President, Development
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Base Salaries
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The Compensation
	Committee recommends a base salary level for the CEO, subject to Board approval, and approves base salary levels for the other
	named executive officers based on individual performance, promotions, and industry information. In considering base salary levels,
	the Compensation Committee gives most weight to the CEO&rsquo;s performance assessment of each named executive officer (other than
	himself). Based on the recommendation by the Compensation Committee in January 2015, Mr. Swirsky&rsquo;s base salary was increased
	by 13.3% to $425,000, and Dr. Butman&rsquo;s salary was increased by 2.5% to $285,000. Dr. Brough did not receive an increase to
	his base salary in 2015.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 57; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	57
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage58"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Annual Performance Award Plan
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Each
	year, the named executive officers have the opportunity to receive annual performance awards through participation in the Company&rsquo;s
	annual performance award plan. Participants in this plan are eligible to receive a target payment that is expressed as a percentage
	of the participant&rsquo;s base salary and that is based on performance of the Company and each named executive officer&rsquo;s
	overall individual performance (with the exception of the CEO, whose target award is based on performance of the Company only).
	For 2015, annual performance award opportunities for Mr. Swirsky and Drs. Brough and Butman remained unchanged from the percentages
	used in the prior year, and were 50% and 30%, respectively.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	For Mr.
	Swirsky, 100% of the annual performance award was based on corporate goals. For Drs. Brough and Butman, 70% was payable based on
	corporate goals and 30% was payable based on individual goals.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The corporate
	goals for 2015 were set on January&nbsp;23, 2015. The goals, level of achievement and weight are described below:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 23%; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Hearing Program
</FONT>
</TD>
<TD STYLE="WIDTH: 77%; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Shelf life extension; tech transfer; pass Audit (weighted 20%)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Business Development
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Enter new license agreements for technology or product program (weighted 30%)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
<A NAME="FIS_UNIDENTIFIED_TABLE_7"></A>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Enterovirus Program
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Advance discovery to lead design (weighted 10%)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Malaria Program
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Expand collaborations to advance the program (weighted 10%)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Therapeutic Program
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Establish academic collaboration to advance the program (weighted 5%)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	NOL Considerations
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Assess net operating loss carryforwards (weighted 10%)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Investor Relations
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Institutional investor outreach (weighted 5%)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Financial Goals
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Manage operations to end 2015 with at least $8 million in cash and investments (weighted 10%)
</FONT>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In general,
	achievement of 100% of the corporate goals and, if applicable, the Compensation Committee&rsquo;s positive evaluation of individual
	performance will result in an annual incentive award payment to the individual at the target level. The Compensation Committee
	retains the discretion, however, to pay the annual performance awards at levels above or below the target level as it evaluates
	the achievement of corporate goals, taking into account the weightings assigned to each goal, and, if applicable, individual performance.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The Compensation
	Committee determined that the Company met a portion of its stated goals for the hearing, malaria, therapeutic, and enterovirus
	programs, and all of its operational goals other than the business development goal. The Compensation Committee determined that
	the Company, while making significant progress in the business development area, had only achieved a small portion of its stated
	goal. As a result the Compensation Committee determined the Company achieved 60% of the 2015 corporate goals.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_8"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT-STYLE: NORMAL; FONT-WEIGHT: NORMAL">
<TD NOWRAP STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Target&nbsp;Award
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Corporate
<BR>
	Goals
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Individual
<BR>
	Goals
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Corporate
<BR>
	Goals
<BR>
	Achieved
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Individual
<BR>
	Goals
<BR>
	Achieved
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	%
	of Target
<BR>
	Award
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Dollar
<BR>
	Amount
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT-STYLE: NORMAL; FONT-WEIGHT: NORMAL">
<TD NOWRAP STYLE="FONT-WEIGHT: NORMAL; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Named&nbsp;Executive&nbsp;Officer
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	($)
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	(%)
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	(%)
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	(%)
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	(%)
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	(%)
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	($)
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="WIDTH: 37%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	President &amp; CEO
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 6%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	212,500
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 6%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	100
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 6%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: NORMAL">
	n/a
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 6%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	60
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 6%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: NORMAL">
	n/a
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 6%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	60
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 6%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	127,500
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	Chief Scientific Officer
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	93,195
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	70
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	30
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	60
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	100
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	72
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	67,100
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	SVP, Development
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	85,500
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	70
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	30
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	60
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	60
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	60
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	51,300
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 58; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	58
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage59"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Annual Stock Option Grants
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The Company
	uses stock options for its equity incentive awards in order to be consistent with its objective of aligning the interests of stockholders
	with those of its executives. Stock options are awarded annually and are considered part of total compensation, along with base
	salary and annual performance awards. Stock options granted in 2015, consistent with awards in prior years, vest over a four-year
	period, with one-eighth of each option grant vesting six months after the date of grant and the remainder vesting ratably over
	the following 42 months. This vesting schedule was selected at the time because of the Company&rsquo;s belief that it was consistent
	with industry practice while still providing a relatively long retention benefit. Future annual stock option grants made under
	the 2015 Plan will continue to vest over a four-year period. However, 25% of each option grant will vest 12 months after the date
	of grant and the remainder will vest ratably over the following 36 months.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Stock
	options that are granted as part of the long-term incentive program are granted with an exercise price equivalent to the closing
	price of the Company&rsquo;s common stock on the NASDAQ Capital Market on the date of grant. The exercise price of stock options
	granted to a newly hired executive officer is set at the closing price of GenVec&rsquo;s common stock on NASDAQ on the start date
	of the executive officer, which is a date on or after approval of the grant by the Compensation Committee. In 2015, Mr. Swirsky
	and Drs. Brough and Butman, received annual stock option grants of 200,000, 90,000, and 60,000, respectively, on January&nbsp;16,
	2015 at an exercise price of&thinsp;$2.97 per share.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Employment, Severance and Change in Control Arrangements
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	GenVec has entered into employment agreements
	with Mr. Swirsky and Drs. Brough and Butman and has entered into a change in control agreement with Mr. Swirsky.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Salary Continuation Agreements.
</I>
	The
	Company entered into a salary continuation agreement with Mr. Swirsky when he joined the Company in 2006, which was pursuant to
	a form of agreement that was adopted in October 2002 and was amended in December 2008 to provide for technical compliance with
	certain Treasury regulations. The Company has also entered into a salary continuation agreement with Drs. Brough and Butman with
	terms substantially similar to the form of agreement adopted in October 2002 as amended by the December 2008 amendment. Under the
	terms of the salary continuation agreements, if the named executive officer is terminated without &ldquo;cause&rdquo; (as defined
	below) and other than by reason of death or disability, the officer will be paid the officer&rsquo;s regular base salary for a
	period of 12 months. The named executive officer will also receive a pro-rata bonus equal to the product of the bonus paid to the
	officer for the fiscal year preceding the termination date, divided by 12 months times the number of months of service during the
	year of termination. These agreements also include continued health and welfare benefits for the same period as the salary continuation,
	a non-compete for the same period as the salary continuation and a non-disparagement clause.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Under the terms of the salary continuation agreements, &ldquo;cause&rdquo;
	is defined to include:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the willful and continued failure of the named executive officer to
	substantially perform his duties;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	willfully engaging in illegal conduct or gross misconduct that is
	materially and demonstrably injurious to the Company;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	personal dishonesty or breach of fiduciary duty to the Company for
	personal benefit at the expense of the Company; or
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	willfully violating any law, rule, regulation, or order in a manner
	that is materially and demonstrably injurious to the Company.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Acceleration of Stock Awards.
</I>
	The
	form of stock option award agreements for stock option awards made to each of the named executive officers provides that in the
	event of a change in control, all unvested awards will accelerate in full. Under the terms of the stock option award agreements,
	a &ldquo;change in control&rdquo; means the occurrence of any of the following events:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	any person becomes the beneficial owner of 40% or more of the
	Company&rsquo;s common stock;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 59; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	59
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage60"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	the Company&rsquo;s stockholders approve a merger, consolidation,
	share exchange, division, or other reorganization of the Company with any other organization;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	the Company&rsquo;s stockholders approve a complete plan of liquidation,
	winding-up of the Company, or an agreement for the sale or disposition of all or substantially all of the Company&rsquo;s assets;
	or
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&bull;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	during any 24-month period, individuals who at the beginning
	of such period constituted the Board cease for any reason to constitute at least a majority of the Board.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Change in Control Agreement with Mr.
	Swirsky.
</I>
	GenVec entered into a change in control agreement with Mr. Swirsky when he joined the Company in September 2006. Mr.
	Swirsky&rsquo;s agreement was amended in December 2008 to provide for technical compliance with certain Treasury regulations. Mr.
	Swirsky is entitled to certain payments upon termination without cause (as defined in the salary continuation agreements described
	above) following a change in control (as defined in the stock option award agreements described above).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Specifically, if Mr. Swirsky&rsquo;s employment
	is terminated without cause other than as a result of his death or disability or if he resigns for good reason within two years
	following a change in control, he is entitled to a lump sum severance payment equal to his monthly salary and average monthly bonus
	times 18, continued health and welfare benefits for an 18-month period, and a pro-rata bonus for the termination year. In addition,
	his agreement provides for an excise tax gross-up payment, reimbursement of certain legal costs related to the enforcement of the
	agreement and the accelerated vesting of all unvested options at termination.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In addition, pursuant to his change in
	control agreement, upon the death or disability of Mr. Swirsky during such time as he is entitled to any payments or benefits under
	the agreement, such payments and benefits are payable to Mr. Swirsky&rsquo;s heirs or estate, respectively. To the extent Mr. Swirsky
	becomes entitled to benefits under the change in control agreement, the salary continuation agreement is superseded and he will
	not receive any benefit under that agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Under the terms of the change in control
	agreement, &ldquo;good reason&rdquo; is defined as the occurrence of any of the following events without the consent of Mr. Swirsky
	in connection with a change of control, unless, if correctable, such circumstances are fully corrected with 30 days of the notice
	of termination given in respect thereof, which notice must be given within 90 days of the occurrence:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the assignment to Mr. Swirsky of any duties inconsistent in any material
	respect with his position, authority, duties or responsibilities, as they were immediately prior to the change in control;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the diminution in any material respect in Mr. Swirsky&rsquo;s position,
	authority, duties, or responsibilities as they were immediately prior to a change in control;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	a reduction by the Company in Mr. Swirsky&rsquo;s annual base salary;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	a relocation of more than 35 miles from where Mr. Swirsky&rsquo;s
	office or location was immediately prior to a change in control;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the failure to continue any compensation plan in which Mr. Swirsky
	participates, unless an equitable arrangement has been made, or the continuation of the plan under materially less favorable terms;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the failure by the Company to pay to Mr. Swirsky any deferred compensation
	when due under any deferred compensation plan or agreement applicable to Mr. Swirsky; or
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	a material breach by the Company of the terms and provisions of the
	change in control agreement.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	To constitute good reason for purposes
	of the change in control agreement, the termination by Mr. Swirsky must occur within two years following the initial occurrence
	of the event constituting the good reason.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 60; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	60
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage61"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Outstanding Equity Awards at Fiscal
	Year End
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The following table provides information with respect to outstanding
	stock options and restricted stock awards held by the named executive officers as of December 31, 2015. All outstanding grants
	issued prior to 2012 were made under the 2002 Plan. Grants made in 2012 and thereafter were made under the 2011 Plan.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_OPTIONS_AGGREGATE>
<A NAME="FIS_OPTIONS_AGGREGATE"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 85%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="13" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	Option Awards
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Number of
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Number of
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Securities
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Securities
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Underlying
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Underlying
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Unexercised
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Unexercised
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Option
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Options
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Options
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Exercise
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Option
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Exercisable
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Unexercisable
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Price
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Expiration
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 2PX SOLID">
	Name
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	(#)
<SUP>
	(1)
</SUP>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	(#)
<SUP>
	(1)(2)
</SUP>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	($)
<SUP>
	(1)
</SUP>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	Date
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: LEFT">
	Douglas J. Swirsky
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	30,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	11.30
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	9/18/2016
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	26.10
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1/18/2017
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	15,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	17.90
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1/16/2018
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	22,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.10
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1/22/2019
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	15,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	22.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1/20/2020
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.70
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1/19/2021
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	58,750
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,250
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.49
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1/18/2022
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	91,145
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	33,855
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.56
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1/22/2023
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	35,937
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	39,063
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.96
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1/23/2024
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	45,833
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	154,167
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.97
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1/16/2025
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Douglas E. Brough
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	16.90
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1/18/2016
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	26.10
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1/18/2017
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	17.90
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1/16/2018
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	21.80
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4/16/2018
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.10
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1/22/2019
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	22.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1/20/2020
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	17.90
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;2/1/2020
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.70
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1/19/2021
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	73,437
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,563
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.49
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1/18/2022
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	61,979
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	23,021
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.56
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1/22/2023
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	23,958
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	26,042
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.96
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1/23/2024
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20,625
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	69,375
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.97
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1/16/2025
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Bryan T. Butman
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	16.90
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1/18/2016
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	26.10
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1/18/2017
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	17,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	17.90
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1/16/2018
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	22,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.10
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1/22/2019
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	15,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	22.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1/20/2020
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.70
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1/19/2021
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	58,750
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,250
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.49
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1/18/2022
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	54,687
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20,313
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.56
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1/22/2023
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	19,166
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20,834
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.96
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1/23/2024
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	13,750
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	46,250
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.97
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1/16/2025
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_OPTIONS_AGGREGATE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 61; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	61
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage62"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(1)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	All awards have been adjusted to reflect the effect of the reverse
	stock split of the Company's Common Stock on April 19, 2011.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(2)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The options indicated in the table above as unexercisable at
	December 31, 2015 result from the following option grants, which vest over a four-year period with 12.5% vesting after six months
	from the date of grant and the remainder vesting ratably over the next 42 months.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	On January 18, 2012, Dr. Brough was granted 75,000 options and
	Mr. Swirsky and Dr. Butman were each granted 60,000 options.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	On January 22, 2013, Mr. Swirsky was granted 125,000 options,
	Dr. Brough was granted 85,000 options, and Dr. Butman was granted 75,000 options.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	On January 23, 2014, Mr. Swirsky was granted 75,000 options,
	Dr. Brough was granted 50,000 options, and Dr. Butman was granted 40,000 options.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	On January 16, 2015, Mr. Swirsky was granted 200,000 options,
	Dr. Brough was granted 90,000 options, and Dr. Butman was granted 60,000 options.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	DIRECTOR COMPENSATION TABLE
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The Compensation
	Committee, pursuant to its charter, periodically reviews the compensation of non-employee directors. The Company&rsquo;s current
	policy for the compensation of non-employee directors, which became effective on January&nbsp;1, 2015, provides that non-employee
	directors of the Company will receive $60,000 annually for their service on the Board of Directors.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In addition,
	pursuant to a policy adopted by the Board in 2012, each non-employee director receives: (i)&nbsp;upon becoming a director, an option
	to purchase 20,000 shares of common stock that is exercisable ratably over a four-year period, and (ii) after our annual meeting
	of stockholders each year, an annual grant of an option to purchase 15,000 shares of common stock. In the case of the Chairman
	of the Board, the annual grant is of an option to purchase 22,500 shares of common stock. Director options have an exercise price
	equal to the fair market value of our common stock on the date of the grant and a 10-year term.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	For annual
	grants made prior to the effectiveness of the 2015 Plan, 50% of the award becomes exercisable six months after the date of the
	grant and 50% becomes exercisable 12 months after the date of the grant. Annual grants made under the 2015 Plan will become fully
	exercisable 12 months after the date of grant.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Directors
	who are employees of GenVec do not receive fees or other compensation for their service as directors. All directors are reimbursed
	for travel and other expenses incurred in the performance of their duties.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 62; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	62
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage63"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The following table shows the total compensation earned by the
	Company&rsquo;s non-employee directors in 2015:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_9"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT-STYLE: NORMAL; FONT-WEIGHT: NORMAL">
<TD STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX; FONT-STYLE: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; FONT-STYLE: NORMAL">
<B>
	Fees
</B>
<BR>
<B>
	Earned or
</B>
<BR>
<B>
	Paid in
</B>
<BR>
<B>
	Cash
<SUP>
	(2)
</SUP>
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX; FONT-STYLE: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; FONT-STYLE: NORMAL">
<B>
	Option&nbsp;Awards
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<B>
<SUP>
	&nbsp;
</SUP>
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX; FONT-STYLE: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; FONT-STYLE: NORMAL">
<B>
	Total
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT-STYLE: NORMAL; FONT-WEIGHT: NORMAL">
<TD STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL; BORDER-BOTTOM: BLACK 2PX SOLID">
<B>
	Name
<SUP>
	(1)
</SUP>
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX; FONT-STYLE: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-STYLE: NORMAL">
<B>
	($)
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX; FONT-STYLE: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-STYLE: NORMAL">
<B>
	($)
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<B>
<SUP>
	&nbsp;
</SUP>
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX; FONT-STYLE: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-STYLE: NORMAL">
<B>
	($)
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<SUP>
	&nbsp;
</SUP>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="WIDTH: 55%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Wayne T. Hockmeyer, Ph.D.
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	60,000
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	36,364
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<SUP>
	(3)
</SUP>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	96,364
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<SUP>
	&nbsp;
</SUP>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	William N. Kelley, M.D.
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	60,000
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	24,243
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<SUP>
	(3)
</SUP>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	84,243
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<SUP>
	&nbsp;
</SUP>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Marc R. Schneebaum
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	60,000
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	24,243
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<SUP>
	(3)
</SUP>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	84,243
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<SUP>
	&nbsp;
</SUP>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Stefan D. Loren, Ph.D.
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	60,000
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	24,243
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<SUP>
	(3)
</SUP>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	84,243
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<SUP>
	&nbsp;
</SUP>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Quinterol J. Mallette, M.D.
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	60,000
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	24,243
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<SUP>
	(3)
</SUP>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	84,243
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<SUP>
	&nbsp;
</SUP>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Michael Richman
<SUP>
	(4)
</SUP>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	41,538
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<SUP>
	(4)
</SUP>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	72,540
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<SUP>
	(3)
</SUP>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	114,078
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(1)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Mr. Swirsky, the President and Chief Executive Officer of GenVec, does not receive compensation
	as a Director of the Company. Compensation for Mr. Swirsky is disclosed in the Summary Compensation Table.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-INDENT: -0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(2)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	All annual retainers payable to the chairman of the board and each director are paid in quarterly
	installments.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-INDENT: -0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(3)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	On
	November 13, 2015, each of the Company's continuing non-management directors received
	a stock option award of 15,000 shares, which had an aggregate grant date fair value of
	$24,243 except for Dr. Hockmeyer, who received a stock option award of 22,500 shares,
	which an aggregate grant date fair value of $36,364. Mr. Richman also received
	an initial grant of 20,000 on April 21, 2015 in connection with his appointment as a
	director, which had an aggregate grant date fair value of $48,297. All fair values have
	been computed in accordance with ASC Topic 718 using the assumptions set forth in Note
	8 to the audited financial statements of the Company.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-INDENT: -0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(4)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Mr. Richman became a member of our Board of Directors on April 21, 2015.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 63; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	63
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage64"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As
	of December 31, 2015, each director had the following number of vested and unvested equity awards outstanding
</FONT>
	:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_10"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT-STYLE: NORMAL; FONT-WEIGHT: NORMAL">
<TD STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX; FONT-STYLE: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; FONT-STYLE: NORMAL">
<B>
	Total
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX; FONT-STYLE: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; FONT-STYLE: NORMAL">
<B>
	Vested
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX; FONT-STYLE: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; FONT-STYLE: NORMAL">
<B>
	Unvested
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT-STYLE: NORMAL; FONT-WEIGHT: NORMAL">
<TD STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL; BORDER-BOTTOM: BLACK 2PX SOLID">
<B>
	Name
<SUP>
	(1)
</SUP>
</B>
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX; FONT-STYLE: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-STYLE: NORMAL">
<B>
	(#)
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX; FONT-STYLE: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-STYLE: NORMAL">
<B>
	(#)
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX; FONT-STYLE: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-STYLE: NORMAL">
<B>
	(#)
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="WIDTH: 55%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Wayne T. Hockmeyer, Ph.D.
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	69,000
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	46,500
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	22,500
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	William N. Kelley, M.D.
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	54,000
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	39,000
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	15,000
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Marc R. Schneebaum
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	54,500
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	39,500
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	15,000
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Stefan D. Loren, Ph.D.
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	65,000
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	40,000
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	25,000
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Quinterol J. Mallette, M.D.
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	50,000
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	20,000
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	30,000
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Michael Richman
<SUP>
	(2)
</SUP>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	35,000
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	35,000
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(1)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Dr. Hockmeyer has 22,500 stock options that will vest on November 13, 2016. Drs. Kelley,
	Loren and Mallette and Messrs. Schneebaum and Richman each have 15,000 stock options that will vest on November 13, 2016. Dr. Loren
	also has 10,000 stock options that will vest ratably over two years beginning on September 19, 2015. Dr. Mallette also has 15,000
	stock options that will vest ratably over three years beginning on October 30, 2015. Mr. Richman also has 20,000 stock options
	that will vest ratably over four years beginning on April 21, 2016.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-INDENT: -0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(2)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Mr. Richman joined our Board on April 21, 2015.
</FONT>
</TD>
</TR>
</TABLE>
</EFX_COMPENSATION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_SECURITY_OWNERS>
<A NAME="FIS_SECURITY_OWNERS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<A NAME="T1600102_10K_HTM_A_018">
</A>
	ITEM 12. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECURITY
	OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
</B>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Security Ownership of Certain Beneficial Owners and Management
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The following table sets forth certain
	information as of March 3, 2016 (unless otherwise specified), regarding the beneficial ownership of the Company&rsquo;s common
	stock by (i) each named executive officer (as defined below) of the Company (ii) each director of the Company and (iii) all current
	directors and executive officers as a group. As of March 3, 2016, there were two persons known to the Company to be the
	beneficial owners of more than 5% of the outstanding shares of common stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Beneficial ownership is determined in
	accordance with the rules of the SEC for computing the number of shares of common stock beneficially owned by a person and the
	percentage ownership of that person. Shares of common stock subject to options currently exercisable or exercisable within 60
	days after March 3, 2016 are considered outstanding for the purpose of computing the percentage ownership of the person holding
	such options, but are not considered outstanding when computing the percentage ownership of each other person. Except as indicated
	in the footnotes to this table, each stockholder named in the table below has sole voting and investment power for the shares
	shown as beneficially owned by them. Percentage of beneficial ownership is based on
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	17,264,359
</FONT>
	shares of common stock outstanding on March 3, 2016. Unless otherwise specified, the address for each director or executive
	officer is care of the Company at its principal office.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 64; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	64
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage65"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_BENEFICIAL_OWNERS>
<A NAME="FIS_BENEFICIAL_OWNERS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 2PX SOLID">
	Name of Beneficial Owner
<SUP>
	(1)
</SUP>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	Total&nbsp;Number
<BR>
	of Shares
<BR>
	Beneficially
<BR>
	Owned
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	% of
<BR>
	Class
<BR>
	Owned
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT">
	Beneficial Owner of More than 5% of the Outstanding Common Stock:
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="WIDTH: 70%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Laurence T. Lytton
<SUP>
	(2)
</SUP>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1,300,954
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	7.5
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Cormorant Global Halthcare Master Fund, LP
<SUP>
	(3)
</SUP>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1,176,235
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	6.8
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT">
	Directors and Named Executive Officers:
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Wayne T. Hockmeyer, Ph.D.
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	124,500
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	*
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	William N. Kelley, Ph.D.
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	114,500
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	*
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Quniterol J. Mallette, M.D.
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	20,000
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	*
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Stefan D. Loren, Ph.D.
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	45,000
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	*
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Marc R. Schneebaum
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	115,000
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	*
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Michael Richman (4)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	5,000
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	*
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Douglas J. Swirsky
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	614,250
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	3.5
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Douglas E. Brough, Ph.D.
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	387,495
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	2.2
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Bryan T. Butman, Ph.D.
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	326,072
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1.9
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	All directors and executive officers as a group (10 persons)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1,831,092
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	10.0
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
</TABLE>
</EFX_BENEFICIAL_OWNERS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 65; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	65
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage66"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(1)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Includes shares of Common Stock issuable upon exercise of options that are exercisable within
	60 days of March 3, 2016 in the following amounts: Wayne T. Hockmeyer, 46,500 shares; William N. Kelley, 39,000 shares; Marc R.
	Schneebaum, 39,500 shares; Stefan D. Loren, 40,000 shares; Quinterol J. Mallette, M.D., 20,000 shares; Michael Richman, 5,000 shares;
	Douglas J. Swirsky, 371,750 shares; Douglas E. Brough 250,812 shares; Bryan T. Butman, 244,687 shares; and directors and executive
	officers as a group (10 people), 1,116,707 shares.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-INDENT: -0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(2)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Based soley on the Schedule 13G filed on January 21, 2016 by Laurence W. Lytton. Amounts
	consists of 1,280,806 shares held by Laurence T. Lytton, and 20,148 held in the AWL Family LLC. Mr. Lytton has sole power to vote
	and investment power over all 1,300,954 shares.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-INDENT: -0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The address for the above person is 467 CPW, New York, New York 10025.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-INDENT: -0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(3)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Based soley on the Schedule 13G/A filed on February 16, 2016 by Cormorant Global Healthcare
	Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Asset Management, LLC and Bihua Chen. As disclosed in the Schedule
	13G/A, the shares are held by Cormorant Global Healthcare Master Fund, LP, for which Cormorant Global Healthcare GP, LLC serves
	as the general partner and Cormorant Asset Management, LLC serves as the investment manager. Bihua Chen serves as the managing
	member of Cormorant Global Healthcare GP, LLC and Cormorant Asset Management, LLC. Each of the reporting persons has shared voting
	and investment power over all 1,176,235 shares.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-INDENT: -0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The address for the above entities and person is 200 Claredon Street, 52nd Floor, Boston,
	Massachussetts 02116.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(4)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Michael Richman joined our Board of Directors on April 21, 2015.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 66; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	66
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage67"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_11"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Equity Compensation Plan Information
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The following table discloses certain information about the
	options issued and available for issuance under all outstanding Company option plans as of December 31, 2015:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(a)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(b)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(c)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 2PX SOLID">
	Plan category
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PX SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	Number
	of
</B>
<BR>
<B>
	securities to be
</B>
<BR>
<B>
	issued upon
</B>
<BR>
<B>
	exercise of
</B>
<BR>
<B>
	outstanding
</B>
<BR>
<B>
	options, warrants
</B>
<BR>
<B>
	and rights
</B>
</P>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PX SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	Weighted-
</B>
<BR>
<B>
	average exercise
</B>
<BR>
<B>
	price of
</B>
<BR>
<B>
	outstanding
</B>
<BR>
<B>
	options, warrants
</B>
<BR>
<B>
	and rights
</B>
</P>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PX SOLID">
	Number of
<BR>
	securities
<BR>
	remaining
<BR>
	available for
<BR>
	future issuance
<BR>
	under equity
<BR>
	compensation
<BR>
	plans (excluding
<BR>
	securities reflected
<BR>
	in column (a))
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="WIDTH: 46%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Equity compensation plans approved by security holders
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	2,237,317
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 15%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	4.16
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1,648,413
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX">
	Equity compensation plans not approved by security holders
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	Total
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	2,237,317
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	4.16
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1,648,413
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
</EFX_SECURITY_OWNERS>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.75IN; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<EFX_OFFICER_TRANSACTIONS>
<A NAME="FIS_OFFICER_TRANSACTIONS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
	ITEM&nbsp;13.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A NAME="T1600102_10K_HTM_A_019">
</A>
	CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
	INDEPENDENCE
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Related Person Transactions
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We review all relationships and transactions
	in which the Company and our directors and executive officers or their immediate family members are participants to determine whether
	such persons have a direct or indirect material interest. The Company&rsquo;s senior management is primarily responsible for the
	development and implementation of processes and controls to obtain information from the directors and executive officers with respect
	to related person transactions, including obtaining annual written certifications of the directors and executive officers with
	respect to their knowledge of related person transactions. The Company&rsquo;s senior management is responsible for then determining,
	based on the facts and circumstances, whether the Company or a related person has a direct or indirect material interest in the
	transaction. The Audit Committee reviews and approves or ratifies any related person transaction that meets the standard for disclosure
	under the SEC rules. The Audit Committee&rsquo;s review of related person transactions, including information reported to the Audit
	Committee by senior management and the written certifications, encompasses transactions with related persons within the meaning
	of Item 404 of Regulation S-K as promulgated by the SEC. The Audit Committee reviews each potential related person transaction
	on its underlying merit. In accordance with the Audit Committee&rsquo;s practices, in the course of its review and approval or
	ratification of related person transactions, the Audit Committee considers:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&bull;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the nature of the related person&rsquo;s interest in the transaction;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&bull;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the material terms of the transaction, including, without limitation, the amount and type of transaction;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&bull;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the importance of the transaction to the related person;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&bull;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	whether the transaction would impair the judgment of a director or executive officer to act in
	the best interest of the Company; and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&bull;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	any other matters the committee deems appropriate.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Any member
	of the Audit Committee who is a related person with respect to a transaction under review may not participate in the deliberations
	or vote respecting approval or ratification of the transaction; provided, however, that such director may be counted in determining
	the presence of a quorum at a meeting of the committee that considers the transaction.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 67; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	67
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage68"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In connection
	with Dr. Horovitz&rsquo;s resignation from the Board of Directors, the Company entered into a consulting agreement with Dr. Horovitz
	effective as of the date of his resignation from the Board of Directors, October&nbsp;24, 2014, in order to have the benefit of
	his scientific knowledge and his institutional knowledge of the Company. The consulting agreement will run through June&nbsp;30,
	2016 and provides that, among other things, Dr.&nbsp;Horovitz will provide consulting services requested by the Board or the Chief
	Executive Officer. The Company paid a consulting fee to Dr. Horovitz of $7,500 in 2014, and has paid and will continue to pay $10,000
	per calendar quarter thereafter until the end of the agreement. The Company does not currently anticipate that it will require
	Dr. Horovitz&rsquo;s services for more than one full day per calendar quarter. However, if the Company requests Dr. Horovitz to
	provide more than one full day of service per calendar quarter, he will receive an additional payment of $1,000 per day. The agreement
	contains other customary terms, including provisions on confidentiality of GenVec information and invention assignment provisions.
	There were no other related person transactions in 2015 or 2014.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Director Independence
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The Board
	of Directors has affirmatively determined that each of the following directors is independent within the meaning of the NASDAQ
	director independence standards: Wayne T. Hockmeyer, Ph.D.; William N. Kelley, M.D.; Stefan D. Loren, Ph.D.; Marc R. Schneebaum;
	Quinterol J. Mallette, M.D.; and Michael Richman. The Board has also determined that all standing committees of the Board of Directors
	are composed entirely of independent directors. The Board of Directors has determined that Douglas J. Swirsky, the Company&rsquo;s
	President and Chief Executive Officer, is not independent within the meaning of the NASDAQ director independence standards.
</FONT>
</P>
</EFX_OFFICER_TRANSACTIONS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<EFX_ACCOUNTANT_FEES>
<A NAME="FIS_ACCOUNTANT_FEES"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="T1600102_10K_HTM_A_020">
</A>
	ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Principal Accountant Fees and Services
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The following is a summary of the fees
	billed to GenVec by KPMG LLP (KPMG), the Company&rsquo;s former principal accountant, and Stegman &amp; Company (Stegman), the
	Company&rsquo;s current principal accountant, for professional services rendered for the years ended December 31, 2015 and 2014:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_12"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 60%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 2PX SOLID; PADDING-LEFT: 0">
	Fee Category
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-LEFT: 0">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="WIDTH: 64%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-LEFT: 0">
	Audit Fees
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 15%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	109,725
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 15%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	143,326
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-LEFT: 0">
	Audit-Related Fees
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	70,000
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	149,531
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-LEFT: 0">
	Tax Fees
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; PADDING-LEFT: 0">
	All Other Fees
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	722
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-LEFT: 0">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX; PADDING-LEFT: 0">
	Total
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	179,725
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	293,579
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<I>
	Audit Fees
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	These fees consist of fees for professional
	services rendered for the audit of GenVec&rsquo;s financial statements, review of the interim financial statements included in
	quarterly reports, and services in connection with regulatory filings. All audit fees in 2015, were paid to Stegman. In 2014, we
	paid $44,800 to KPMG and $98,526 to Stegman for audit fees.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<I>
	Audit-Related Fees
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	These fees comprise assurance and related
	services that are reasonably related to the performance of the audit or review of the Company&rsquo;s financial statements and
	are not reported under &ldquo;Audit Fees&rdquo; above. In 2015, we paid $50,000 to KPMG and $20,000 to Stegman for audit-related
	fees. In 2014, we paid $137,836 to KPMG and $11,695 to Stegman for audit-related fees.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<I>
</I>
</P>
<!-- FIELD: PAGE; SEQUENCE: 68 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	68
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage69"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<I>
	Tax Fees
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	These fees comprise tax compliance and
	tax preparation assistance for state and federal filings, consultations concerning tax-related matters, and other tax compliance
	projects. GenVec did not incur such fees with KPMG or Stegman during 2015 or 2014.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<I>
	All Other Fees
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	All other fees consist of fees not included in any of the other
	categories above. GenVec did not incur such fees in 2015. In, 2014, these fees were paid for services rendered by Stegman.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Audit Committee Pre-Approval Policies
	and Procedures
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Audit Committee&rsquo;s policy is
	to pre-approve all audit and non-audit services provided by Stegman and KPMG, our independent registered public accounting firms
	during 2015. On an ongoing basis, management of GenVec defines and communicates specific projects and categories of service for
	which the advance approval of the Audit Committee is requested. The Audit Committee reviews these requests and advises management
	if the Audit Committee approves the engagement of the Company&rsquo;s independent accounting firm. On a periodic basis, GenVec&rsquo;s
	management reports to the Audit Committee regarding the actual spending for such projects and services compared to the approved
	amounts. In 2015, all fees paid to Stegman and KPMG were pre-approved pursuant to the Audit Committee&rsquo;s policy. To ensure
	prompt handling of unexpected matters, the Audit Committee&rsquo;s charter authorizes its Chairman to act on behalf of the Audit
	Committee between regularly scheduled meetings, including pre-approving services provided by the Company&rsquo;s independent accounting
	firm. If the Chairman exercises this authority, he reports the action taken to the Audit Committee at its next regular meeting.
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 69; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	69
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_ACCOUNTANT_FEES>
</EFX_PART_III>
<A NAME="eolPage70"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_PART_IV>
<A NAME="FIS_PART_IV"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<A NAME="T1600102_10K_HTM_A_021">
</A>
	PART IV
</B>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-INDENT: -1IN">
	&nbsp;
</P>
<EFX_EXHIBITS>
<A NAME="FIS_EXHIBITS"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="T1600102_10K_HTM_A_022">
</A>
	ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(a)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Financial Statements &ndash; See &ldquo;Index to Financial Statements&rdquo; on page F-1
	below for a list of the financial statements being filed herein.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Financial Statements
	Schedules &ndash; All financial statement schedules are omitted because they are not applicable, not required under the instructions,
	or all the information required is set forth in the financial statements or notes thereto
</FONT>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Exhibits &ndash;
	The following exhibits are filed or incorporated by reference as part of this report.
</FONT>
</P>
</EFX_EXHIBITS>
</EFX_PART_IV>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_EXHIBIT_INDEX>
<A NAME="FIS_EXHIBIT_INDEX"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	Index
	to ExhibitS
</B>
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-TOP: 0; BORDER-BOTTOM: BLACK 2PX SOLID; WIDTH: 10%; PADDING-BOTTOM: 0">
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	EXHIBIT
<BR>
	NUMBER
</P>
</TD>
<TD STYLE="PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="PADDING-TOP: 0; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; WIDTH: 88%; PADDING-BOTTOM: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	DESCRIPTION
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	3.1
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Amended &amp; Restated Certificate of Incorporation, as amended, of the Company.
<SUP>
	(16)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	3.1(a)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Certificate of Designation of Series B Junior Participating Preferred Stock of the Company.
<SUP>
	(17)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	3.1(b)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Certificate of Amendment of the Amended and Restated Certificate of Incorporation, as amended, of the Company
<SUP>
	(26)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	3.2
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Amended &amp; Restated Bylaws of the Company.
<SUP>
	(17)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	4.1
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Specimen Common Stock Certificate.
<SUP>
	(1)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	4.2
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Rights Agreement dated as August 11, 2011 between the Company and American Stock Transfer &amp; Trust Company, LLC, the form of Certificate of Designation of Series B Junior Participating Preferred Stock attached as Exhibit A thereto, the form of Summary of Rights attached as Exhibit B thereto, and the form of Rights Certificate attached as Exhibit C thereto.
<SUP>
	(17)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	10.1&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Form of Indemnification Agreement for Directors and Officers.*
<SUP>
	(1)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	10.2&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	2002 Stock Incentive Plan as amended and forms of agreements thereunder.*
<SUP>
	(4)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	10.3&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Amendment to the GenVec, Inc. 2002 Stock Incentive Plan.*
<SUP>
	(10)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	10.4&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	2011 Omnibus Incentive Plan.*
<SUP>
	(18)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	10.5
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Amendment to 2011 Omnibus Incentive Plan dated July 11, 2012.
<SUP>
	(19)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	10.6
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Amendment to 2011 Omnibus Incentive Plan dated November 22, 2013.
<SUP>
	(20)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	10.7
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	GenVec, Inc. 2015 Omnibus Incentive Plan.*
<SUP>
	(25)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	10.8
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Form of Incentive Stock Option Agreement under GenVec, Inc. 2015 Omnibus Incentive Plan.* (filed herewith)
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	10.9
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Form of Director Non-Qualified Stock Option Agreement (Annual Director Awards) under GenVec, Inc. 2015 Omnibus Incentive Plan.* (filed herewith)
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	10.10
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Form of Director Non-Qualified Stock Option Agreement (New Director Awards) under GenVec, Inc. 2015 Omnibus Incentive Plan.* (filed herewith)
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	10.11&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Amendment to Common Stock Warrant Agreement dated March 18, 2002 between the Company and Cornell Research Foundation, Inc.
<SUP>
	(2)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;10.12&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Lease Agreement dated May 4, 1999 between MOR BENNINGTON LLP and the Company.
<SUP>
	(1)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	10.13
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Amendment to Lease Agreement
	between MOR BENNINGTON LLP and the Company dated March 11, 2009.
<SUP>
	(5)
</SUP>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 70; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	70
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage71"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_13"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-TOP: 0; BORDER-BOTTOM: BLACK 2PX SOLID; PADDING-BOTTOM: 0">
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	EXHIBIT
<BR>
	NUMBER
</P>
</TD>
<TD STYLE="PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="PADDING-TOP: 0; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	DESCRIPTION
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; WIDTH: 10%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; WIDTH: 88%">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	10.14
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Salary Continuation Agreement between the Company and Douglas J. Swirsky dated September 18, 2006.*
<SUP>
	(6)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	10.15
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Amendment to Salary Continuation Agreement between the Company and Douglas J. Swirsky dated December 9, 2008.*
<SUP>
	(5)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	10.16
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Change in Control Agreement between the Company and Douglas J. Swirsky dated September 18, 2006.*
<SUP>
	(6)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	10.17
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Amendment to Change in Control Agreement between the Company and Douglas J. Swirsky dated December 9, 2008.*
<SUP>
	(5)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	10.18
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Salary Continuation Agreement between the Company and Douglas E. Brough dated February 1, 2010.*
<SUP>
	(20)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	10.19
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Salary Continuation Agreement between the Company and Bryan T. Butman dated October 15, 2002.*
<SUP>
	(20)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	10.20
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Amendment to Salary Continuation Agreement between the Company and Bryan T. Butman dated December 9, 2008.*
<SUP>
	(21)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	10.21
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Form of Indemnification and Advancement of Expenses Agreement dated December 10, 2003.*
<SUP>
	(3)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	10.22
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Agreement with the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases of the National Institutes of Health for the supporting the transfer of the Company&rsquo;s manufacturing processes dated September 30, 2006.+
<SUP>
	(13)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	10.23
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Agreement with the United States Department of Homeland Security for the development of adenovector-based foot and mouth vaccine candidates dated January 30, 2007.+
<SUP>
	(26)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	10.24
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Amendment to Agreement with the United States Department of Homeland Security for the development of adenovector-based foot and mouth vaccine candidates dated August 30, 2007.+
<SUP>
	(14)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	10.25
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Amendment to Agreement with the United States Department of Homeland Security for the development of adenovector-based foot and mouth vaccine candidates dated November 9, 2007.
<SUP>
	(15)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	10.26
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Agreement with the United States Department of Homeland Security for development of adenovector-based foot and mouth vaccine, dated February 12, 2010.
<SUP>
	(9)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	10.27
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Amendment to Agreement with the United States Department of Homeland Security for the development of adenovector-based foot-and-mouth vaccine candidates, dated September 20, 2010.+
<SUP>
	(24)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	10.28
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Amendment to Agreement with the United States Department of Homeland Security for the development of adenovector-based foot-and-mouth vaccine candidates, dated December 31, 2012.+
<SUP>
	(23)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	10.29
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Amendment to Agreement with the United States Department of Homeland Security for the development of adenovector-based foot-and-mouth vaccine candidates, dated March 19, 2013.+
<SUP>
	(23)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	10.30
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Research Collaboration and License Agreement, dated January 13, 2010, by and between GenVec, Inc. and Novartis Institutes for BioMedical Research, Inc.+
<SUP>
	(8)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	10.31
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Amendment, dated January 24, 2012, to Research Collaboration and License Agreement, dated January 13, 2010, by and between GenVec, Inc. and Novartis Institutes for BioMedical Research, Inc.+
<SUP>
	(20)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	10.32
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Amendment, dated January 12, 2013, to Research Collaboration and License Agreement, dated January 13, 2010, by and between GenVec, Inc. and Novartis Institutes for BioMedical Research, Inc.+
<SUP>
	(21)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; FONT-STYLE: NORMAL">
	10.33
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	Amendment No.
	1 to Research Collaboration and License Agreement, dated November 10, 2015, by and between Genvec, Inc. and Novartis Institutes
	for Biomedical Research, Inc. (filed herewith)
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	10.34
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Amended and Restated License Agreement, dated June 23, 1998, between the Company and the Cornell Research Foundation.+
<SUP>
	(1)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	10.35
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Amendment to Amended and Restated License Agreement, dated March 18, 2002, between the Company and the Cornell Research Foundation.+
<SUP>
	(2)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	10.36
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Agreement for the Supply of Services related to Development Materials, dated August 4, 2010, between Novartis Pharma AG and GenVec, Inc.+
<SUP>
	(11)
</SUP>
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 71; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	71
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage72"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_14"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-TOP: 0; BORDER-BOTTOM: BLACK 2PX SOLID; PADDING-BOTTOM: 0">
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	EXHIBIT
<BR>
	NUMBER
</P>
</TD>
<TD STYLE="PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="PADDING-TOP: 0; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	DESCRIPTION
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; WIDTH: 10%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; WIDTH: 88%">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	10.37
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Agreement, dated November 3, 2009, between GenVec, Inc. and SAIC-Frederick, Inc.+
<SUP>
	(12)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	10.38
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Equity Distribution Agreement, dated February 11, 2014, between the Company and Roth Capital Partners.
<SUP>
	(22)
</SUP>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	23.1&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Consent of Independent Registered Public Accounting Firm. (filed herewith)
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	24.1&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Power of Attorney. (filed herewith)
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	31.1&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Rule 13a-14(a) Certification by Principal Executive Officer. (filed herewith)
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	31.2&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Rule 13a-14(a) Certification by Principal Financial Officer. (filed herewith)
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	32.1&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Rule 13a-14(b) Certification by Principal Executive Officer pursuant to 18 United States Code Section 1350. (filed herewith)
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	32.2&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Rule 13a-14(b) Certification by Principal Financial Officer pursuant to 18 United States Code Section 1350. (filed herewith)
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	101.INS&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	XBRL Instance Document.
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	101.SCH&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	XBRL Taxonomy Extension Schema Document
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	101.CAL&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	XBRL Taxonomy Extension Calculation Linkbase Document.
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	101.DEF&nbsp;&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	XBRL Taxonomy Extension Definition Linkbase Document.
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	101.LAB&nbsp;&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	XBRL Taxonomy Extension Label Linkbase Document.
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	101.PRE&nbsp;&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 0; PADDING-BOTTOM: 0; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	XBRL Taxonomy Extension Presentation Linkbase Document.
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 72; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	72
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage73"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	*
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Compensatory plan, contract or arrangement.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	+
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Certain portions of this exhibit have been omitted based upon a request for confidential
	treatment. The omitted portions have been filed with the Commission pursuant to our application for confidential treatment.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(1)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Incorporated by reference to our Registration Statement on Form S-1, as amended (File No.
	333-47408) declared effective by the Securities and Exchange Commission on December 12, 2000.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(2)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Incorporated by reference from our Annual Report on Form 10-K (File No. 0-24469) filed with
	the Securities and Exchange Commission on March 31, 2003.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(3)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Incorporated by reference from our Annual Report on Form 10-K (File No. 0-24469) filed with
	the Securities and Exchange Commission on March 15, 2004.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(4)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Incorporated by reference from our Annual Report on Form 10-K (File No. 0-24469) filed with
	the Securities and Exchange Commission on March 17, 2008.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(5)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Incorporated by reference from our Annual Report on Form 10-K (File No. 0-24469) filed with
	the Securities and Exchange Commission on March 16, 2009.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(6)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Incorporated by reference from our Current Report on Form 8-K (File No: 0-24469) filed with
	the Securities and Exchange Commission on September 19, 2006.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(7)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Incorporated by reference from our Quarterly Report on Form 10-Q (File No. 0-24469) filed
	with the Securities and Exchange Commission on November 10, 2003.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(8)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Incorporated by reference from our Current Report on Form 8-K (File No. 0-24469) filed with
	the Securities and Exchange Commission on January 19, 2010.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(9)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Incorporated by reference from our Annual Report on Form 10-K (File No. 0-24469) filed with
	the Securities and Exchange Commission on March 12, 2010.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(10)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Incorporated by reference from our Current Report on Form 8-K (File No. 0-24469) filed with
	the Securities and Exchange Commission on June 18, 2010.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(11)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Incorporated by reference from our Quarterly Report on Form 10-Q (File No. 0-24469) filed
	with the Securities and Exchange Commission on August 6, 2010.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(12)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Incorporated by reference from our Quarterly Report on Form 10-Q (File No. 0-24469) filed
	with the Securities and Exchange Commission on November 9, 2010.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(13)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Incorporated by reference from our Quarterly Report on Form 10-Q (File No. 0-24469) filed
	with the Securities and Exchange Commission on November 9, 2006.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(14)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Incorporated by reference from our Quarterly Report on Form 10-Q (File No. 0-24469) filed
	with the Securities and Exchange Commission on November 9, 2007.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(15)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Incorporated by reference from our Quarterly Report on Form 10-Q (File No. 0-24469) filed
	with the Securities and Exchange Commission on August 8, 2008.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(16)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Incorporated by reference from our Quarterly Report on Form 10-Q (File No. 0-24469) filed
	with the Securities and Exchange Commission on August 9, 2011.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(17)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Incorporated by reference from our Current Report on Form 8-K (File No. 0-24469) filed with
	the Securities and Exchange Commission on August 12, 2011.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(18)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Incorporated by reference from our Proxy Statement on Schedule 14A (File No. 0-24469) filed
	with the Securities and Exchange Commission on November 4, 2014.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(19)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Incorporated by reference from our Quarterly Report on Form 10-Q (File No. 0-24469) filed
	with the Securities and Exchange Commission on November 9, 2012.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(20)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Incorporated by reference from our Annual Report on Form 10-K (File No. 0-24469) filed with
	the Securities and Exchange Commission on March 15, 2012.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 73; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	73
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage74"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(21)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Incorporated by reference from our Annual Report on Form 10-K (File No. 0-24469) filed with
	the Securities and Exchange Commission on March 22, 2013.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(22)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Incorporated by reference from our Current Report on Form 8-K (File No. 0-24469) filed with
	the Securities and Exchange Commission on February 13, 2014.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(23)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Incorporated by reference from our Quarterly Report on Form 10-Q (File No. 0-24469) filed
	with the Securities and Exchange Commission on May 10, 2013.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(24)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Incorporated by reference from our Annual Report on Form 10-K (File No. 0-24469) filed with
	the Securities and Exchange Commission on March 11, 2011.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(25)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Incorporated by reference from our Current Report on Form 8-K (File No. 0-24469) filed with
	the Securities and Exchange Commission on November 16, 2015.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(26)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Incorporated by reference from our Quarterly Report on Form 10-Q (File No. 0-24469) filed
	with the Securities and Exchange Commission on May 10, 2007.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 31.7PT; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 74; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	74
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_EXHIBIT_INDEX>
<A NAME="eolPage75"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 31.7PT; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_SIGNATURES>
<A NAME="FIS_SIGNATURES"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<A NAME="T1600102_10K_HTM_A_023">
</A>
	SIGNATURES
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Pursuant to the requirements
	of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
	by the undersigned, thereunto duly authorized.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD; WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; WIDTH: 10%">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; WIDTH: 40%">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	GENVEC, INC.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	By:&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	/s/
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
	DOUGLAS J. SWIRSKY
</FONT>
</FONT>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Douglas J. Swirsky
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Date:
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	President, Chief Executive Officer and Director
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	March 9, 2016
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Pursuant to the requirements
	of the Securities Exchange Act of 1934, this report has been signed below by the following persons in the capacities and on the
	dates indicated.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD; WIDTH: 39%">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; WIDTH: 39%">
	TITLE
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; WIDTH: 18%">
	DATE
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BORDER-BOTTOM: BLACK 2PX SOLID">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	/s/ DOUGLAS J. SWIRSKY
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	President, Chief Executive Officer,
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	March 9, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Douglas J. Swirsky
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Corporate Secretary, and Director
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(Principal Executive Officer)
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BORDER-BOTTOM: BLACK 2PX SOLID">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	/s/ JAMES V. LAMBERT
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Sr. Director, Accounting &amp; Finance,
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	March 9, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	James V. Lambert
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Corporate Controller, and Treasurer
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(Principal Financial Officer and Principal
	Accounting Officer)
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BORDER-BOTTOM: BLACK 2PX SOLID">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	*
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Director
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	March 9, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Wayne T. Hockmeyer, Ph.D.
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BORDER-BOTTOM: BLACK 2PX SOLID">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	*
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Director
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	March 9, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	William N. Kelley, M.D.
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BORDER-BOTTOM: BLACK 2PX SOLID">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	*
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Director
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	March 9, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Marc R. Schneebaum
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BORDER-BOTTOM: BLACK 2PX SOLID">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	*
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Director
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	March 9, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Stefan D. Loren
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BORDER-BOTTOM: BLACK 2PX SOLID">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	*
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Director
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	March 9, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Quinterol J. Mallette, M.D.
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BORDER-BOTTOM: BLACK 2PX SOLID">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	*
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Director
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	March 9, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Michael Richman
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD; WIDTH: 8%">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	*By:
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BORDER-BOTTOM: BLACK 2PX SOLID; WIDTH: 31%">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	/s/ DOUGLAS J. SWIRSKY
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; WIDTH: 61%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Douglas J. Swirsky, attorney-in-fact
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 75; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	75
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage76"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<A NAME="T1600102_10K_HTM_A_024">
</A>
	GENVEC, INC.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	INDEX TO FINANCIAL STATEMENTS
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX; WIDTH: 85%">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 2PX; WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; WIDTH: 13%">
	PAGE NO.
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: AZURE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM; LAYOUT-GRID-MODE: LINE; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<A HREF="#T1600102_10K_HTM_A_025">
	Report of Independent Registered Public Accounting Firm
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	F-1
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: AZURE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_026">
	Balance Sheets as of December 31, 2015 and 2014
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	F-2
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: AZURE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_027">
	Statements of Operations and Comprehensive Loss &mdash;Years Ended December 31, 2015 and 2014
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	F-3
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: AZURE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_028">
	Statements of Changes in Stockholders&rsquo; Equity &mdash;Years Ended December 31, 2015 and 2014
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	F-4
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: AZURE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_029">
	Statements of Cash Flows&mdash;Years Ended December 31, 2015 and 2014
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	F-5
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: AZURE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A HREF="#T1600102_10K_HTM_A_030">
	Notes to Financial Statements
</A>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	F-6 to F-22
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 76; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	76
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_SIGNATURES>
<A NAME="eolPage77"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<A NAME="T1600102_10K_HTM_A_025">
</A>
	REPORT OF INDEPENDENT
	REGISTERED PUBLIC ACCOUNTING FIRM
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	To the Board of Directors and Stockholders
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	of GenVec, Inc.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 10PT; TEXT-ALIGN: JUSTIFY">
	We have audited the accompanying
	balance sheets of GenVec, Inc. (the &ldquo;Company&rdquo;) as of December 31, 2015 and 2014, and the related statements of operations
	and comprehensive loss, changes in stockholders&rsquo; equity, and cash flows for each of the years in the two-year period ended
	December 31, 2015. These financial statements are the responsibility of the Company&rsquo;s management. Our responsibility is
	to express an opinion on these financial statements based on our audits.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 10PT; TEXT-ALIGN: JUSTIFY">
	We conducted our audits in accordance
	with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and
	perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. We
	were not engaged to perform an audit of the Company&rsquo;s internal control over financial reporting. Accordingly, we express
	no such opinion. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial
	statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall
	financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	In our opinion, the financial statements
	referred to above present fairly, in all material respects, the financial position of GenVec, Inc. as of December 31, 2015 and
	2014, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2015
	in conformity with accounting principles generally accepted in the United States of America.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<U>
	/s/ Stegman &amp; Company
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Baltimore, Maryland
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0PT; TEXT-ALIGN: JUSTIFY">
	March 9, 2016
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 10PT; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 77; OPTIONS: NEWSECTION; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	1
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_AUDITORS_OPINION>
<A NAME="eolPage78"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_BALANCE_SHEET>
<A NAME="FIS_BALANCE_SHEET"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<A NAME="T1600102_10K_HTM_A_026">
</A>
	GENVEC, INC.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	BALANCE SHEETS
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC">
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	As of December 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: WHITE">
<I>
	(in thousands, except per share data)
</I>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD">
	ASSETS
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Current assets:
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="WIDTH: 70%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: 10PT">
	Cash and cash equivalents
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	7,015
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	7,968
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: 10PT">
	Investments - available for sale, at fair value
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1,661
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	6,724
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: 10PT">
	Accounts receivable, net
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	166
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	325
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; TEXT-INDENT: 10PT">
	Prepaid expenses and other
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	245
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	219
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; TEXT-INDENT: 20.1PT">
	Total current assets
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	9,087
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	15,236
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Property and equipment, net
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	279
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	276
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX">
	Other assets
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	97
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	97
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; PADDING-LEFT: 27PT">
	Total assets
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	9,463
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	15,609
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	LIABILITIES AND STOCKHOLDERS' EQUITY
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Current liabilities:
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: 10PT">
	Accounts payable
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1,096
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1,146
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: 10PT; PADDING-BOTTOM: 2PX">
	Accrued expenses and other
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2PX SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PX SOLID">
	598
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2PX SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PX SOLID">
	1,076
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; TEXT-INDENT: 20.1PT">
	Total current liabilities
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1,694
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	2,222
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-INDENT: 20.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; TEXT-INDENT: 10PT">
	Other long term liabilities
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	89
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	89
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; TEXT-INDENT: 20.1PT">
	Total liabilities
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1,783
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	2,311
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-INDENT: 20PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Commitments and Contingencies
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Stockholders' equity:
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.1IN; PADDING-LEFT: 16.2PT">
	Preferred stock, $0.001 par value; 5,000 shares authorized in 2015 and 2014; none issued and outstanding in 2015 and 2014
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: 10PT">
	Common stock, $0.001 par value; 55,000 shares authorized in 2015 and 30,000
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: 20PT">
	shares authorized in 2014; 17,264 and 17,270 shares issued and
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: 20PT">
	outstanding in 2015 and 2014
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	17
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	17
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: 10PT">
	Additional paid-in capital
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	292,508
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	291,609
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: 10PT">
	Accumulated other comprehensive loss
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(5
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(33
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; TEXT-INDENT: 10PT">
	Accumulated deficit
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(284,840
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(278,295
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; TEXT-INDENT: 20.1PT">
	Total stockholders' equity
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	7,680
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	13,298
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; PADDING-LEFT: 27PT">
	Total liabilities and stockholders' equity
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	9,463
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	15,609
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_BALANCE_SHEET>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<I>
	See accompanying notes
	to financial statements.
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<I>
	&nbsp;
</I>
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 78; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage79"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<EFX_INCOME_STATEMENT>
<A NAME="FIS_INCOME_STATEMENT"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<A NAME="T1600102_10K_HTM_A_027">
</A>
	GENVEC, INC.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	STATEMENTS OF OPERATIONS AND COMPREHENSIVE
	LOSS
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC">
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	Years ended December 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: WHITE">
<B>
<I>
	(in thousands, except per share data)
</I>
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="WIDTH: 70%; FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	Revenues
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	885
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	6,041
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Operating expenses:
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	General and administrative
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	4,901
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	6,314
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; PADDING-LEFT: 9PT">
	Research and development
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	2,551
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	2,264
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; PADDING-LEFT: 9PT">
	Total operating expenses
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	7,452
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	8,578
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Operating loss
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(6,567
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(2,537
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Other income:
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; PADDING-LEFT: 9PT">
	Interest and Other Income, net
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	22
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	22
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX">
	Net loss
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(6,545
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(2,515
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX">
	Basic and diluted net loss per share
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(0.39
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(0.16
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX">
	Shares used in computation of basic and diluted net loss per share
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	16,778
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	15,827
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Comprehensive Loss:
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Net loss
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(6,545
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(2,515
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX">
	Unrealized holding gain (loss) on securities available for sale
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	28
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(11
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX">
	Comprehensive loss
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(6,517
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(2,526
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_INCOME_STATEMENT>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<I>
	See accompanying notes
	to financial statements.
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<I>
	&nbsp;
</I>
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 79; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage80"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<EFX_STOCKHOLDERS_EQUITY>
<A NAME="FIS_STOCKHOLDERS_EQUITY"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<A NAME="T1600102_10K_HTM_A_028">
</A>
	GENVEC, INC.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	STATEMENTS OF CHANGES IN STOCKHOLDERS'
	EQUITY
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	Accumulated
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	Additional
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	Other
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Common
	Stock
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	Paid-in
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	Comprehensive
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	Accumulated
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC; PADDING-BOTTOM: 2PX">
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Shares
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Amount
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Capital
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Loss
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Deficit
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Total
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD COLSPAN="21" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
<I>
	(in thousands)
</I>
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="WIDTH: 34%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-SIZE: 8PT">
	Balance, January 1, 2014
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	13,678
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	14
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	280,398
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(22
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(275,780
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	4,610
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Net loss
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(2,515
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(2,515
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Unrealized change in investments,
	net
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(11
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(11
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.1IN; PADDING-LEFT: 0.1IN">
<FONT STYLE="FONT-SIZE: 8PT">
	Restricted
	stock issued under stock benefit plans
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	3,592
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	3
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	10,663
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	10,666
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-SIZE: 8PT">
	Stock-based compensation
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	548
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	548
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-SIZE: 8PT">
	Balance, December 31, 2014
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	17,270
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	17
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	291,609
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(33
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(278,295
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	13,298
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Net loss
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(6,545
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(6,545
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Unrealized change in investments,
	net
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	28
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	28
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.1IN; PADDING-LEFT: 0.1IN">
<FONT STYLE="FONT-SIZE: 8PT">
	Cost
	of common stock issued under shelf registration
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(6
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(24
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(24
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-SIZE: 8PT">
	Stock-based compensation
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	923
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	-
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	923
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 4PX">
<FONT STYLE="FONT-SIZE: 8PT">
	Balance, December 31, 2015
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	17,264
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	17
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	292,508
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(5
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(284,840
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	7,680
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_STOCKHOLDERS_EQUITY>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<I>
	See accompanying notes
	to financial statements.
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 80; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage81"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_CASH_FLOW>
<A NAME="FIS_CASH_FLOW"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<A NAME="T1600102_10K_HTM_A_029">
</A>
	GENVEC, INC.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	STATEMENTS OF CASH FLOWS
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC">
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	Years ended December 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<I>
	(in thousands)
</I>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Cash flows from operating activities:
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 70%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Net loss
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(6,545
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(2,515
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Adjustments to reconcile net loss to net cash used in operating activities:
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: 10PT">
	Depreciation and amortization
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	97
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	220
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: 10PT">
	Bad debt expense
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	24
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: 10PT">
	Non-cash charges for stock-based compensation
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	923
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	548
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: 10PT">
	(Gain)/loss on sale of long lived assets
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(18
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	58
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: 10PT">
	Changes in current assets and liabilities, net
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(509
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(428
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: 10PT; PADDING-BOTTOM: 2PX">
	Changes in non-current assets, net
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2PX SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PX SOLID">
	89
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2PX SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PX SOLID">
	89
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; TEXT-INDENT: 20PT">
	Net cash used in operating activities
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(5,939
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(2,028
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Cash flows provided by investing activities:
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-INDENT: 10PT">
	Purchases of equipment
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(100
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(44
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: 10PT">
	Proceeds from sale of property and equipment
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	18
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	5
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: 10PT">
	Purchases of investment securities
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(9,723
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; TEXT-INDENT: 10PT">
	Proceeds from sale or maturity of investment securities
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	5,092
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	3,843
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; TEXT-INDENT: 20PT">
	Net cash provided by/(used in) investing activities
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	5,010
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(5,919
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Cash flows from financing activities:
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; TEXT-INDENT: 10PT">
	(Costs)/proceeds from issuance of common stock
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(24
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	10,666
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX">
	Cash flows from financing activities:
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(24
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	10,666
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-INDENT: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Change in cash and cash equivalents
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(953
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	2,719
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX">
	Beginning balance of cash and cash equivalents
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	7,968
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	5,249
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-INDENT: 20PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX">
	Ending balance of cash and cash equivalents
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	7,015
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	7,968
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_CASH_FLOW>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<I>
	See accompanying notes
	to financial statements.
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<I>
	&nbsp;
</I>
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 81; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage82"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<A NAME="T1600102_10K_HTM_A_030">
</A>
	GENVEC, INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<EFX_NOTES_TO_FINANCIAL_STATEMENT>
<A NAME="FIS_NOTES_TO_FINANCIAL_STATEMENT"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	NOTES TO FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(1) ORGANIZATION AND BUSINESS DESCRIPTION
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	GenVec,
	Inc. (GenVec, we, our, or the Company) is a clinical-stage biopharmaceutical company with an entrepreneurial focus on leveraging
	its proprietary AdenoVerse&trade; gene delivery platform to develop a pipeline of cutting-edge therapeutics and vaccines. The Company
	is a pioneer in the design, testing and manufacture of adenoviral-based product candidates that can deliver on the promise of gene-based
	medicine. GenVec&rsquo;s lead product candidate, CGF166, is licensed to Novartis Institutes for BioMedical Research, Inc. (together
	with Novartis AG and its subsidiary corporations, including Novartis Pharma AG, Novartis) and is currently in a Phase 1/2 clinical
	study for the treatment of hearing loss and balance disorders. In addition to our internal and partnered pipeline, we also focus
	on opportunities to license our proprietary technology platform, including vectors and production cell lines to potential collaborators
	in the biopharmaceutical industry for the development and manufacture of therapeutics and vaccines.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	A key
	component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with
	prominent companies and organizations such as Novartis, Merial Limited, and the U.S. government, as well as promising young companies
	such as TheraBiologics, to support a portfolio of programs that address the prevention and treatment of a number of significant
	human and animal health concerns. GenVec&rsquo;s combination of internal and partnered development programs addresses therapeutic
	areas such as hearing loss and balance disorders and oncology; as well as vaccines against infectious diseases including respiratory
	syncytial virus (RSV), herpes simplex virus (HSV) and malaria. In the area of animal health we are developing vaccines against
	foot-and-mouth disease (FMD).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Our AdenoVerse
	gene delivery technology has the important advantage of localizing protein delivery in the body. This is accomplished by using
	our adenovector platform to locally deliver genes to cells, which then direct production of the desired protein. This approach
	reduces side effects typically associated with systemic delivery of proteins. For therapeutics, the goal is for the protein produced
	to have meaningful effect in treating the cause, manifestation, or progression of the disease. For vaccines, the goal is to induce
	an immune response against a target protein or antigen. This is accomplished by using an adenovector to deliver a gene that causes
	production of an antigen, which then stimulates the desired immune reaction by the body.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Our research
	and development activities yield product candidates that utilize our technology platform and represent potential commercial opportunities.
	For example, preclinical research in hearing loss and balance disorders indicates that the delivery of the atonal gene using GenVec&rsquo;s
	adenovector technology may have the potential to restore hearing and balance function. We are currently working with Novartis on
	the development of novel treatments for hearing loss and balance disorders that emerged from these research and development efforts.
	There are currently no effective therapeutic treatments available for patients who have lost all balance function, and hearing
	loss remains a major unmet medical problem.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL; COLOR: BLACK">
	We
	have multiple vaccine candidates that leverage our core adenovector technology including our preclinical vaccine candidates for
	the prevention or treatment of RSV and HSV. We also have a program to develop a vaccine for malaria, a program in which we are
	currently working in collaboration with
</FONT>
<FONT STYLE="FONT-WEIGHT: NORMAL; COLOR: BLACK">
	the Laboratory of Malaria Immunology
	and Vaccinology (LMIV) of the National Institute of Allergy and Infectious Diseases, National Institutes of Health. In the field
	of animal health, we are working with Merial Limited to commercialize vaccines for the prevention of a major animal health problem,
	FMD. Development efforts for this program were supported by the U.S. Department of Homeland Security (DHS) and performed in collaboration
	with the U.S. Department of Agriculture (USDA).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Our business
	strategy is focused on entering into collaborative arrangements with third parties to complete the development and commercialization
	of our product candidates. In the event that third parties take over the development for one or more of our product candidates,
	the estimated completion date would largely be under the control of that third party rather than us. We cannot forecast with any
	degree of certainty which proprietary products or indications, if any, will be subject to future collaborative arrangements, in
	whole or in part, or how such arrangements would affect our development plan or capital requirements. Our programs may also benefit
	from subsidies, grants or government or agency-sponsored studies that could reduce our development costs.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 82; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage83"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	An element
	of our business strategy is to pursue, as resources permit, the research and development of a range of product candidates for a
	variety of indications. This is intended to allow us to diversify the risks associated with our research and development expenditures.
	To the extent we are unable to maintain a broad range of product candidates, our dependence on the success of one or a few product
	candidates would increase.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	As a
	result of the uncertainties involved in our business, we are unable to estimate the duration and completion costs of our research
	and development projects or when, if ever, and to what extent we will receive cash inflows from the commercialization and sale
	of a product. Our inability to complete our research and development projects in a timely manner or our failure to enter into
	collaborative agreements, when appropriate, could significantly increase our capital requirements and could adversely impact our
	liquidity. These uncertainties could force us to seek additional, external sources of financing from time to time in order to
	continue with our business strategy. Our inability to raise additional capital, or to do so on terms reasonably acceptable to
	us, would jeopardize the future success of our business. Our estimated future capital requirements are uncertain and could change
	materially as a result of many factors, including the progress of our research, development, clinical, manufacturing, and commercialization
	activities. However we believe our current cash and investments and committed and expected revenues from our strategic collaborations
	are expected to be sufficient to continue our current research, development and collaborative activities into the second quarter
	of 2017.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT">
	(2) SUMMARY OF SIGNIFICANT ACCOUNTING
	POLICIES
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(a) USE OF ESTIMATES
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The preparation
	of financial statements, in conformity with U.S. generally accepted accounting principles, requires management to make estimates
	and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, and revenues
	and expenses during the period. Critical accounting policies involved in applying our accounting policies are those that require
	management to make assumptions about matters that are highly uncertain at the time the accounting estimate was made and those for
	which different estimates reasonably could have been used for the current period. Critical accounting estimates are also those
	which are reasonably likely to change from period to period, and would have a material impact on the presentation of our financial
	condition, changes in financial condition or results of operations. Our most critical accounting estimates relate to accounting
	policies for strategic collaborations and research contract revenues, research and development activities, and stock-based compensation.
	Management bases its estimates on historical experience and on various other assumptions that it believes are reasonable under
	the circumstances. Actual results could differ from these estimates.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(b) CASH AND CASH EQUIVALENTS
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Cash
	equivalents consist of highly liquid debt instruments, time deposits, and money market funds with original maturities of three
	months or less.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	(c) INVESTMENTS
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Our investments
	consist primarily of corporate stock and bonds, government agency bonds, and commercial paper. These investments are classified
	as available-for-sale securities, which are carried at fair value, with the unrealized holding gains and losses reported as a separate
	component of accumulated other comprehensive income (loss) until realized. Realized gains and losses from the sale of available-for-sale
	securities are determined on a specific-identification basis.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	A decline
	in the market value of any available-for-sale security below cost that is deemed to be other-than-temporary results in a reduction
	in carrying amount to fair value. The impairment is charged to earnings and a new cost basis for the security is established. To
	determine whether impairment is other-than-temporary, we consider whether we have the ability and intent to hold the investment
	until a market price recovery and consider whether evidence indicating the cost of the investment is recoverable outweighs evidence
	to the contrary. Evidence considered in this assessment includes the reasons for the impairment, the severity and duration of the
	impairment, changes in value subsequent to year-end, forecasted performance of the investee, and the general market condition in
	the geographic area or industry the investee operates. Premiums and discounts are amortized or accreted over the life of the related
	security as an adjustment to yield using the effective interest method. Dividend and interest income are recognized when earned.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 83; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage84"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(d) FAIR VALUE OF FINANCIAL INSTRUMENTS
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The carrying
	amounts of our financial instruments, as reflected in the accompanying balance sheets, approximate fair value. Financial instruments
	consist of cash and cash equivalents, investments, accounts receivable, and accounts payable.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(e) PROPERTY AND EQUIPMENT
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Property
	and equipment are stated at cost and depreciated on a straight-line basis over the estimated useful lives of assets, which are
	generally three to five years for equipment and seven years for furniture and fixtures. Leased property meeting certain criteria
	is capitalized at the lower of the present value of the future minimum lease payments or fair value at the inception of the lease.
	Amortization of capitalized leased assets is computed on a straight-line basis over the shorter of the lease term or estimated
	useful life of the asset. We incur maintenance costs with respect to some of our major equipment. Repair and maintenance costs
	are expensed as incurred.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT">
	(f) REVENUE RECOGNITION
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Revenue
	is recognized when all four of the following criteria are met (i) a contract is executed, (ii) the contract price is fixed and
	determinable, (iii) delivery of the services or products has occurred, and (iv)&nbsp;collectability of the contract amounts is
	considered probable.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Our
	collaborative research and development agreements provide for upfront license fees, research payments, and/or substantive
	milestone payments. Upfront non-refundable fees associated with license and development agreements where we have continuing
	involvement in the agreement are recorded as deferred revenue and recognized over the estimated service period. If the
	estimated service period is subsequently modified, the period over which the upfront fee is recognized is modified
	accordingly on a prospective basis. Upfront non-refundable license and development fees for which no future
	performance obligations exist are recognized when collection is assured. Substantive milestone payments are considered
	performance payments and are recognized upon achievement of the milestone if all of the following criteria are met:
	(i)&nbsp;achievement of the milestone involves a degree of risk and was not reasonably assured at the inception of the
	arrangement; (ii) substantive effort is involved in achieving the milestone; and (iii) the amount of the milestone payment is
	reasonable in relation to all of the deliverables and payment terms within the arrangement. Determination of whether a
	milestone meets the aforementioned conditions involves the judgment of management.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Research
	and development revenue from cost-reimbursement and cost-plus fixed-fee agreements is recognized as earned based on the performance
	requirements of the contract. Revisions in revenues, cost, and billing factors, such as indirect rate estimates, are accounted
	for in the period of change. Reimbursable costs under such contracts are subject to audit and retroactive adjustment. Contract
	revenues and accounts receivable reported in the financial statements are recorded at the amount expected to be received. Contract
	revenues are adjusted to actual upon final audit and retroactive adjustment. Estimated contractual allowances are provided based
	on management&rsquo;s evaluation of current contract terms and past experience with disallowed costs and reimbursement levels.
	Payments received in advance of work performed are recorded as deferred revenue.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Research
	and development revenue from fixed-price best efforts arrangements is recognized as earned based on the performance requirements
	of the contract. Revenue under these arrangements is recognized when delivery to and acceptance by the customer has been received.
	During the period of performance, recoverable contract costs are accumulated on the balance sheet in other current assets, but
	no revenue or profit is recorded prior to customer acceptance of the contractually stated deliverables. Recoverable contract costs
	that are accumulated on the balance sheet include all direct costs associated with the arrangement and an allocation of indirect
	costs. Payments received in advance of customer acceptance are recorded as deferred revenue. Once customer acceptance has been
	received, revenue and recoverable contract costs are recognized. Over the course of the arrangement, we routinely evaluate whether
	revenue and profitability should be recognized in the current period. Any known or probable losses on projects are charged to operations
	in the period in which such losses are determined.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(g) RESEARCH AND DEVELOPMENT
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Research
	and development costs are charged to operations as incurred. Advance payments to acquire goods or pay for services that will be
	consumed or performed in a future period in conducting research and development activities are recorded as an asset when the advance
	payments are made. Capitalized amounts are recognized as expense when the research and development activities are performed; that
	is, when the goods without alternative future use are acquired or the service is rendered.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 84; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage85"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Research
	and development costs include internal research and development expenditures (such as salaries and benefits, raw materials, supplies,
	and allocated facility expenses), contracted services (such as sponsored research, consulting, manufacture of drug supply, and
	testing services of proprietary research), and development activities and similar expenses associated with collaborative research
	agreements. These costs are expensed as incurred.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(h) INCOME TAXES
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Income
	taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future
	tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities
	and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured
	using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be
	recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the
	period that includes the enactment date. We recognize the effect of income tax positions only if those positions are more likely
	than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50 percent
	likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.
	We include any interest or penalties incurred in connection with income taxes as part of other expense.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We have
	significant net operating loss carryforwards to potentially reduce future federal and state taxable income, and research and experimentation
	tax credit carryforwards available to potentially offset future federal income taxes. Due to the Company&rsquo;s prior equity transactions,
	the Company&rsquo;s net operating loss and research and experimentation credit carryforwards may expire unutilized due to changes
	in our ownership as defined within Section 382 of the Internal Revenue Code.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The ultimate
	realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those
	temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future
	taxable income, and tax planning strategies in making that assessment. We recorded a full valuation allowance against all estimated
	net deferred tax assets at December&nbsp;31, 2015 and 2014.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(i) NET LOSS PER SHARE
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Basic
	earnings per share is computed based upon the net loss available to common stock stockholders divided by the weighted average number
	of common stock shares outstanding during the period. The dilutive effect of common stock equivalents is included in the calculation
	of diluted earnings per share only when the effect of the inclusion would be dilutive. For the years ended December&nbsp;31, 2015
	and 2014 all common stock equivalent shares associated with our stock option plans, unvested restricted shares, and stock equivalent
	shares associated with our warrants were excluded from the denominator in the diluted loss per share calculation as their inclusion
	would have been antidilutive.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(j) COMPREHENSIVE INCOME (LOSS)
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Comprehensive
	income (loss) consists of net loss and unrealized holding gains and losses from available-for-sale securities.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(k) STOCK-BASED COMPENSATION
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We use
	the modified prospective method to account for stock-based compensation. Under this method, we measure stock-based compensation
	expense based on the grant date fair value of the awards which is then recognized over the period during which service is required
	to be provided. We estimate grant date fair value using the Black-Scholes option-pricing model. Stock-based compensation cost amounted
	to $0.9 million and $0.5 million for the years ended December&nbsp;31, 2015 and 2014, respectively.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(l) LONG-LIVED ASSETS
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL; COLOR: BLACK">
	Long-lived
	assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the
	carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset be tested for possible impairment,
	we first compare undiscounted cash flows expected to be generated by an asset to the carrying value of the asset. If the carrying
	value of the long-lived asset is not recoverable on an undiscounted cash flow basis, impairment is recognized to the extent that
	the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash
	flow models, quoted market values, and third party independent appraisals, as necessary.
</FONT>
<FONT STYLE="FONT-WEIGHT: NORMAL; BACKGROUND-COLOR: YELLOW">
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 85; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage86"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(m) COMMITMENTS AND CONTINGENCIES
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Liabilities
	for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is
	probable that a liability has been incurred and the amount of the assessment and/or remediation can be reasonably estimated. Legal
	costs incurred in connection with loss contingencies are expensed as incurred.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(n) RECENT ACCOUNTING PRONOUNCEMENTS
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL; COLOR: BLACK">
	In
	January 2016, the
</FONT>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Financial Accounting Standards Board (&ldquo;FASB&rdquo;),
<FONT STYLE="COLOR: BLACK">
	issued
</FONT>
	Accounting Standards Update
<FONT STYLE="COLOR: BLACK">
	(&ldquo;ASU&rdquo;) 2016-01, &ldquo;Financial Instruments-Overall
	(Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities,&rdquo; which amends the guidance
	in U.S. generally accepted accounting principles on the classification and measurement of financial instruments. Changes to the
	current guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and
	the presentation and disclosure requirements for financial instruments. In addition, the ASU clarifies guidance related to the
	valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt
	securities. The new standard is effective for fiscal years and interim periods beginning after December 15, 2017, and are to be
	adopted by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which
	the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial
	liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company
	is currently evaluating the impact of adopting this standard.
</FONT>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL; COLOR: BLACK">
	In
	November 2015, the FASB issued ASU 2015-17, &ldquo;Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes,&rdquo;
	which simplifies the presentation of deferred income taxes by requiring that deferred tax liabilities and assets be classified
	as noncurrent in a classified statement of financial position. This ASU is effective for financial statements issued for annual
	periods beginning after December 16, 2016, and interim periods within those annual periods.
</FONT>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The
	adoption of this standard will not have any impact on the Company&rsquo;s financial position, results of operations and disclosures.
<FONT STYLE="COLOR: BLACK">
</FONT>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In April&nbsp;2015, the FASB issued ASU
	No. 2015-05, &ldquo;Intangibles &ndash; Goodwill and Other &ndash; Internal-Use Software (Subtopic 350-40): Customer&rsquo;s Accounting
	for Fees Paid in a Cloud Computing Arrangement.&rdquo; This ASU provides clarification on whether a cloud computing arrangement
	includes a software license.&nbsp;If a software license is included, the customer should account for the license consistent with
	its accounting of other software licenses. If a software license is not included, the arrangement should be accounted for as a
	service contract.&nbsp;The update is effective for reporting periods beginning after December 15, 2015 and for interim periods
	within those fiscal years. Entities have the option of applying either a full retrospective approach to all periods presented or
	a prospective approach to all arrangements entered into or materially modified after the effective date. The adoption of this standard
	will not have any impact on the Company&rsquo;s financial position, results of operations and disclosures.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In April 2015, the FASB issued ASU No.
	2015-03, &ldquo;Interest&mdash;Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs.&rdquo;&nbsp;&nbsp;To
	simplify the presentation of debt issuance costs, the amendments in this ASU require that debt issuance costs related to a recognized
	debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent
	with debt discounts.&nbsp;&nbsp;The recognition and measurement guidance for debt issuance costs are not affected by the amendments
	in this ASU.&nbsp;&nbsp;The amendments in this ASU are effective for financial statements issued for fiscal years beginning after
	December 15, 2015 and interim periods within fiscal years beginning after December 15, 2016.&nbsp;&nbsp;Early adoption of the amendments
	in this ASU is permitted for financial statements that have not been previously issued.&nbsp;&nbsp;The adoption of this standard
	will not have any impact on the Company&rsquo;s financial position, results of operations and disclosures.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In January 2015, the FASB issued ASU No.
	2015-01, &ldquo;Income Statement &mdash; Extraordinary and Unusual Items (Subtopic 225-20):&nbsp;&nbsp;Simplifying Income Statement
	Presentation by Eliminating the Concept of Extraordinary Items.&rdquo; Extraordinary items are transactions or events that are
	both unusual in nature and infrequent in occurrence, and, currently, are required to be presented separately in an entity&rsquo;s
	income statement, net of income tax, after income from continuing operations. The changes eliminate the concept of extraordinary
	items and, therefore, the presentation of such items will no longer be required.&nbsp;&nbsp;Notwithstanding this change, an entity
	will still be required to present and disclose transactions or events that are both unusual in nature and infrequent in occurrence
	in the notes to the financial statements.&nbsp;&nbsp;The new standard is effective for fiscal years, and interim periods within
	those fiscal years, beginning after December 15, 2015.&nbsp;&nbsp;The adoption of this standard will not have any impact on the
	Company&rsquo;s financial position, results of operations and disclosures.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 86; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage87"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In August&nbsp;2014,
	the FASB issued ASU No. 2014-15, &ldquo;Presentation of Financial Statements &mdash; Going Concern (Topic 205),&rdquo; which requires
	management to assess an entity&rsquo;s ability to continue as a going concern and to provide related disclosures in certain circumstances.
	Under the new standard, disclosures are required when conditions or events give rise to substantial doubt about an entity&rsquo;s
	ability to continue as a going concern within one year from the financial statement issuance date. The new standard is effective
	for annual periods ending after December&nbsp;15, 2016, and all annual and interim periods thereafter. Early application is permitted.
	The adoption of this standard will not have any impact on the Company&rsquo;s financial position and results of operations and,
	at this time, the Company does not expect any impact on its disclosures.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In May&nbsp;2014,
	the FASB issued ASU No. 2014-09, &ldquo;Revenue from Contracts with Customers (Topic 606),&rdquo; which supersedes all existing
	revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue
	when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive
	for those goods or services. ASU 2014-09 was originally going to be effective for us on January 1, 2017; however, the FASB recently
	issued
<I>
	ASU 2015-14, &ldquo;Revenue from Contracts with Customers (Topic 606) &ndash; Deferral of the Effective Date,&rdquo;
</I>
	which deferred the effective date of ASU 2014-09 by one year to January 1, 2018. We are currently evaluating the potential impact
	of ASU 2014-09 on our financial statements.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	There
	are no other new accounting pronouncements issued by but not effective until after December&nbsp;31, 2015 that could have a significant
	effect on our financial position or results of operations.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	(3) FAIR VALUE MEASUREMENTS
</B>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	For assets
	and liabilities measured at fair value we utilize FASB Accounting Standards Codification (ASC) Section 820 &ldquo;Fair Value Measurements
	and Disclosures&rdquo; (ASC 820), which defines fair value and establishes a framework for fair value measurements. This standard
	establishes a three-level hierarchy for disclosure of fair value measurements. The hierarchy is based upon the transparency of
	inputs to the valuation of an asset or liability as of the measurement date. The three levels of inputs used to measure fair value
	are as follows:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 38.25PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-WEIGHT: NORMAL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Level 1 &ndash; Quoted prices in active markets for identical assets or liabilities;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 38.25PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 38.25PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-WEIGHT: NORMAL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Level 2 &ndash; Observable inputs other than quoted prices included in Level 1, such as quoted
	prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets
	that are not active; or other inputs that are observable (e.g. interest rates, yield curves, volatilities and default rates, among
	others) or can be corroborated by observable market data; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 38.25PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 38.25PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-WEIGHT: NORMAL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Level 3 &ndash; Unobservable inputs that are supported by little or no market activity and
	that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow
	methodologies, and similar techniques that use significant unobservable inputs.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 87; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage88"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The following
	table presents information about assets recorded at fair value on a recurring basis on the Balance Sheet at December 31, 2015:
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_15"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Quoted Prices in
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Active Markets for
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Significant
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Total Carrying
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Identical
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Other Observable
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Value on the
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Assets/Liabilities
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Inputs
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: ITALIC; PADDING-BOTTOM: 2PX">
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	Balance Sheet
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	(Level 1)
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	(Level 2)
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: ITALIC; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="10" STYLE="TEXT-ALIGN: CENTER">
<I>
	(
<B>
	in thousands
</B>
	)
</I>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD">
	Assets:
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="WIDTH: 40%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Cash and cash equivalents
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 17%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	7,015
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 17%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	7,015
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 17%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Corporate notes and bonds
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1,593
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1,593
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX">
	Equity Securities
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	68
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	68
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX">
	Total assets at fair value
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	8,676
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	7,083
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1,593
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The following table presents
	information about assets and liabilities recorded at fair value on a recurring basis on the Balance Sheet at December 31, 2014:
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_16"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Quoted Prices in
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Active Markets for
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Significant
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Total Carrying
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Identical
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Other Observable
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Value on the
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Assets/Liabilities
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Inputs
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: ITALIC; PADDING-BOTTOM: 2PX">
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	Balance Sheet
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	(Level 1)
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	(Level 2)
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: ITALIC; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="10" STYLE="TEXT-ALIGN: CENTER">
<I>
	(
<B>
	in thousands
</B>
	)
</I>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD">
	Assets:
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="WIDTH: 40%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Cash and cash equivalents
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 17%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	7,968
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 17%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	7,968
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 17%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Corporate notes and bonds
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	6,475
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	6,475
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	U.S. Government and agency securities
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	200
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	200
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX">
	Equity Securities
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	49
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	49
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX">
	Total assets at fair value
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	14,692
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	8,017
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	6,675
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We determine
	fair value for our investments with Level 1 inputs through quoted market prices and have classified them as available-for-sale.
	Our Level 2 investments consist of corporate notes and bonds maturing at various times into 2016.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We
	review all investments for other-than-temporary impairment at least quarterly or as indicators of impairment exist. Indicators
	of impairment include the duration and severity of the decline in fair value as well as the intent and ability to hold the investment
	to allow for a recovery in the market value of the investment. In addition, we consider qualitative factors that include, but are
	not limited to: (i) the financial condition and business plans of the investee including its future earnings potential; (ii) the
	investee&rsquo;s credit rating; and (iii) the current and expected market and industry conditions in which the investee operates.
	If a decline in the fair value of an investment is deemed by management to be other-than-temporary, we write down the cost basis
	of the investment to fair value, and the amount of the write down is included in net earnings. Such a determination is dependent
	on the facts and circumstances relating to each investment. We have determined there have been no such impairments in 2015 or 2014;
	however, as of December&nbsp;31, 2015, the Company has an accumulated unrealized loss of&thinsp;$5,000; which is related to our
	equity security holding which has been in a loss position for over 12 months.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	All unrealized
	holding gains or losses related to our investments in marketable securities are reflected in our statements of operations and comprehensive
	loss.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 88; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage89"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	A summary of investments is
	shown below:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_17"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	Gross Unrealized
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	December 31, 2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	Amortized&nbsp;Cost
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	Gains
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	Losses
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	Fair Value
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD COLSPAN="14" STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC; TEXT-ALIGN: CENTER">
	(in thousands)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL">
	Investments
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 48%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; PADDING-LEFT: 9PT">
	Corporate and agency notes and corporate stock
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1,666
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(5
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1,661
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX">
	Total investments
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1,666
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(5
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1,661
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	December 31, 2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	Amortized Cost
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	Gains
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	Losses
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	Fair Value
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD COLSPAN="14" STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC; TEXT-ALIGN: CENTER">
	(in thousands)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL">
	Investments
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 48%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; PADDING-LEFT: 9PT">
	Corporate and agency notes and corporate stock
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	6,757
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(33
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	6,724
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX">
	Total investments
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	6,757
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(33
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	6,724
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_18"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(4) PROPERTY AND EQUIPMENT
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Property and equipment consists
	of the following at December 31:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC; TEXT-ALIGN: CENTER">
	(in thousands)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="WIDTH: 74%; FONT-WEIGHT: NORMAL">
	Equipment
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	881
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1,018
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Leasehold improvements
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	66
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	35
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX">
	Furniture and fixtures
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	105
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	99
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1,052
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1,152
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX">
	Less accumulated depreciation and amortization
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(773
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(876
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	279
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	276
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Depreciation and amortization
	expense related to property and equipment was $0.1 million and $0.2 million for the years ended December&nbsp;31, 2015 and 2014,
	respectively. In September&nbsp;2014, we sold office equipment and other long-lived assets for $5,000. Due to the sale, we recognized
	a loss of&thinsp;$41,000. Additionally, we incurred $39,000 of accelerated depreciation for long-lived assets that have been taken
	out of service during the third quarter of 2014. In the fourth quarter of 2015, we sold laboratory equipment and recognized a gain
	on the sales of $18,000.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In 2014,
	our lease on our facility at 65 W. Watkins Mill Road expired. As a result, we have removed leasehold improvements related to that
	facility as well as fully depreciated furniture and equipment that were disposed of. Gains and losses associated with the sale
	of long-lived equipment and the impairment of long-lived assets have been recorded within general and administrative expense, as
	applicable.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 89; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage90"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_19"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(5) ACCRUED EXPENSES AND OTHER
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Accrued expenses and other
	consist of the following at December 31:
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 70%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC; TEXT-ALIGN: CENTER">
	(in thousands)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="WIDTH: 70%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Payroll, compensation, and benefits
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	450
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	602
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Professional fees
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	131
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	354
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	Other
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	17
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	120
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX">
	Total accrued expenses
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	598
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1,076
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(6) STRATEGIC COLLABORATIONS AND RESEARCH CONTRACTS
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We have
	established collaborations and research contracts with pharmaceutical and biotechnology companies and governmental agencies to
	enhance our ability to discover, evaluate, develop, and commercialize multiple product opportunities as well as other licensing
	arrangements. Revenue earned under these contracts is summarized as follows:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_20"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC; TEXT-ALIGN: CENTER">
	(in thousands)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="WIDTH: 70%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Hearing Program
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	424
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	5,529
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Foot and Mouth Disease Program
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	180
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	404
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Malaria Program
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	131
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	108
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX">
	Other strategic collaborations and research grants
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	150
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	885
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	6,041
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(a) NOVARTIS
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In January&nbsp;2010,
	we signed a research collaboration and license agreement (the Agreement) with Novartis to discover and develop novel treatments
	for hearing loss and balance disorders. Under terms of the Agreement, we licensed the world-wide rights to our preclinical hearing
	loss and balance disorders program to Novartis. We received a $5.0 million non-refundable upfront license fee and Novartis purchased
	$2.0 million of our common stock. The common stock was recorded at fair value of $3.3 million on the date of issuance. The upfront
	non-refundable fee was recognized ratably over the initial term of the two-year research and collaboration term of the Agreement.
	Revenue recognized from the non-refundable upfront license fee was $3.7 million by the end of the initial Agreement due to the
	pricing agreement associated with the sale of our common stock. In each of January 2012 and January 2013, we announced that we
	had extended the Agreement. Under the extensions, Novartis funded research at GenVec through January 2014 to support the hearing
	loss and balance disorders program. In addition, we receive funding under the Agreement from Novartis for a research program focused
	on developing additional adenovectors for hearing loss. For each of the years ended December&nbsp;31, 2015 and 2014 we recognized
	$0.2 million for work performed under the Agreement.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Under
	the Agreement, we are eligible to receive milestones payments of up to $206.6 million; including up to $0.6 million for the achievement
	of preclinical development activities, up to $26.0 million for the achievement of clinical milestones including (non-rejection
	of an IND with respect to a covered product, the first patient visit in Phase I, Phase IIb and Phase III clinical trials), up to
	$45.0 million for the receipt of regulatory approvals and up to $135.0 million for sales-based milestones.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 90; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage91"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	During
	each of the years ended December&nbsp;31, 2011 and 2010, we recognized $0.3 million of milestone payments as a result of the successful
	completion of preclinical development activities. In 2012 and 2013, there were no milestone payments received. In February&nbsp;2014,
	we achieved the third milestone in the collaboration with Novartis. The $2.0 million milestone was triggered by the non-rejection
	by the FDA of the IND filed by Novartis for CGF166. In October&nbsp;2014, we achieved the fourth milestone in the collaboration
	with Novartis. The $3.0 million milestone was triggered when the first patient was dosed in a Phase 1/2 clinical trial sponsored
	by Novartis utilizing GenVec technology for the treatment of severe-to-profound bilateral hearing loss.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	As
	of December&nbsp;31, 2015, milestones available under the Agreement include $21.0 million of additional clinical milestones, $45.0
	million in regulatory milestones, and $135.0 million of sales-based milestones. We are also entitled to royalties on future sales.
	There were no milestones achieved during 2015.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In January
	2016, we were notified by Novartis that enrollment was paused in the clinical study for CGF166. This pause was based on a review
	of data by the trial&rsquo;s Data Safety Monitoring Board in accordance with criteria in the trial protocol. Novartis will continue
	to collect safety and efficacy data on the nine patients currently enrolled in the study before determining whether to proceed
	with incremental patients.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In August&nbsp;2010,
	we signed an agreement for the supply of services relating to development materials with Novartis, related to our collaboration
	in hearing loss and balance disorders. Under this agreement, valued at $14.9 million, we agreed to manufacture clinical trial material
	for up to two lead candidates. During the years ended December&nbsp;31, 2015 and 2014 we recognized $0.2 million and $0.3 million,
	respectively, for services performed under this agreement.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(b) U.S. DEPARTMENT OF HOMELAND SECURITY (DHS)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In February&nbsp;2010,
	we signed a contract with the DHS to continue the development of adenovector-based vaccines against FMD. Under this contract, GenVec
	was to receive $3.8 million in program funding the first year and an additional $2.1 million if DHS exercises its renewal options
	under the contract. Under this contract, we were to use our adenovector technology to develop additional FMD-serotype candidate
	vaccines and also explore methods to increase the potency and simplify the production process of adenovector-based FMD vaccines.
	During the years ended December&nbsp;31, 2015 and 2014, we recognized $0.2 million and $0.4 million, respectively, for services
	performed under this agreement. As of December&nbsp;31, 2015, $5.8 million in revenue has been recognized under this contract since
	inception. Work under this agreement was completed in February&nbsp;2015.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT">
	(c) VACCINE RESEARCH CENTER
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In March&nbsp;2012,
	we received a grant from the NIAID, valued at approximately $600,000 to identify novel highly protective antigens for malaria vaccine
	development. We recognized $0.1 million in revenue for each of the years ended December&nbsp;31, 2015 and 2014.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(d) OTHER STRATEGIC COLLABORATIONS
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We have
	entered into other research grants with the government and recognized revenue derived from other collaborations during 2015. Revenue
	recognized under these collaborations and other licensing arrangements totaled $0.2 million and $6,000 in revenue for the years
	ended December&nbsp;31, 2015 and 2014.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(7) COMMITMENTS AND CONTINGENCIES
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(a) LEASE AGREEMENTS
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We have
	a non-cancelable operating lease for our facility in Gaithersburg, MD through June 30, 2021. Rent expense under all operating leases
	was approximately $0.2 million and $0.7 million for the years ended December&nbsp;31, 2015 and 2014, respectively.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 91; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage92"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Future
	minimum lease payments as of December&nbsp;31, 2015 under our non-cancelable operating leases are as follows (in thousands):
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_21"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 70%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.5IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="WIDTH: 80%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	2016
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 17%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	331
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	2017
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	391
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	2018
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	383
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	2019
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	391
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	2020
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	398
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	2021
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	202
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(b) LICENSE AGREEMENT
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In November&nbsp;2001,
	we entered into an exclusive, worldwide license agreement with Baylor College of Medicine for the rights related to the Atoh1 gene.
	Under the terms of the license agreement, we agreed to pay a non-refundable initial license fee of&thinsp;$50,000 at the time of
	execution of the license agreement and we also agreed to pay a minimum annual license maintenance fee, a percentage of product
	royalties, and milestone payments based on our achievement of certain clinical and regulatory related milestones for these rights.
	Our ability to meet the milestones is dependent on a number of factors including final approvals by regulatory agencies and the
	continued enforceability of patent claims.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT">
	(c) RESTRUCTURING
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Costs
	associated with the elimination of positions have been recorded as a general and administrative personnel cost.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	At December&nbsp;31,
	2015 and 2014, liabilities of approximately $0 and $128,000, respectively, remained in accrued expenses for the unpaid portion
	of the severance costs.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(8) STOCKHOLDERS&rsquo; EQUITY
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(a)
</TD>
<TD>
	CAPITAL STOCK
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In January&nbsp;2014,
	we filed a $75.0 million shelf registration statement on Form S-3 (the 2014 shelf registration statement), with the Securities
	and Exchange Commission. The 2014 shelf registration statement was declared effective February&nbsp;11, 2014 and allows us to obtain
	financing through the issuance of any combination of common stock, preferred stock or warrants. Pursuant to General Instruction
	I.B.6 of Form S-3, in no event will we sell securities in a public primary offering with a value exceeding more than one-third
	of our public float in any 12-month period so long as our public float remains below $75.0 million.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	On February&nbsp;11,
	2014, we entered into an Equity Distribution Agreement (the EDA) with Roth Capital Partners, LLC (Roth Capital Partners), pursuant
	to which we may sell from time to time up to $10.0 million of shares of our common stock, par value $0.001 per share, through
	Roth Capital Partners (the ATM Offering). Sales of shares in the ATM Offering, if any, may be made by any method permitted by
	law deemed to be an &ldquo;at the market&rdquo; offering as defined in Rule 415 of the Securities Act of 1933, as amended, including
	without limitation directly on the NASDAQ Capital Market, or any other existing trading market for the shares or through a market
	maker, or, if agreed by the Company and Roth Capital Partners, by any other method permitted by law, including but not limited
	to in negotiated transactions. The ATM Offering is being made pursuant to the 2014 shelf registration statement. We have used
	and intend to continue using the net proceeds from the sale of shares in the ATM Offering, if any, for operating costs,
	working capital and general corporate purposes. At the time of the registered direct offering described immediately below, we
	suspended the ATM Offering. We will continue to evaluate the market and look for opportunities to resume activity under the ATM
	Offering. As of March&nbsp;31, 2014, we had sold 721,677 shares in the ATM Offering for gross proceeds of approximately
	$2.6 million. We have not sold any shares under the ATM Offering since that date.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	On March&nbsp;18,
	2014, we sold 2,870,000 shares of our common stock in a registered direct offering pursuant to the 2014 shelf registration statement
	(the Registered Direct Offering), at a price of&thinsp; $3.15 per share, resulting in gross proceeds of approximately $9.0 million.
	We have used and intend to continue using the net proceeds, $8.4 million, from the sale of shares in the Registered Direct Offering
	for operating costs, working capital and general corporate purposes.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 92; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage93"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Effective
	September 7, 2011 we entered into a Stockholder Rights Agreement between the Company and American Stock Transfer &amp; Trust Company,
	LLC, as rights agent. The Stockholder Rights Agreement was not adopted in response to any specific effort to acquire control of
	the Company. In connection with the adoption of the Stockholder Rights Agreement, the Company&rsquo;s Board of Directors declared
	a dividend of one preferred stock purchase right, or Right, for each outstanding share of common stock to stockholders of record
	as of the close of business on September&nbsp;7, 2011. Initially, the Rights will be represented by GenVec&rsquo;s common stock
	certificates or book entry notations, will not be traded separately from the common stock and will not be exercisable. In the event
	that any person acquires beneficial ownership of 20% or more of the outstanding shares of GenVec&rsquo;s common stock, or upon
	the occurrence of certain other events, each holder of a Right, other than the acquirer, would be entitled to receive, upon payment
	of the purchase price, which is initially set at $32 per Right, a number of shares of GenVec common stock having a value equal
	to two times such purchase price. The Company&rsquo;s Board of Directors is entitled to redeem the Rights at $0.001 per right at
	any time before a person or group has acquired 20% or more of the Company&rsquo;s common stock. The Rights will expire on September&nbsp;7,
	2021, subject to the Company&rsquo;s right to extend such date, unless earlier redeemed or exchanged by the Company or terminated.
	The Rights will at no time have any voting rights. The Company has authorized 30,000 shares of Series B Junior Participating Preferred
	Stock in connection with the adoption of the new Stockholder Rights Agreement. There was no Series B Junior Participating Preferred
	Stock issued or outstanding as of December&nbsp;31, 2015 or December&nbsp;31, 2014.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL; COLOR: BLACK">
	In
	addition to the common stock reflected on our balance sheets, the following items are reflected in the capital accounts as of December&nbsp;31,
	2015 and 2014:
</FONT>
<FONT STYLE="COLOR: BLACK">
</FONT>
<FONT STYLE="FONT-WEIGHT: NORMAL; BACKGROUND-COLOR: YELLOW">
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-WEIGHT: NORMAL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	4,400,000 shares of $0.001 par value preferred stock have been authorized; none are issued
	or outstanding.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-WEIGHT: NORMAL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	600,000 shares of $0.001 par value Series A junior participating preferred stock have been
	authorized in connection with the preferred stock purchase rights referred to above; none are issued or outstanding.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(b) STOCK-BASED COMPENSATION
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Stock Incentive Plans
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Our stockholders
	approved the 2015 Omnibus Incentive Plan (2015 Plan) in November&nbsp;2015. The 2015 Plan increased the number of shares of common
	stock that are available to be issued through grants or awards made thereunder or through the exercise of options granted by 1,500,000
	shares. At December&nbsp;31, 2015 there were 1,648,413 shares available for future issuance and 2,237,317 outstanding options under
	the 2015 Plan, the 2011 Omnibus Incentive Plan (2011 Plan), the CEO Incentive Plan, and the 2002 Stock Incentive Plan (2002 Plan).
	Options outstanding under the 2015 Plan at December&nbsp;31, 2015 expire through 2025.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Stock
	options granted under the 2015 Plan generally have a contractual term of 10 years and vest ratably over a four- year service period,
	when the option is fully exercisable. The Compensation Committee administers the 2015 Plan, approves the individuals to whom options,
	restricted stock, or other awards will be granted, and determines the terms of the awards, including the number of shares granted
	and exercise price of each option.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The 2015
	Plan amends and restates the 2011 Plan, which was approved in June 2011 as the replacement to the 2002 Plan, which was approved
	in June&nbsp;2002. There were 97,500 outstanding options and no
	outstanding restricted stock awards under the 2015 Plan at December&nbsp;31, 2015. There were 1,710,333 outstanding options and
	no outstanding restricted stock awards under the 2011 Plan at December&nbsp;31, 2015. There were 346,151 outstanding options and
	no outstanding restricted stock awards under the 2002 Plan at December&nbsp;31, 2015. Options outstanding under the 2015 Plan at
	December&nbsp;31, 2015 expire through 2025. Options outstanding under the 2011 Plan at December&nbsp;31, 2015 expire through 2025.
	Options outstanding under the 2002 Plan at December&nbsp;31, 2015 expire through 2021.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	As of
	December 31, 2015 there are no unvested restricted stock awards under the 2015 Plan, the 2011 Plan or the 2002 Plan.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In May&nbsp;2012,
	the Company granted an Inducement Award to purchase shares of common stock to our then President and Chief Executive Officer pursuant
	to a CEO inducement award agreement. The Inducement Award allowed for the purchase of up to 250,000 shares of common stock
	at an exercise price per share equal to $2.54. The option has a ten-year term and vested ratably over a four-year service
	period, when the option was to be fully exercisable. When the former CEO departed the Company she forfeited her unvested
	shares as of September&nbsp;3, 2013. There are 83,333 outstanding options awards under the CEO inducement plan at December&nbsp;31,
	2015.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 93; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage94"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_22"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Stock-Based Compensation Expense
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The following table summarizes stock-based
	compensation expense related to employee stock options for the years ended December 31, 2015 and 2014, which was allocated as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	Years ended December 31,
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: CENTER">
<B>
	(in thousands)
</B>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="WIDTH: 66%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	General and administrative
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	554
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	312
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX">
	Research and development
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	369
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	236
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	923
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	548
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We use the Black-Scholes pricing model
	to value stock options. The weighted-average estimated fair value of employee stock options granted during the 12 months ended
	December 31, 2015 and 2014 was calculated using the Black-Scholes model with the following weighted-average assumptions:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_23"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 70%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Range of risk-free interest rate
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	1.42%-1.87%
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	1.82%-2.01%
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 66%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Expected dividend yield
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	0.00
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	0.00
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Expected volatility
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	103.61
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	97.92
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Expected life (years)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	6.30
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	6.25
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Weighted-average fair value of options granted
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	2.27
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	2.60
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The risk-free
	interest rate assumption is based upon various U.S. Treasury rates as of the date of the grants. The dividend yield is based on
	the assumption that we are not expected to declare a dividend over the life of the options.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The
	volatility assumption for 2015 and 2014 is based on the weighted average volatility for the most recent one-year period as well
	as the volatility over the expected life of 6.30 and 6.25 respectively. The expected life of employee stock options represents
	the weighted average combining the actual life of the options that have already been exercised or cancelled with the expected
	life of all outstanding options. The expected life of outstanding options is calculated assuming the options will be exercised
	at the midpoint of the vesting date and the full contractual term.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The Company
	estimates forfeiture rates at the time of grant and revises these estimates, if necessary, in subsequent periods if actual forfeitures
	differ from those estimates. Forfeitures are estimated based on the demographics of current option holders and standard probabilities
	of employee turnover. Stock-based compensation expense recognized in the statement of operations for the year ended December&nbsp;31,
	2015 and 2014 has been adjusted for actual forfeitures during the respective periods. We do not record tax-related effects on stock-based
	compensation given our historical and anticipated operating experience and offsetting changes in our valuation allowance which
	fully reserves against potential deferred tax assets.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 94; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage95"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_24"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Stock Options
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The activity of the plans from January 1, 2014 to December 31,
	2015 is as follows: &nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
<B>
	Number
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
<B>
	Weighted
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
<B>
	Weighted
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
<B>
	of Shares
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
<B>
	Average
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
<B>
	Average
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
<B>
	Aggregate
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
<B>
	Under
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
<B>
	Exercise
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
<B>
	Contractual
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
<B>
	Intrinsic
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: ITALIC; BORDER-BOTTOM: BLACK 2PX SOLID">
<I>
	(in thousands, except per share data)
</I>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
<B>
	Option
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
<B>
	Price
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
<B>
	Life (years)
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
<B>
	Value
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="WIDTH: 48%; FONT-WEIGHT: BOLD">
	Outstanding at January 1, 2014
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1,346
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	5.35
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL">
	Granted
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	345
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	3.29
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL">
	Forfeited
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(2
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	31.00
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	Cancelled
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(10
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	31.82
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD">
	Outstanding at December&nbsp;31, 2014
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1,679
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	4.74
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL">
	Granted
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	572
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	2.79
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL">
	Exercised
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL">
	Forfeited
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL">
	Cancelled
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(14
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	18.37
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN; PADDING-BOTTOM: 4PX; PADDING-LEFT: 0IN">
	Stock options outstanding at December&nbsp;31, 2015
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 4PX DOUBLE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 4PX DOUBLE">
	2,237
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 4PX DOUBLE">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 4PX DOUBLE">
	4.16
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 4PX DOUBLE">
	7.0
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 4PX DOUBLE">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 4PX DOUBLE">
	119
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN; PADDING-BOTTOM: 4PX">
	Vested or expected to vest at December&nbsp;31, 2015
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 4PX DOUBLE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 4PX DOUBLE">
	2,111
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 4PX DOUBLE">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 4PX DOUBLE">
	4.23
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 4PX DOUBLE">
	6.9
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 4PX DOUBLE">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 4PX DOUBLE">
	116
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 4PX">
	Exercisable at December&nbsp;31, 2015
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 4PX DOUBLE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 4PX DOUBLE">
	1,516
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 4PX DOUBLE">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 4PX DOUBLE">
	4.83
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 4PX DOUBLE">
	6.2
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 4PX DOUBLE">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 4PX DOUBLE">
	84
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Unrecognized stock-based compensation expense
	related to stock options was approximately $1.4 million as of December 31, 2015. This amount is expected to be expensed over a
	weighted average period of 2.5 years. There were no stock options exercised during the years ended December 31, 2015 or 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The following table summarizes information about our stock options
	outstanding at December 31, 2015: &nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
<A NAME="FIS_UNIDENTIFIED_TABLE_25"></A>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="10" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	Outstanding
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	Exercisable
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Weighted
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	average
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Weighted
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Weighted
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	remaining
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	average
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	average
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Number
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	contractual
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	exercise
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Number
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	exercise
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 2PX SOLID">
	Range of exercise prices
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	of shares
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	life
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	price
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	of shares
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	price
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD COLSPAN="18" STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC; TEXT-ALIGN: CENTER">
	(number of shares in thousands)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="WIDTH: 35%; FONT-WEIGHT: NORMAL">
	$0.00 - $10.00
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	2,043
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	7.5
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	2.73
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1,322
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	2.72
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL">
	$10.01 - $20.00
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	110
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1.4
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	15.50
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	110
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	15.50
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL">
	$20.01 - $30.00
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	82
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	3.0
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	23.57
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	82
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	23.57
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	$30.01 - $41.00
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	2
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1.3
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	41.00
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	2
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	41.00
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	2,237
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	7 years
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	4.16
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1,516
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	4.83
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	As of
	December 31, 2015 options covering 1,515,536 shares were exercisable at $0.84 to $41.00 per share (average $4.83 per share) and
	there were 1,648,413 shares available for future issuance under the 2015 Plan.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 95; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage96"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Restricted Stock Awards
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In September&nbsp;2013,
	the Company issued 730,000 shares of restricted common stock under the 2011 Plan. The restricted stock awarded in 2013 vested in
	full two years after the date of grant in September 2015. After the net settlement of a portion of the restricted stock awards
	to satisfy tax withholding requirements in connection with vesting, 724,397 shares of the stock originally subject to the awards
	remained issued and outstanding. As of December 31, 2015 there are no unvested restricted stock awards.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT">
	(c) WARRANTS
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Warrants to purchase common stock were
	granted to organizations and institutions in conjunction with certain funding activities. The warrants typically vest six months
	after issuance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On May 29, 2014, 711,539 warrants with
	an exercise price of $8.58 issued in May 2009 expired. On February 1, 2015, 420,000 warrants with an exercise price of $27.50 issued
	in February 2009 expired. There were no warrants exercised during the year ended December 31, 2015 nor were there any warrants
	outstanding at December 31, 2015.&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT">
	(9) INCOME TAXES
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	For the
	years ended December 31, 2015 and 2014 there is no provision for income taxes included in the statement of operations. We have
	incurred operating losses, but have not recorded an income tax benefit for 2015 and 2014 as we have recorded a valuation allowance
	against our net operating losses and other net deferred tax assets due to uncertainties related to the ability to realize these
	tax assets. A reconciliation of tax credits computed at the statutory federal tax rate (34%) on operating loss before income taxes
	to the actual income tax expense is as follows (in thousands):
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_26"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 85%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="WIDTH: 70%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Tax provision computed at the statutory rate
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(2,225
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(855
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	State income taxes, net of federal income tax provision
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(356
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(137
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Book expenses not deductible for tax purposes
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	3
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	2
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Nondeductible compensation expense
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	151
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	113
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Tax credits and other
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(386
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	37
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX">
	Change in valuation allowance for deferred tax assets
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	2,813
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	840
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX">
	Income tax expense
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 4PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PX DOUBLE; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The Company
	provides for the recognition of deferred tax assets if realization of such assets is more likely than not. Based upon the weight
	of available evidence, which includes our historical operating performance and the reported accumulated net losses to date, we
	have provided a full valuation allowance against our deferred tax assets.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Deferred
	income taxes reflect the net effects of net operating loss carryforwards and the temporary differences between the carrying amounts
	of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components
	of our deferred tax assets are as follows (in thousands):
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_27"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 85%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="WIDTH: 70%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Net operating loss carryforwards
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	102,229
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	99,900
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Research and experimentation tax credit
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	14,568
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	14,226
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Property and equipment, principally due to differences in depreciation
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(78
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(74
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Accrued severance
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Deferred compensation expense
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1,063
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	869
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL">
	Other
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	153
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	210
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Total deferred tax assets
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	117,935
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	115,131
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT; PADDING-BOTTOM: 2PX">
	Valuation allowance
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2PX SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PX SOLID">
	(117,935
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2PX SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2PX SOLID">
	(115,131
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Net deferred tax assets
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 4PX DOUBLE">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 4PX DOUBLE">
	&mdash;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 4PX DOUBLE">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 4PX DOUBLE">
	&mdash;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 96; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage97"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The difference
	reflected in the change in the valuation allowance as it appears in the analysis of deferred tax assets in comparison to the reconciliation
	of income tax expense is the result of the tax impact of other comprehensive income.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	At December&nbsp;31,
	2015, we had net operating loss carryforwards of approximately $259.0 million for federal income tax purposes that expire at various
	dates through 2035. We have research and experimentation tax credit carryforwards of&thinsp;$14.6 million at December&nbsp;31,
	2015 that will expire at various dates through 2030.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Our NOL
	and tax credit carryforwards may be significantly limited under Section 382 of the Internal Revenue Code (IRC). NOL and tax credit
	carryforwards are limited under Section 382 when there is a significant &ldquo;ownership change&rdquo; as defined in the IRC. The
	amount of U.S. loss carryforward which can be used by the Company each year is limited due to the changes in the Company&rsquo;s
	ownership that occurred in 2003. Thus a portion of the Company&rsquo;s loss carryforward may expire unused.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The limitation
	imposed by Section 382 would place an annual limitation on the amount of NOL and tax credit carryforwards that can be utilized.
	When we complete the necessary studies, the amount of NOL carryforwards available may be reduced significantly. However, since
	the valuation allowance fully reserves for all available carryforwards, the effect of the reduction would be offset by a reduction
	in the valuation allowance. Thus, the resolution of this matter would have no effect on the reported assets, liabilities, revenues,
	or expenses for the periods presented.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	As discussed
	in Note 2, we recognize the effect of income tax positions only if those positions are more likely than not of being sustained
	effective January&nbsp;1, 2007. At December&nbsp;31, 2015 and December&nbsp;31, 2014, we had no gross unrecognized tax benefits.
	We do not expect any significant changes in unrecognized tax benefits over the next 12 months. In addition, we did not recognize
	any interest or penalties related to uncertain tax positions at December&nbsp;31, 2015 and 2014.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We file
	U.S. and state income tax returns in jurisdictions with varying statutes of limitations. The 2012 through 2015 tax years generally
	remain subject to examination by federal and most state tax authorities. In addition, we would remain open to examination for earlier
	years if we were to utilize net operating losses or tax credit carryforwards that originated prior to 2012.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_28"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(10) QUARTERLY RESULTS (UNAUDITED)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Our unaudited quarterly information
	is as follows:
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 2PX SOLID">
	2015 (unaudited)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	Q1
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	Q2
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	Q3
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	Q4
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD COLSPAN="14" STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: CENTER">
<B>
	(in thousands, except per share data)
</B>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="WIDTH: 48%; FONT-WEIGHT: NORMAL">
	Revenue
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	405
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	127
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	193
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	160
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Operating loss
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(1,536
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(1,875
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(1,511
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(1,645
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Net loss
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(1,529
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(1,869
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(1,505
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(1,642
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Basic and diluted net loss per share
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(0.09
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(0.11
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(0.09
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(0.10
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 2PX SOLID">
	2014 (unaudited)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	Q1
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	Q2
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	Q3
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 2PX SOLID">
	Q4
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD COLSPAN="14" STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: CENTER">
<B>
	(in thousands, except per share data)
</B>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="WIDTH: 48%; FONT-WEIGHT: NORMAL">
	Revenue
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	2,131
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	129
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	252
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	3,529
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Operating income/(loss)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(964
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(1,676
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(1,605
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1,708
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: AZURE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Net income/(loss)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(963
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(1,672
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(1,596
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	1,716
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	Basic and diluted net income/(loss) per share
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(0.07
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(0.10
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	(0.10
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT">
	0.11
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The net income/ (loss) per
	share was calculated for each three-month period on a stand-alone basis. As a result, the sum of the net income/ (loss) per share
	for the four quarters may not equal the loss per share for the respective 12-month period.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 97; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage98"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(11) SUBSEQUENT EVENTS
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	On February
	24, 2016, we received notification from NASDAQ that the minimum bid price of our common stock had remained below $1.00 per share
	for 30 consecutive business days, and we therefore are not in compliance with the minimum bid price requirement for continued listing
	set forth in Marketplace Rule 5550(a)(2). The notification letter stated that we would be afforded 180 calendar days, or until
	August 22, 2016, to regain compliance with the minimum bid price requirement. &nbsp;To regain compliance, the closing bid price
	of our common stock must meet or exceed $1.00 per share for at least ten consecutive business days.&nbsp;&nbsp;NASDAQ may, in its
	discretion, require our common stock to maintain a bid price of at least $1.00 per share for a period in excess of ten consecutive
	business days, but generally no more than 20 consecutive business days, before determining we have demonstrated an ability to maintain
	long-term compliance.&nbsp;&nbsp;If we do not regain compliance by August 22, 2016, we may be afforded a second 180 calendar day
	grace period. To qualify, we would be required to meet the continued listing requirement for market value of publicly held shares
	($1 million) and all other initial listing standards for NASDAQ, with the exception of the minimum bid price requirement. In addition,
	we would be required to provide written notice of our intention to cure the minimum bid price deficiency, and it must appear to
	NASDAQ that it is possible for us to cure the deficiency.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 98; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_NOTES_TO_FINANCIAL_STATEMENT>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
</EFX_FORM>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage99"></A>
<A NAME="T1600102_EX10-8_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10"></A>
<DIV STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Exhibit
	10.8
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 95%; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Option
	No.:
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	GENVEC,
	INC.
</B>
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2015
	OMNIBUS INCENTIVE PLAN
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	INCENTIVE STOCK OPTION AGREEMENT
</B>
<BR>
<B>
	COVER SHEET
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	GenVec, Inc., a Delaware
	corporation (the &ldquo;
<B>
	Company
</B>
	&rdquo;), hereby grants an option (the &ldquo;
<B>
	Option
</B>
	&rdquo;) to purchase shares of
	its common stock, par value $0.001 per share (the &ldquo;
<B>
	Stock
</B>
	&rdquo;), to the individual named below as the Grantee. The
	terms and conditions of the Option are set forth in this cover sheet and in the attached Incentive Stock Option Agreement (collectively,
	the &ldquo;
<B>
	Agreement
</B>
	&rdquo;) and in the Company&rsquo;s 2015 Omnibus Incentive Plan (as amended from time to time, the &ldquo;
<B>
	Plan
</B>
	&rdquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_29"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 25%; PADDING-RIGHT: 5.4PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Grant
	Date:
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 75%; BORDER-BOTTOM: BLACK 2PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-LEFT: 5.4PT">
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Name
	of Grantee:
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 2PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-LEFT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Number
	of Shares of Stock Covered by the Option:
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 2PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-LEFT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Option
	Price per share of Stock:
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 2PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-LEFT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Vesting
	Start Date:
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 2PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-LEFT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Vesting
	Schedule:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-LEFT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Subject to the terms of this Agreement
	and provided you continue in Service on each applicable vesting date:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;One-fourth (1/4) of the shares of Stock covered by this Option shall vest on the first (1
<SUP>
	st
</SUP>
	) anniversary of the Vesting
	Start Date, and
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
	Beginning on the first day of each month thereafter, an additional one-forty-eighth (1/48) of the shares of Stock covered
	by this Option shall vest.
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: NEWSECTION -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 9PT ARIAL, HELVETICA, SANS-SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage100"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	By
	signing this cover sheet, you agree to all of the terms and conditions described in this Agreement and in the Plan, a copy of
	which is located on the Company&rsquo;s intranet or will be provided upon request. You acknowledge that you have carefully reviewed
	the Plan and agree that the Plan will control in the event any provision of this Agreement should appear to be inconsistent with
	the Plan. Certain capitalized terms used in this Agreement are defined in the Plan and have the meaning set forth in the Plan.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<EFX_UNIDENTIFIED_TABLE>
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 6%; VERTICAL-ALIGN: BOTTOM">
<A NAME="FIS_UNIDENTIFIED_TABLE_30"></A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Grantee:
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 43%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 3%; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Date:
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 32%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 14%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(Signature)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Company:
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Date:
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(Signature)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Name:
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Title:
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 1IN 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Attachment
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	This
	is not a stock certificate or a negotiable instrument.
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 2; OPTIONS: NEWSECTION; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: LOWERROMAN; NAME: PAGENO -->
	ii
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage101"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_31"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	GENVEC,
	INC.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2015
	OMNIBUS INCENTIVE PLAN
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	INCENTIVE
	STOCK OPTION AGREEMENT
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 15%; PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Incentive
	Stock Option
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 85%; PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	This
	Option is intended to be an Incentive Stock Option under Code Section 422 and will be interpreted accordingly.&nbsp;&nbsp;If
	you cease to be an employee of the Company, its parent, or a subsidiary (&ldquo;
<B>
	Employee
</B>
	&rdquo;) but continue to provide
	Service, this Option will be deemed a Non-qualified Stock Option three (3) months after you cease to be an Employee.&nbsp;&nbsp;In
	addition, to the extent that all or part of this Option exceeds the $100,000 rule of Code Section 422(d), this Option or the
	lesser excess part will be deemed to be a Non-qualified Stock Option.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Vesting
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	This
	Option is only exercisable before it expires and then only with respect to the vested portion of the Option.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Your
	right to purchase shares of Stock under this Option vests as set forth in the Vesting Schedule on the cover sheet, provided
	you continue in Service on each applicable vesting date. Notwithstanding the foregoing, for purposes of vesting, fractional
	number of shares of Stock shall be rounded down to the nearest whole number. You cannot vest in more than the number of
	shares covered by this Option.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	No
	additional shares of Stock will vest after your Service has terminated for any reason.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Change
	in Control
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Notwithstanding
	the Vesting Schedule on the cover sheet, upon the consummation of a Change in Control, this Option will become one hundred
	percent (100%) vested (i) if it is not assumed, or equivalent options are not substituted for the Option, by the Company,
	the Company&rsquo;s successor, or the surviving entity in the Change in Control, or a parent or subsidiary of the foregoing,
	or (ii) if assumed or substituted for, upon your termination of Service without Cause or your resignation for Good Reason
	within the twelve (12)-month period following the consummation of the Change in Control.
<B>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&ldquo;
<B>
	Good
	Reason
</B>
	&rdquo; shall have the meaning set forth in an applicable agreement between you and the Company or an Affiliate, and
	in the absence of any such agreement, means (a) a material reduction by the Company in your annual base salary, (b) the Company&rsquo;s
	requirement that you be based at any office or location that is more than thirty-five (35) miles from your office or location
	immediately prior to a Change in Control, (c) the failure by the Company (i) to continue in effect any compensation plan in which
	you participate immediately prior to a Change in Control that is material to your total compensation, unless an equitable arrangement
	(embodied in an ongoing substitute or alternative plan) has been made with respect to such plan, or (ii) to continue your participation
	therein (or in such substitute or alternative plan) on a basis not materially less favorable, both in terms of the amount of benefits
	provided and the level of your participation relative to other participants, than existed prior to the Change in Control, or (d)
	the failure by the Company to continue to provide you with benefits substantially similar to those enjoyed by you under any of
	the Company&rsquo;s pension, life insurance, medical, health and accident, disability, or other welfare plans in which you were
	participating immediately prior to the Change in Control. For purposes of this definition, &ldquo;Company&rdquo; shall include
	the Company, the Company&rsquo;s successor, or the surviving entity in the Change in Control, or a parent or subsidiary of the
	foregoing.
</FONT>
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 3; OPTIONS: NEWSECTION; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	1
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage102"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_32"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; WIDTH: 15%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Term
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY; WIDTH: 85%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Your
	Option will expire in any event at the close of business at Company headquarters on the day before the tenth (10
<SUP>
	th
</SUP>
	)
	anniversary of the Grant Date, as shown on the cover sheet.&nbsp;&nbsp;Your Option will expire earlier (but never later) if
	your Service terminates, as described below.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Regular
	Termination
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If
	your Service terminates for any reason, except as otherwise provided below in this Agreement, then your Option will expire
	at the close of business at Company headquarters on the ninetieth (90
<SUP>
	th
</SUP>
	) day after your termination of Service.&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Termination
	for
</B>
<BR>
<B>
	Cause
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If
	your Service is terminated for Cause, then you shall immediately forfeit all rights to your Option (both vested and unvested),
	and the Option shall automatically expire upon your termination of Service.&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Death
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If
	your Service terminates because of your death, then your Option will expire at the close of business at Company headquarters
	on the date three (3) years after the date of death. During that period, your estate or heirs may exercise the vested
	portion of your Option.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	addition, if you die during the ninety (90)-day period described above in connection with a regular termination (i.e.,
	a termination of your Service not on account of your death, Disability, or Cause), and a vested portion of your Option
	has not yet been exercised, then your Option will instead expire on the date three (3) years after your termination of
	Service. In such a case, during the period following your death up to the date three (3) years after your termination
	of Service, your estate or heirs may exercise the vested portion of your Option.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Disability
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If
	your Service terminates because of your Disability, then your Option will expire at the close of business at Company headquarters
	on the date three (3) years after your termination of Service.
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 4; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage103"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_33"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; WIDTH: 15%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Leaves
	of Absence
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; WIDTH: 85%">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	For
	purposes of this Option, your Service does not terminate when you go on a
<I>
	bona fide
</I>
	employee leave of absence that
	was approved by the Company in writing, if the terms of the leave provide for continued Service crediting or when continued
	Service crediting is required by Applicable Laws. However, your Service will be treated as terminating ninety (90) days
	after you went on employee leave, unless your right to return to active work is guaranteed by law or by a contract. Your
	Service terminates in any event when the approved leave ends unless you immediately return to active employee work.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Committee determines, in its sole discretion, which leaves count for this purpose and when your Service terminates for
	all purposes under the Plan.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Notice of
	Exercise
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Option may be exercised, in whole or in part, to purchase a whole number of vested shares of Stock of not less than one
	hundred (100) shares, unless the number of vested shares purchased is the total number available for purchase under the
	Option, by following the procedures set forth in the Plan and below.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	When
	you wish to exercise this Option, you must notify the Company or its designee or agent by filing the proper &ldquo;Notice
	of Exercise&rdquo; form at the address given on the form. Your notice must specify how many shares of Stock you wish to
	purchase and how your shares of Stock should be registered (in your name only or in your and your spouse&rsquo;s names
	as joint tenants with right of survivorship). The notice will be effective when it is received by the Company or its designee
	or agent and when it is accompanied by payment in full of the Option Price of the shares of Stock for which such Option
	is being exercised, plus the amount (if any) of federal, state, local, or foreign tax or withholding payment which the
	Company may, in its judgment, be required to withhold with respect to the exercise of such Option.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If
	someone else wants to exercise this Option after your death, that person must prove to the Company&rsquo;s satisfaction
	that he or she is entitled to do so.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Form of
	Payment
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	When
	you submit your notice of exercise, you must include payment of the Option Price for the shares of Stock you are purchasing.
	Payment may be made in one (or a combination) of the following forms:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash,
	your personal check, a cashier&#8217;s check, a money order, or another cash equivalent acceptable to the Company.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By
	surrender to the Company of shares of Stock which you already own. The value of the surrendered shares of Stock, determined
	as of the effective date of the exercise of the Option, will be applied to the Option Price.
</FONT>
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 5; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage104"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_34"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; WIDTH: 15%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY; WIDTH: 85%">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By
	delivery (on a form prescribed by the Company) of an irrevocable direction to a licensed
	securities broker acceptable to the Company to sell Stock and to deliver all or part
	of the sale proceeds to the Company in payment of the aggregate Option Price and any
	withholding taxes.
</FONT>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Withholding
	Taxes
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	You
	will not be allowed to exercise this Option unless you make acceptable arrangements to pay any withholding or other taxes
	that may be due as a result of the Option exercise or sale of Stock acquired under this Option.&nbsp;&nbsp;In the event that
	the Company determines that any federal, state, local, or foreign tax or withholding payment is required relating to the exercise
	or sale of shares of Stock arising from this Option, the Company shall have the right to require such payments from you or
	withhold such amounts from other payments due to you from the Company or any Affiliate.&nbsp;&nbsp;Subject to the prior approval
	of the Company, which may be withheld by the Company, in its sole discretion, you may elect to satisfy this withholding obligation,
	in whole or in part, by causing the Company to withhold shares of Stock otherwise issuable to you or by delivering to the
	Company shares of Stock.&nbsp;&nbsp;The shares of Stock so withheld or delivered must have an aggregate Fair Market Value
	equal to the withholding obligation and may not be subject to any repurchase, forfeiture, unfulfilled vesting, or other similar
	requirements.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Transfer
	of Option
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	During
	your lifetime, only you (or, in the event of your legal incapacity or incompetency, your guardian or legal representative)
	may exercise the Option. Other than by will or the laws of descent and distribution, the Option may not be sold, assigned,
	transferred, pledged, hypothecated, or otherwise encumbered, whether by operation of law or otherwise, nor may the Option
	be made subject to execution, attachment, or similar process. For instance, you may not sell this Option or use it as
	security for a loan. If you attempt to do any of these things, you will immediately and automatically forfeit your Option.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Regardless
	of any marital property settlement agreement, the Company is not obligated to honor a notice of exercise from your spouse,
	nor is the Company obligated to recognize your spouse&rsquo;s interest in your Option in any other way.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Retention
	Rights
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Neither
	your Option nor this Agreement give you the right to be retained or employed by the Company (or any of its Affiliates) in
	any capacity.&nbsp;&nbsp;The Company (and any Affiliate) reserves the right to terminate your Service at any time and for
	any reason.
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 6; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage105"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_35"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; WIDTH: 15%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Shareholder
	Rights
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY; WIDTH: 85%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	You,
	or your estate or heirs, have no rights as a shareholder with respect to the shares of Stock underlying the Option unless
	and until the shares of Stock underlying the Option have been issued upon exercise of your Option and either a certificate
	evidencing your Stock has been issued or an appropriate entry has been made on the Company&rsquo;s books.&nbsp;&nbsp;No adjustments
	are made for dividends or other rights if the applicable record date occurs before your stock certificate is issued or an
	appropriate book entry has been made, except as described in the Plan.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Forfeiture
	of Rights
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If
	you should take actions in violation or breach of, or in conflict with, (a) employment agreement, (b) non-competition
	agreement, (c) agreement prohibiting solicitation of employees or clients of the Company or any of its Affiliates, (d)
	confidentiality obligation with respect to the Company or any of its Affiliates, (e) material Company or Affiliate policy
	or procedure, (f) other material agreement, or (g) other material obligation to the Company or any of its Affiliates,
	the Company has the right to cause an immediate forfeiture of your rights to this Option, and the Option (both vested
	and unvested) shall immediately and automatically expire.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	addition, if you have exercised any portion of the Option during the two (2)-year period prior to your actions, you will
	owe the Company a cash payment (or forfeiture of shares of Stock) in an amount determined as follows: (1) for any shares
	of Stock that you have sold prior to receiving notice from the Company, the amount will be the proceeds received from
	the sale(s), less the Option Price, and (2) for any shares of Stock that you still own, the amount will be the number
	of shares of Stock owned times the Fair Market Value of the shares of Stock on the date you receive notice from the Company,
	less the Option Price (provided, that the Company may require you to satisfy your payment obligations hereunder either
	by forfeiting and returning to the Company the shares or any other shares of Stock or making a cash payment or a combination
	of these methods as determined by the Company in its sole discretion).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Clawback
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.9PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	This
	Option is subject to mandatory repayment by you to the Company to the extent you are or in the future become subject to
	any Company or Affiliate &ldquo;clawback&rdquo; or recoupment policy or to any Applicable Laws that require the repayment
	by you to the Company of compensation paid by the Company to you in the event that you fail to comply with, or violate,
	the terms or requirements of such policy or Applicable Laws.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.9PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If
	the Company is required to prepare an accounting restatement due to the material noncompliance of the Company, as a result of
	misconduct, with any financial reporting requirement under Applicable Laws, and you knowingly engaged in the misconduct, were
	grossly negligent in engaging in the misconduct, knowingly failed to prevent the misconduct, or were grossly negligent in failing
	to prevent the misconduct, you shall reimburse the Company the amount of any payment in settlement of this Option earned or accrued
	during the twelve (12)-month period following the first public issuance or filing with the United States Securities and Exchange
	Commission (whichever first occurred) of the financial document that contained such material noncompliance.
</FONT>
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 7; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage106"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_36"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; WIDTH: 15%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Adjustments
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; WIDTH: 85%">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	the event of any recapitalization, reclassification, stock split, reverse stock split, spin-off, combination of stock,
	exchange of stock, stock dividend or other distribution payable in capital stock, or other increase or decrease in shares
	of Stock effected without receipt of consideration by the Company, the number of shares covered by this Option and the
	Option Price per share shall be adjusted (and rounded down to the nearest whole number) pursuant to the Plan. The Committee
	adjustments will be final, binding, and conclusive on all persons.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Your
	Option shall be subject to the terms of the agreement of merger, liquidation, or reorganization in the event the Company
	is subject to such corporate activity, consistent with Section 16 of the Plan.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Applicable
	Law
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	This
	Agreement will be interpreted and enforced under the laws of the State of Delaware, other than any conflicts or choice of
	law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of
	another jurisdiction.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	The Plan
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	text of the Plan is incorporated in this Agreement by reference.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Certain
	capitalized terms used in this Agreement are defined in the Plan and have the meaning set forth in the Plan.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	This
	Agreement and the Plan constitute the entire understanding between you and the Company regarding this Option. Any prior
	agreements, commitments, or negotiations concerning this Option are superseded; except that any written employment, consulting,
	confidentiality, non-competition, non-solicitation, and/or severance agreement between you and the Company or an Affiliate,
	as applicable, shall supersede this Agreement with respect to its subject matter.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Data
	Privacy
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	order to administer the Plan, the Company may process personal data about you. Such data includes, but is not limited to the information
	provided in this Agreement and any changes thereto, other appropriate personal and financial data about you, such as home address
	and business addresses and other contact information, payroll information, and any other information that might be deemed appropriate
	by the Company to facilitate the administration of the Plan.
</FONT>
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 8; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage107"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; WIDTH: 15%">
<A NAME="FIS_UNIDENTIFIED_TABLE_37"></A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY; WIDTH: 85%">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	By
	accepting this Option, you give explicit consent to the Company to process any such personal
	data. You also give explicit consent to the Company to transfer any such personal data
	outside the country in which you work or are employed, including, with respect to non-U.S.
	resident Grantees, to the United States, to transferees who shall include the Company
	and other persons who are designated by the Company to administer the Plan.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Consent
	to Electronic Delivery
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company may choose to deliver certain statutory materials relating to the Plan in electronic form.&nbsp;&nbsp;By accepting
	this Option, you agree that the Company may deliver the Plan prospectus and the Company&rsquo;s annual report to you in an
	electronic format and, if requested, agree to participate in the Plan through an on-line or electronic system established
	and maintained by the Company or another third party designated by the Company, and your consent shall remain in effect throughout
	your term of Service and thereafter until you withdraw such consent in writing to the Company.&nbsp;&nbsp;If at any time you
	would prefer to receive paper copies of the Plan prospectus and the Company&rsquo;s annual report, as you are entitled to,
	the Company would be pleased to provide copies.&nbsp;&nbsp;Please contact
<B>
</B>
	Senior Director, Finance and Accounting to
	request paper copies of these documents.
</FONT>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Certain
	Dispositions
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If
	you dispose of shares of Stock issued pursuant to the exercise of the Option prior to the second (2
<SUP>
	nd
</SUP>
	) anniversary
	of the Grant Date or the first (1
<SUP>
	st
</SUP>
	) anniversary of the applicable date of exercise, you agree that you will notify
	the Company of such disposition immediately and in no event later than ten (10) days thereafter.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Code
	Section 409A
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	grant of the Option under this Agreement is intended to be exempt from, or to the extent subject thereto, to comply with,
	Code Section 409A (&ldquo;
<B>
	Section 409A
</B>
	&rdquo;), and, accordingly, to the maximum extent permitted, this Agreement
	will be interpreted and administered to be in compliance with Section 409A.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Notwithstanding
	anything to the contrary in the Plan or this Agreement, neither the Company, any Affiliate, the Board, nor the Committee
	will have any obligation to take any action to prevent the assessment of any excise tax or penalty on you under Section
	409A, and neither the Company, any Affiliate, the Board, nor the Committee will have any liability to you or other person
	for such tax or penalty.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	By
	signing the cover sheet of this Agreement, you agree to all of the terms and
</I>
<I>
	conditions described above and in the Plan.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 9; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0">
</P>
</DIV>
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage108"></A>
<A NAME="T1600102_EX10-9_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10_2"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit 10.9
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 95%; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Option
	No.:
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	GENVEC,
	INC.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2015
	OMNIBUS INCENTIVE PLAN
</B>
<BR>
<BR>
<B>
	DIRECTOR NON-QUALIFIED STOCK OPTION AGREEMENT
</B>
<BR>
<B>
	COVER SHEET
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	GenVec,
	Inc., a Delaware corporation (the &ldquo;
<B>
	Company
</B>
	&rdquo;), hereby grants an Option (the &ldquo;
<B>
	Option
</B>
	&rdquo;) to
	purchase shares of its common stock, par value $0.001 per share (the &ldquo;
<B>
	Stock
</B>
	&rdquo;), to the individual named below
	as the Grantee. The terms and conditions of the Option are set forth in this cover sheet and in the attached Director Non-Qualified
	Stock Option Agreement (collectively, the &ldquo;
<B>
	Agreement
</B>
	&rdquo;) and in the Company&rsquo;s 2015 Omnibus Incentive Plan
	(as amended from time to time, the &ldquo;
<B>
	Plan
</B>
	&rdquo;).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_38"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 25%; PADDING-RIGHT: 5.4PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Grant
	Date:
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 75%; BORDER-BOTTOM: BLACK 2PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-LEFT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Name
	of Grantee:
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 2PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-LEFT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
	Number of Shares of Stock Covered by the Option:
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 2PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-LEFT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Option
	Price per share of Stock:
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 2PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-LEFT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Vesting
	Start Date:
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 2PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-LEFT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Vesting
	Schedule:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-LEFT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Subject to the terms of this Agreement
	and provided you continue in Service on such date, one hundred percent (100%) of the shares of Stock covered by this Option shall
	vest on the first (1
<SUP>
	st
</SUP>
	) anniversary of the Vesting Start Date.
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	By
	signing this cover sheet, you agree to all of the terms and conditions described in this Agreement and in the Plan, a copy of
	which is also attached. You acknowledge that you have carefully reviewed the Plan and agree that the Plan will control in the
	event any provision of this Agreement should appear to be inconsistent with the Plan. Certain capitalized terms used in this Agreement
	are defined in the Plan and have the meaning set forth in the Plan.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<EFX_UNIDENTIFIED_TABLE>
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 6%; VERTICAL-ALIGN: BOTTOM">
<A NAME="FIS_UNIDENTIFIED_TABLE_39"></A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Grantee:
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 43%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 3%; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Date:
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 32%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 14%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(Signature)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Company:
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Date:
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(Signature)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Name:
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Title:
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 9PT ARIAL, HELVETICA, SANS-SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage109"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Attachment
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	This
	is not a stock certificate or a negotiable instrument.
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 2; OPTIONS: NEWSECTION; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: LOWERROMAN; NAME: PAGENO -->
	ii
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage110"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_40"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	GENVEC,
	INC.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2015
	OMNIBUS INCENTIVE PLAN
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	DIRECTOR
	NON-QUALIFIED STOCK OPTION AGREEMENT
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 15%; PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Non-Qualified
	Stock Option
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 85%; PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	This
	Option is not intended to be an Incentive Stock Option under Code Section 422 and will be interpreted accordingly.&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Vesting
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	This
	Option is only exercisable before it expires and then only with respect to the vested portion of the Option.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Your right to purchase shares of Stock
	under this Option vests as set forth in the Vesting Schedule on the cover sheet, provided you then continue in Service. You cannot
	vest in more than the number of shares covered by this Option.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	No
	additional shares of Stock will vest after your Service has terminated for any reason.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Change
	in Control
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Notwithstanding
	the Vesting Schedule on the cover sheet, upon the consummation of a Change in Control, this Option will become one hundred
	percent (100%) vested, provided you continue in Service as of immediately prior to the consummation of the Change in Control.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Term
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Your
	Option will expire in any event at the close of business at Company headquarters on the day before the tenth (10
<SUP>
	th
</SUP>
	)
	anniversary of the Grant Date, as shown on the cover sheet.&nbsp;&nbsp;Your Option will expire earlier (but never later) if
	your Service terminates, as described below.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Termination
	for Cause
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If
	your Service is terminated for Cause, then you shall immediately forfeit all rights to your Option (both vested and unvested),
	and the Option shall automatically expire upon your termination of Service.&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Notice of
	Exercise
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Option may be exercised, in whole or in part, to purchase a whole number of vested shares of Stock of not less than one
	hundred (100) shares, unless the number of vested shares purchased is the total number available for purchase under the
	Option, by following the procedures set forth in the Plan and below.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	When
	you wish to exercise this Option, you must notify the Company or its designee or agent by filing the proper &ldquo;Notice
	of Exercise&rdquo; form at the address given on the form. Your notice must specify how many shares of Stock you wish to
	purchase and how your shares of Stock should be registered (in your name only or in your and your spouse&rsquo;s names
	as joint tenants with right of survivorship). The notice will be effective when it is received by the Company or its designee
	or agent and when it is accompanied by payment in full of the Option Price of the shares of Stock for which such Option
	is being exercised, plus the amount (if any) of federal, state, local, or foreign tax or withholding payment which the
	Company may, in its judgment, be required to withhold with respect to the exercise of such Option.
</FONT>
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 3; OPTIONS: NEWSECTION; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	1
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage111"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_41"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If
	someone else wants to exercise this Option after your death, that person must prove to the Company&rsquo;s satisfaction
	that he or she is entitled to do so.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; WIDTH: 15%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Form of
	Payment
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; WIDTH: 85%; TEXT-ALIGN: JUSTIFY">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	When
	you submit your notice of exercise, you must include payment of the Option Price for the shares of Stock you are purchasing.
	Payment may be made in one (or a combination) of the following forms:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash,
	your personal check, a cashier&#8217;s check, a money order, or another cash equivalent acceptable to the Company.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By
	surrender to the Company of shares of Stock which you already own. The value of the surrendered shares of Stock, determined
	as of the effective date of the exercise of the Option, will be applied to the Option Price.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By
	delivery (on a form prescribed by the Company) of an irrevocable direction to a licensed securities broker acceptable
	to the Company to sell Stock and to deliver all or part of the sale proceeds to the Company in payment of the aggregate
	Option Price and any withholding taxes.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Withholding
	Taxes
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	You
	will not be allowed to exercise this Option unless you make acceptable arrangements to pay any withholding or other taxes
	that may be due as a result of the Option exercise or sale of Stock acquired under this Option.&nbsp;&nbsp;In the event that
	the Company determines that any federal, state, local, or foreign tax or withholding payment is required relating to the exercise
	or sale of shares of Stock arising from this Option, the Company shall have the right to require such payments from you or
	withhold such amounts from other payments due to you from the Company or any Affiliate.&nbsp;&nbsp;Subject to the prior approval
	of the Company, which may be withheld by the Company, in its sole discretion, you may elect to satisfy this withholding obligation,
	in whole or in part, by causing the Company to withhold shares of Stock otherwise issuable to you or by delivering to the
	Company shares of Stock.&nbsp;&nbsp;The shares of Stock so withheld or delivered must have an aggregate Fair Market Value
	equal to the withholding obligation and may not be subject to any repurchase, forfeiture, unfulfilled vesting, or other similar
	requirements.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Transfer
	of Option
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	During
	your lifetime, only you (or, in the event of your legal incapacity or incompetency, your guardian or legal representative)
	may exercise the Option. Other than by will or the laws of descent and distribution, the Option may not be sold, assigned,
	transferred, pledged, hypothecated, or otherwise encumbered, whether by operation of law or otherwise, nor may the Option
	be made subject to execution, attachment, or similar process. For instance, you may not sell this Option or use it as
	security for a loan. If you attempt to do any of these things, you will immediately and automatically forfeit your Option.
</FONT>
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 4; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage112"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_42"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; WIDTH: 15%">
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; WIDTH: 85%">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Regardless
	of any marital property settlement agreement, the Company is not obligated to honor a notice of exercise from your spouse,
	nor is the Company obligated to recognize your spouse&rsquo;s interest in your Option in any other way.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Retention
	Rights
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Neither
	your Option nor this Agreement give you the right to be retained or employed by the Company (or any of its Affiliates) in
	any capacity.&nbsp;&nbsp;The Company (and any Affiliate) reserves the right to terminate your Service at any time and for
	any reason.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Shareholder
	Rights
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	You,
	or your estate or heirs, have no rights as a shareholder with respect to the shares of Stock underlying the Option unless
	and until the shares of Stock underlying the Option have been issued upon exercise of your Option and either a certificate
	evidencing your Stock has been issued or an appropriate entry has been made on the Company&rsquo;s books.&nbsp;&nbsp;No adjustments
	are made for dividends or other rights if the applicable record date occurs before your stock certificate is issued or an
	appropriate book entry has been made, except as described in the Plan.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Clawback
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.9PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	This
	Option is subject to mandatory repayment by you to the Company to the extent you are or in the future become subject to
	any Company or Affiliate &ldquo;clawback&rdquo; or recoupment policy or to any Applicable Laws that require the repayment
	by you to the Company of compensation paid by the Company to you in the event that you fail to comply with, or violate,
	the terms or requirements of such policy or Applicable Laws.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.9PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If
	the Company is required to prepare an accounting restatement due to the material noncompliance of the Company, as a result
	of misconduct, with any financial reporting requirement under Applicable Laws, and you knowingly engaged in the misconduct,
	were grossly negligent in engaging in the misconduct, knowingly failed to prevent the misconduct, or were grossly negligent
	in failing to prevent the misconduct, you shall reimburse the Company the amount of any payment in settlement of this
	Option earned or accrued during the twelve (12)-month period following the first public issuance or filing with the United
	States Securities and Exchange Commission (whichever first occurred) of the financial document that contained such material
	noncompliance.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 5; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage113"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_43"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; WIDTH: 15%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Adjustments
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; WIDTH: 85%">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	the event of any recapitalization, reclassification, stock split, reverse stock split, spin-off, combination of stock,
	exchange of stock, stock dividend or other distribution payable in capital stock, or other increase or decrease in shares
	of Stock effected without receipt of consideration by the Company, the number of shares covered by this Option and the
	Option Price per share shall be adjusted (and rounded down to the nearest whole number) pursuant to the Plan. The Committee
	adjustments will be final, binding, and conclusive on all persons.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Your
	Option shall be subject to the terms of the agreement of merger, liquidation, or reorganization in the event the Company
	is subject to such corporate activity, consistent with Section 16 of the Plan.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Applicable
	Law
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	This
	Agreement will be interpreted and enforced under the laws of the State of Delaware, other than any conflicts or choice of
	law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of
	another jurisdiction.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	The Plan
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	text of the Plan is incorporated in this Agreement by reference.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Certain
	capitalized terms used in this Agreement are defined in the Plan and have the meaning set forth in the Plan.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	This
	Agreement and the Plan constitute the entire understanding between you and the Company regarding this Option. Any prior
	agreements, commitments, or negotiations concerning this Option are superseded; except that any written employment, consulting,
	confidentiality, non-competition, non-solicitation, and/or severance agreement between you and the Company or an Affiliate,
	as applicable, shall supersede this Agreement with respect to its subject matter.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Data Privacy
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	order to administer the Plan, the Company may process personal data about you. Such data includes, but is not limited
	to the information provided in this Agreement and any changes thereto, other appropriate personal and financial data about
	you, such as home address and business addresses and other contact information, payroll information, and any other information
	that might be deemed appropriate by the Company to facilitate the administration of the Plan.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	By
	accepting this Option, you give explicit consent to the Company to process any such personal data. You also give explicit consent
	to the Company to transfer any such personal data outside the country in which you work or are employed, including, with respect
	to non-U.S. resident Grantees, to the United States, to transferees who shall include the Company and other persons who are designated
	by the Company to administer the Plan.
</FONT>
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 6; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage114"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; WIDTH: 15%">
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY; WIDTH: 85%">
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<A NAME="FIS_UNIDENTIFIED_TABLE_44"></A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Consent
	to Electronic Delivery
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company may choose to deliver certain statutory materials relating to the Plan in electronic form.&nbsp;&nbsp;By accepting
	this Option, you agree that the Company may deliver the Plan prospectus and the Company&rsquo;s annual report to you in an
	electronic format and, if requested, agree to participate in the Plan through an on-line or electronic system established
	and maintained by the Company or another third party designated by the Company, and your consent shall remain in effect throughout
	your term of Service and thereafter until you withdraw such consent in writing to the Company.&nbsp;&nbsp;If at any time you
	would prefer to receive paper copies of the Plan prospectus and the Company&rsquo;s annual report, as you are entitled to,
	the Company would be pleased to provide copies.&nbsp;&nbsp;Please contact Senior Director, Finance and Accounting
<B>
</B>
	to
	request paper copies of these documents.
</FONT>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Code Section
	409A
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	grant of the Option under this Agreement is intended to be exempt from, or to the extent subject thereto, to comply with,
	Code Section 409A (&ldquo;
<B>
	Section 409A
</B>
	&rdquo;), and, accordingly, to the maximum extent permitted, this Agreement
	will be interpreted and administered to be in compliance with Section 409A.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Notwithstanding
	anything to the contrary in the Plan or this Agreement, neither the Company, any Affiliate, the Board, nor the Committee
	will have any obligation to take any action to prevent the assessment of any excise tax or penalty on you under Section
	409A, and neither the Company, any Affiliate, the Board, nor the Committee will have any liability to you or other person
	for such tax or penalty.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
<B>
<I>
	By
	signing the cover sheet of this Agreement, you agree to all of the terms and conditions described above and in the Plan.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 7; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage115"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: RIGHT">
<B>
	Exhibit
	10.9
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Exhibit
	A
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	GenVec,
	Inc. 2015 Omnibus Incentive Plan
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	[
<I>
	Please
	see attached.
</I>
	]
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 8 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage116"></A>
<A NAME="T1600102_EX10-10_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10_3"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit 10.10
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 95%; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Option
	No.:
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	GENVEC,
	INC.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2015
	OMNIBUS INCENTIVE PLAN
</B>
<BR>
<BR>
<B>
	DIRECTOR NON-QUALIFIED STOCK OPTION AGREEMENT
</B>
<BR>
<B>
	COVER SHEET
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	GenVec,
	Inc., a Delaware corporation (the &ldquo;
<B>
	Company
</B>
	&rdquo;), hereby grants an Option (the &ldquo;
<B>
	Option
</B>
	&rdquo;) to
	purchase shares of its common stock, par value $0.001 per share (the &ldquo;
<B>
	Stock
</B>
	&rdquo;), to the individual named below
	as the Grantee. The terms and conditions of the Option are set forth in this cover sheet and in the attached Director Non-Qualified
	Stock Option Agreement (collectively, the &ldquo;
<B>
	Agreement
</B>
	&rdquo;) and in the Company&rsquo;s 2015 Omnibus Incentive Plan
	(as amended from time to time, the &ldquo;
<B>
	Plan
</B>
	&rdquo;).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_45"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 25%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Grant
	Date:
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 75%; BORDER-BOTTOM: BLACK 2PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Name
	of Grantee:
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 2PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Number of Shares of Stock Covered by the Option:
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 2PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Option
	Price per share of Stock:
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 2PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Vesting
	Start Date:
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 2PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Vesting
	Schedule:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-LEFT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Subject
	to the terms of this Agreement and provided you continue in Service on each applicable vesting date, one-fourth (1/4)
	of the shares of Stock covered by this Option shall vest on each of the first (1
<SUP>
	st
</SUP>
	), second (2
<SUP>
	nd
</SUP>
	),
	third (3
<SUP>
	rd
</SUP>
	), and fourth (4
<SUP>
	th
</SUP>
	) anniversaries of the Vesting Start Date.
</FONT>
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	By
	signing this cover sheet, you agree to all of the terms and conditions described in this Agreement and in the Plan, a copy of
	which is also attached. You acknowledge that you have carefully reviewed the Plan and agree that the Plan will control in the
	event any provision of this Agreement should appear to be inconsistent with the Plan. Certain capitalized terms used in this Agreement
	are defined in the Plan and have the meaning set forth in the Plan.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<EFX_UNIDENTIFIED_TABLE>
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 6%; VERTICAL-ALIGN: BOTTOM">
<A NAME="FIS_UNIDENTIFIED_TABLE_46"></A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Grantee:
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 43%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 3%; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Date:
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 32%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 14%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(Signature)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Company:
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Date:
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(Signature)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Name:
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Title:
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage117"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Attachment
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	This
	is not a stock certificate or a negotiable instrument.
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 2; OPTIONS: NEWSECTION; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: LOWERROMAN; NAME: PAGENO -->
	ii
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage118"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_47"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	GENVEC,
	INC.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2015
	OMNIBUS INCENTIVE PLAN
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	DIRECTOR
	NON-QUALIFIED STOCK OPTION AGREEMENT
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 15%; PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Non-Qualified
	Stock Option
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 85%; PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	This
	Option is not intended to be an Incentive Stock Option under Code Section 422 and will be interpreted accordingly.&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Vesting
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	This
	Option is only exercisable before it expires and then only with respect to the vested portion of the Option.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Your
	right to purchase shares of Stock under this Option vests as set forth in the Vesting Schedule on the cover sheet, provided
	you continue in Service on each applicable vesting date. Notwithstanding the foregoing, for purposes of vesting, fractional
	number of shares of Stock shall be rounded down to the nearest whole number. You cannot vest in more than the number of
	shares covered by this Option.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	No
	additional shares of Stock will vest after your Service has terminated for any reason.
</FONT>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Change
	in Control
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Notwithstanding
	the Vesting Schedule on the cover sheet, upon the consummation of a Change in Control, this Option will become one hundred
	percent (100%) vested, provided you continue in Service as of immediately prior to the consummation of the Change in Control.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Term
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Your
	Option will expire in any event at the close of business at Company headquarters on the day before the tenth (10
<SUP>
	th
</SUP>
	)
	anniversary of the Grant Date, as shown on the cover sheet.&nbsp;&nbsp;Your Option will expire earlier (but never later) if
	your Service terminates, as described below.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Termination
	for Cause
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If
	your Service is terminated for Cause, then you shall immediately forfeit all rights to your Option (both vested and unvested),
	and the Option shall automatically expire upon your termination of Service.&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Notice of
	Exercise
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Option may be exercised, in whole or in part, to purchase a whole number of vested shares of Stock of not less than one
	hundred (100) shares, unless the number of vested shares purchased is the total number available for purchase under the
	Option, by following the procedures set forth in the Plan and below.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	When
	you wish to exercise this Option, you must notify the Company or its designee or agent by filing the proper &ldquo;Notice of Exercise&rdquo;
	form at the address given on the form. Your notice must specify how many shares of Stock you wish to purchase and how your shares
	of Stock should be registered (in your name only or in your and your spouse&rsquo;s names as joint tenants with right of survivorship).
	The notice will be effective when it is received by the Company or its designee or agent and when it is accompanied by payment
	in full of the Option Price of the shares of Stock for which such Option is being exercised, plus the amount (if any) of federal,
	state, local, or foreign tax or withholding payment which the Company may, in its judgment, be required to withhold with respect
	to the exercise of such Option.
</FONT>
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 3; OPTIONS: NEWSECTION; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	1
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage119"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<A NAME="FIS_UNIDENTIFIED_TABLE_48"></A>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If
	someone else wants to exercise this Option after your death, that person must prove to the Company&rsquo;s satisfaction
	that he or she is entitled to do so.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; WIDTH: 15%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Form of
	Payment
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; WIDTH: 85%">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	When
	you submit your notice of exercise, you must include payment of the Option Price for the shares of Stock you are purchasing.
	Payment may be made in one (or a combination) of the following forms:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash,
	your personal check, a cashier&#8217;s check, a money order, or another cash equivalent acceptable to the Company.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By
	surrender to the Company of shares of Stock which you already own. The value of the surrendered shares of Stock, determined
	as of the effective date of the exercise of the Option, will be applied to the Option Price.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By
	delivery (on a form prescribed by the Company) of an irrevocable direction to a licensed securities broker acceptable
	to the Company to sell Stock and to deliver all or part of the sale proceeds to the Company in payment of the aggregate
	Option Price and any withholding taxes.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Withholding
	Taxes
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	You
	will not be allowed to exercise this Option unless you make acceptable arrangements to pay any withholding or other taxes
	that may be due as a result of the Option exercise or sale of Stock acquired under this Option.&nbsp;In the event that
	the Company determines that any federal, state, local, or foreign tax or withholding payment is required relating to the exercise
	or sale of shares of Stock arising from this Option, the Company shall have the right to require such payments from you or
	withhold such amounts from other payments due to you from the Company or any Affiliate.&nbsp;Subject to the prior approval
	of the Company, which may be withheld by the Company, in its sole discretion, you may elect to satisfy this withholding obligation,
	in whole or in part, by causing the Company to withhold shares of Stock otherwise issuable to you or by delivering to the
	Company shares of Stock.&nbsp;The shares of Stock so withheld or delivered must have an aggregate Fair Market Value
	equal to the withholding obligation and may not be subject to any repurchase, forfeiture, unfulfilled vesting, or other similar
	requirements.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 4; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage120"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_49"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; WIDTH: 15%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Transfer
	of Option
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; WIDTH: 85%">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	During
	your lifetime, only you (or, in the event of your legal incapacity or incompetency, your guardian or legal representative)
	may exercise the Option. Other than by will or the laws of descent and distribution, the Option may not be sold, assigned,
	transferred, pledged, hypothecated, or otherwise encumbered, whether by operation of law or otherwise, nor may the Option
	be made subject to execution, attachment, or similar process. For instance, you may not sell this Option or use it as
	security for a loan. If you attempt to do any of these things, you will immediately and automatically forfeit your Option.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Regardless
	of any marital property settlement agreement, the Company is not obligated to honor a notice of exercise from your spouse,
	nor is the Company obligated to recognize your spouse&rsquo;s interest in your Option in any other way.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Retention
	Rights
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Neither
	your Option nor this Agreement give you the right to be retained or employed by the Company (or any of its Affiliates) in
	any capacity.&nbsp;&nbsp;The Company (and any Affiliate) reserves the right to terminate your Service at any time and for
	any reason.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Shareholder
	Rights
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	You,
	or your estate or heirs, have no rights as a shareholder with respect to the shares of Stock underlying the Option unless
	and until the shares of Stock underlying the Option have been issued upon exercise of your Option and either a certificate
	evidencing your Stock has been issued or an appropriate entry has been made on the Company&rsquo;s books.&nbsp;&nbsp;No adjustments
	are made for dividends or other rights if the applicable record date occurs before your stock certificate is issued or an
	appropriate book entry has been made, except as described in the Plan.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Clawback
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.9PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	This
	Option is subject to mandatory repayment by you to the Company to the extent you are or in the future become subject to
	any Company or Affiliate &ldquo;clawback&rdquo; or recoupment policy or to any Applicable Laws that require the repayment
	by you to the Company of compensation paid by the Company to you in the event that you fail to comply with, or violate,
	the terms or requirements of such policy or Applicable Laws.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.9PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If
	the Company is required to prepare an accounting restatement due to the material noncompliance of the Company, as a result
	of misconduct, with any financial reporting requirement under Applicable Laws, and you knowingly engaged in the misconduct,
	were grossly negligent in engaging in the misconduct, knowingly failed to prevent the misconduct, or were grossly negligent
	in failing to prevent the misconduct, you shall reimburse the Company the amount of any payment in settlement of this
	Option earned or accrued during the twelve (12)-month period following the first public issuance or filing with the United
	States Securities and Exchange Commission (whichever first occurred) of the financial document that contained such material
	noncompliance.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 5; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage121"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_50"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; WIDTH: 15%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Adjustments
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; WIDTH: 85%">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	the event of any recapitalization, reclassification, stock split, reverse stock split, spin-off, combination of stock,
	exchange of stock, stock dividend or other distribution payable in capital stock, or other increase or decrease in shares
	of Stock effected without receipt of consideration by the Company, the number of shares covered by this Option and the
	Option Price per share shall be adjusted (and rounded down to the nearest whole number) pursuant to the Plan. The Committee
	adjustments will be final, binding, and conclusive on all persons.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Your
	Option shall be subject to the terms of the agreement of merger, liquidation, or reorganization in the event the Company
	is subject to such corporate activity, consistent with Section 16 of the Plan.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Applicable
	Law
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	This
	Agreement will be interpreted and enforced under the laws of the State of Delaware, other than any conflicts or choice of
	law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of
	another jurisdiction.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	The Plan
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	text of the Plan is incorporated in this Agreement by reference.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Certain
	capitalized terms used in this Agreement are defined in the Plan and have the meaning set forth in the Plan.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	This
	Agreement and the Plan constitute the entire understanding between you and the Company regarding this Option. Any prior agreements,
	commitments, or negotiations concerning this Option are superseded; except that any written employment, consulting, confidentiality,
	non-competition, non-solicitation, and/or severance agreement between you and the Company or an Affiliate, as applicable, shall
	supersede this Agreement with respect to its subject matter.
</FONT>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Data Privacy
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	order to administer the Plan, the Company may process personal data about you. Such data includes, but is not limited
	to the information provided in this Agreement and any changes thereto, other appropriate personal and financial data about
	you, such as home address and business addresses and other contact information, payroll information, and any other information
	that might be deemed appropriate by the Company to facilitate the administration of the Plan.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	By
	accepting this Option, you give explicit consent to the Company to process any such personal data. You also give explicit
	consent to the Company to transfer any such personal data outside the country in which you work or are employed, including,
	with respect to non-U.S. resident Grantees, to the United States, to transferees who shall include the Company and other
	persons who are designated by the Company to administer the Plan.
</FONT>
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 6; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage122"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; WIDTH: 15%">
<A NAME="FIS_UNIDENTIFIED_TABLE_51"></A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Consent
	to Electronic Delivery
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY; WIDTH: 85%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company may choose to deliver certain statutory materials relating to the Plan in electronic form.&nbsp;&nbsp;By accepting
	this Option, you agree that the Company may deliver the Plan prospectus and the Company&rsquo;s annual report to you in an
	electronic format and, if requested, agree to participate in the Plan through an on-line or electronic system established
	and maintained by the Company or another third party designated by the Company, and your consent shall remain in effect throughout
	your term of Service and thereafter until you withdraw such consent in writing to the Company.&nbsp;&nbsp;If at any time you
	would prefer to receive paper copies of the Plan prospectus and the Company&rsquo;s annual report, as you are entitled to,
	the Company would be pleased to provide copies.&nbsp;&nbsp;Please contact Senior Director, Finance and Accounting
<B>
</B>
	to
	request paper copies of these documents.
</FONT>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Code Section
	409A
</B>
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	grant of the Option under this Agreement is intended to be exempt from, or to the extent subject thereto, to comply with,
	Code Section 409A (&ldquo;
<B>
	Section 409A
</B>
	&rdquo;), and, accordingly, to the maximum extent permitted, this Agreement
	will be interpreted and administered to be in compliance with Section 409A.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Notwithstanding
	anything to the contrary in the Plan or this Agreement, neither the Company, any Affiliate, the Board, nor the Committee
	will have any obligation to take any action to prevent the assessment of any excise tax or penalty on you under Section
	409A, and neither the Company, any Affiliate, the Board, nor the Committee will have any liability to you or other person
	for such tax or penalty.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
<B>
<I>
	By
	signing the cover sheet of this Agreement, you agree to all of the terms and conditions described above and in the Plan.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 7; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage123"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: RIGHT">
<B>
	Exhibit
	10.10
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Exhibit
	A
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	GenVec,
	Inc. 2015 Omnibus Incentive Plan
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	[
<I>
	Please
	see attached.
</I>
	]
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 8 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage124"></A>
<A NAME="T1600102_EX10-33_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10_4"></A>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
</B>
</P>
<HR NOSHADE SIZE="1" STYLE="COLOR: BLACK; WIDTH: 100%; MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit 10.33
</B>
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	AMENDMENT NO. 1
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	TO RESEARCH COLLABORATION AND LICENSE AGREEMENT
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	This Amendment No. 1 to
	Research Collaboration and License Agreement (this &ldquo;
<U>
	Amendment
</U>
	&rdquo;) is made as of this 10th day of November 2015
	(the &ldquo;
<U>
	Effective Date
</U>
	&rdquo;), by and between GenVec, Inc., a Delaware corporation (&ldquo;
<U>
	GenVec
</U>
	&rdquo;) and
	Novartis Institutes for Biomedical Research, Inc., a Delaware corporation (&ldquo;
<U>
	Novartis
</U>
	&rdquo;), and amends that Research
	Collaboration and License Agreement dated January 13, 2010 (the &ldquo;
<U>
	License Agreement
</U>
	&rdquo;), by and between Novartis
	and GenVec. Capitalized terms used in this Amendment without definition shall have the meanings given those terms in License Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	RECITALS
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	WHEREAS, on the terms and
	conditions of the License Agreement, Novartis obtained exclusive rights to research, develop and commercialize Products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	WHEREAS, under Section
	2.4 of the License Agreement, the Parties agreed that GenVec would not conduct any research, development, commercialization, distribution,
	or marketing or sales activities in the field of hearing loss.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	WHEREAS, since the effective
	date of the License Agreement, the Parties have developed, and Novartis is sponsoring a clinical trial with, CGF 166, a recombinant
	adenovirus 5 (Ad5) vector containing a CDNA encoding the human Atonal transcription factor (Hath1), a Product that is being studied
	for severe-to-profound bi-lateral hearing loss with intact vestibular function in the non-operative ear (the &ldquo;
<U>
	Clinical
	Product Candidate
</U>
	&rdquo;)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	WHEREAS, GenVec has significant
	experience in the field of otology and would like to conduct certain research and development activities on potential product candidates
	that are not competitive with the Clinical Product Candidate (&ldquo;
<U>
	New GenVec Products
</U>
	&rdquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	WHEREAS, both Novartis
	and GenVec would like for GenVec to conduct research and development activities on New GenVec Products, on the terms and conditions
	set forth in this Amendment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	NOW, THEREFORE, in consideration
	of the foregoing, and of other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the
	Parties agree as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	1.
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
<B>
	Amendment to Section 2.4
</B>
	. Section 2.4 of the License Agreement is deleted in its entirety, and in its place the following
	shall be inserted:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&ldquo;2.4&#9;
<U>
	Non-Compete
</U>
	.
	Until the last to expire Royalty Term for all Products, neither GenVec nor its Affiliates will, directly or indirectly (including
	by granting a license or other grants rights to a Third Party), conduct any research, development, commercialization, distribution
	or marketing or sales activities with a product containing Gene Fragments, except for the activities conducted by GenVec pursuant
	to and in accordance with this Agreement.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID; TEXT-ALIGN: CENTER">
	1
</DIV>
<A NAME="eolPage125"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	2.
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
<B>
	Right of First Negotiation
</B>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 58.5PT">
	(a)
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
	With respect to any product researched or developed by GenVec in the field of hearing loss other than a Licensed Product
	(a &ldquo;
<U>
	Permitted Otology Product
</U>
	&rdquo;), Novartis shall have an exclusive option to obtain an exclusive license to such
	Product, in accordance with this
<U>
	Section 2
</U>
	. Within one (1) month prior to the first of the following events; a pre-IND meeting
	or the start of GLP toxicology studies for a Permitted Otology Product (the &ldquo;
<U>
	Option Trigger
</U>
	&rdquo;), GenVec shall
	notify Novartis thereof and provide Novartis with a copy of GenVec&rsquo;s pre-IND package therefor (the date of such notice being
	the &ldquo;
<U>
	Option Trigger Date
</U>
	&rdquo;). Within sixty (60) days of the Option Trigger Date, Novartis shall provide GenVec
	with written notice of whether it desires to exercise its exclusive option to negotiate an exclusive license to the Permitted Otology
	Product. If Novartis provides GenVec with such written notice, then Novartis and GenVec shall negotiate in good faith for a period
	of six (6) months thereafter, to enter into a mutually agreeable exclusive license agreement for the Permitted Otology Product.
	If at the end of such six-month (6-month) period, Novartis and GenVec have not been able to agree on the terms of an exclusive
	license agreement for the Permitted Otology Product, then GenVec shall be permitted to license the Permitted Otology Product to
	a third party, or continue to develop, commercialize, distribute market and sell the Permitted Otology Product on its own.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 58.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 85.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 58.5PT">
	(b)
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
	Notwithstanding subsection (a) above, if a third party presents a bona fide offer to GenVec to license or otherwise acquire
	rights exclusively to a Permitted Otology Product(s) prior to the Option Trigger, then GenVec may notify Novartis that it has received
	such an offer and that it has the good faith intention of accepting an offer from such party if GenVec and that party can mutually
	agree on the terms thereof (a &ldquo;
<U>
	Third Party Offer Notice
</U>
	&rdquo;). Along with the Third Party Offer Notice, GenVec will
	provide Novartis with access to substantially the same information about the Permitted Otology Product that GenVec provided to
	the third party making the offer. If GenVec presents Novartis with a Third Party Offer Notice, then Novartis shall have thirty
	(30) days (subject to the extension set forth in subsection (c), below) to notify GenVec in writing whether it desires to obtain
	an exclusive license to the Permitted Otology Product (an &ldquo;
<U>
	Early Option Exercise Notice
</U>
	&rdquo;). If Novartis provides
	an Early Option Exercise Notice, then Novartis and GenVec shall negotiate in good faith for a period of three (3) months thereafter,
	to enter into a mutually agreeable exclusive license agreement for the Permitted Otology Product. If at the end of such three-month
	(3-month) period (the &ldquo;
<U>
	Early Option Period
</U>
	&rdquo;), Novartis and GenVec have not been able to agree on the terms of
	an exclusive license agreement for the Permitted Otology Product, then GenVec shall be permitted to license or otherwise transfer
	the rights to the Permitted Otology Product to the third party referred to in the Third Party Offer Notice; provided, that such
	transaction is completed within three (3) months of the Early Option Period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 58.5PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 58.5PT">
	(c)
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
	The thirty-day (30-day) period referred to in subsection (b) above, may be extended by Novartis, for one additional fifteen-day
	(15-day) period, if during the thirty-day (30-day) period, Novartis reasonably determines that it is (i) impracticable to make
	a determination as to whether it wishes to obtain an exclusive license to the Permitted Otology Product, and (ii) considering in
	good faith whether it wishes to obtain an exclusive license to the Permitted Otology Product. If Novartis exercises the fifteen-day
	(15-day) extension provided in this subsection (c), it will provide GenVec with written notice thereof during the initial thirty-day
	(30-day) period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 58.5PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID; TEXT-ALIGN: CENTER">
	2
</DIV>
<A NAME="eolPage126"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	3.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	General Provisions
</B>
	.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 58.5PT">
	(a)
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
	This Amendment may be executed in multiple counterparts, each of which shall be deemed an original and all of which together
	shall constitute one and the same instrument.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 58.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 85.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 58.5PT">
	(b)
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
	This Amendment shall form part of the License Agreement, and each party thereto and hereto shall be bound by this Amendment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 58.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 85.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 58.5PT">
	(c)
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
	From and after the Effective Date, any reference to the License Agreement shall be deemed a reference to the License Agreement,
	as amended hereby.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 58.5PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 58.5PT">
	(d)
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
	Except as expressly set forth herein or as the context of this Amendment may require, the License Agreement shall remain
	unchanged and in full force and effect in accordance with its terms.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 58.5PT">
	(e)
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
	The validity, construction and performance of this Amendment will be governed by and construed in accordance with the substantive
	laws of the State of Delaware, excluding any conflicts or choice of law or principle that might otherwise refer construction or
	interpretation of this Amendment to the substantive law of another jurisdiction.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<I>
	signature page follows
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<I>
	&nbsp;
</I>
</P>
<!-- FIELD: PAGE; SEQUENCE: 3 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID; TEXT-ALIGN: CENTER">
	3
</DIV>
<A NAME="eolPage127"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	IN WITNESS WHEREOF, Novartis
	and GenVec have caused this Amendment to be duly executed by their authorized representatives, under seal, on the Effective Date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9%">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	By:
</P>
</TD>
<TD STYLE="WIDTH: 43%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
	NOVARTIS INSTITUTES FOR
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
	BIOMEDICAL RESEARCH,
	INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-LEFT: 0; TEXT-ALIGN: JUSTIFY">
	/s/ Scott A. Brown
</P>
</TD>
<TD STYLE="WIDTH: 2%; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 9%">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	By:
</P>
</TD>
<TD STYLE="WIDTH: 37%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	GENVEC, INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	/s/ Douglas J. Swirsky
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT">
	Name:
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	Scott A. Brown
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Name:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Douglas J. Swirsky
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT">
	Title:
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	VP, General Counsel
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Title:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	President &amp; Chief Executive Officer
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;4
</B>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 3; OPTIONS: LAST -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage128"></A>
<A NAME="T1600102_EX23-1_HTM"></A>
<EFX_EXHIBIT_23>
<A NAME="FIS_EXHIBIT_23"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	EXHIBIT 23.1
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_EXPERTS_CONSENT>
<A NAME="FIS_EXPERTS_CONSENT"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U>
	Consent of Independent Registered
	Public Accounting Firm
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Board of Directors:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	GenVec, Inc.:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We
	consent to the incorporation by reference in the Registration Statements on Form S-3 (File No. 333-164862, No. 333-140373, No.
	333-133366, No. 333-123968, No. 333-101963, No. 333-76886, and No.333-193511)
</FONT>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	and on Form
	S-8 (File No. 333-208105, No. 333-153694, No. 333-183182, No. 333-183179, No. 333-176215, No. 333-153693, and No. 333-110446) of
	GenVec, Inc. of our report dated March 9, 2016, with respect to the balance sheets of GenVec, Inc., as of December 31, 2015 and
	the related statements of operations and comprehensive loss, changes in stockholders&rsquo; equity, and cash flows for the year
	then ended which report appears in the December 31, 2015 Annual Report on Form 10-K of GenVec, Inc.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<U>
	/s/ Stegman &amp; Company
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Baltimore, Maryland
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	March 9, 2016
</P>
</EFX_EXPERTS_CONSENT>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
</EFX_EXHIBIT_23>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage129"></A>
<A NAME="T1600102_EX24-1_HTM"></A>
<EFX_EXHIBIT_24>
<A NAME="FIS_EXHIBIT_24"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	EXHIBIT 24.1
</B>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	GENVEC, INC.
</P>
<EFX_POWER_OF_ATTORNEY>
<A NAME="FIS_POWER_OF_ATTORNEY"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Power of Attorney
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	KNOW
	ALL MEN BY THESE PRESENTS that each of the undersigned officers and directors of GenVec, Inc., a Delaware corporation (the &ldquo;Corporation&rdquo;),
	hereby constitutes and appoints Douglas J. Swirsky and James V. Lambert the true and lawful agents and attorneys-in-fact of the
	undersigned with full power of substitution and full power and authority in said agents and attorneys-in-fact, and any one or more
	of them, in connection with the Corporation&rsquo;s Annual Report on Form 10-K (the &ldquo;Form 10-K&rdquo;) for the fiscal year
	ended December 31, 2015 under the Securities Exchange Act of 1934, as amended, including, without limitation, to sign the Form
	10-K in the name and on behalf of the Corporation or on behalf of the undersigned, and in their respective names as officers and
	as directors of the Corporation, and any amendments to the Form 10-K and any instrument, contract, document or other writing, of
	or in connection with the Form 10-K or amendments thereto, and to file the same, with all exhibits thereto, and other documents
	in connection therewith, including this power of attorney, with the Securities and Exchange Commission and any applicable securities
	exchange or securities self-regulatory body, and the undersigned hereby ratifies and confirms all that said attorneys-in-fact and
	agents, each acting alone, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 70%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: BOLD; WIDTH: 70%">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Name and Title
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2PX; WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; FONT-WEIGHT: BOLD; WIDTH: 28%">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Date
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BORDER-BOTTOM: BLACK 2PX SOLID">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	/s/ Douglas J. Swirsky
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	March 9, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Douglas J. Swirsky
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	President, Chief Executive Officer and Corporate Secretary
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BORDER-BOTTOM: BLACK 2PX SOLID">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	/s/ James V. Lambert
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	March 9, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	James V. Lambert
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Senior Director of Accounting and Finance, Corporate Controller and Treasurer
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BORDER-BOTTOM: BLACK 2PX SOLID">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	/s/ Wayne T. Hockmeyer
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	March 7, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Wayne T. Hockmeyer, Ph.D.
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Director
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BORDER-BOTTOM: BLACK 2PX SOLID">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	/s/ William N. Kelley
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	March 1, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	William N. Kelley, M.D.
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Director
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BORDER-BOTTOM: BLACK 2PX SOLID">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	/s/ Marc R. Schneebaum
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	March 4, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Marc R. Schneebaum
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Director
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BORDER-BOTTOM: BLACK 2PX SOLID">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	/s/ Stefan D. Loren
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	March 8, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Stefan D. Loren
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Director
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BORDER-BOTTOM: BLACK 2PX SOLID">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	/s/ Quinterol J. Mallette
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	March 4, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Quinterol J. Mallette, M.D.
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Director
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BORDER-BOTTOM: BLACK 2PX SOLID">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	/s/ Michael Richman
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	March 2, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Michael Richman
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Director
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_POWER_OF_ATTORNEY>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
</EFX_EXHIBIT_24>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage130"></A>
<A NAME="T1600102_EX31-1_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	Exhibit 31.1
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<U>
	CERTIFICATION
</U>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	I, Douglas
	J. Swirsky, certify that:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	1.
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	I have reviewed this Annual Report on Form 10-K of GenVec, Inc.;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	2.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Based on my knowledge, this report does not contain any untrue statement of a material fact
	or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements
	were made, not misleading with respect to the period covered by this report;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	3.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Based on my knowledge, the financial statements, and other financial information included
	in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant
	as of, and for, the periods presented in this report;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	4.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The registrant&rsquo;s other certifying officer and I are responsible for establishing and
	maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
	over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	a.)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	designed such disclosure controls and procedures, or caused such disclosure controls and
	procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its
	consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report
	is being prepared;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	b.)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	designed such internal control over financial reporting, or caused such internal control
	over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial
	reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	c.)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures
	and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of
	the period covered by this report based on such evaluation; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	d.)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	disclosed in this report any change in the registrant&rsquo;s internal control over financial
	reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter
	in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s
	internal control over financial reporting; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	5.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent
	evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the Audit Committee of the registrant&rsquo;s
	Board of Directors (or persons performing the equivalent functions):
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	a.)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	all significant deficiencies and material weaknesses in the design or operation of internal
	control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process,
	summarize and report financial information; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.75IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	b.)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	any fraud, whether or not material, that involves management or other employees who have
	a significant role in the registrant&rsquo;s internal control over financial reporting.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Date: March 9, 2016
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BORDER-BOTTOM: BLACK 2PX SOLID; WIDTH: 50%">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	/s/ Douglas J. Swirsky
</FONT>
</TD>
<TD STYLE="WIDTH: 50%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Douglas J. Swirsky
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
	President and Chief Executive Officer and Corporate Secretary
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<I>
	(Principal Executive Officer)
</I>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage131"></A>
<A NAME="T1600102_EX31-2_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31_2"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	Exhibit 31.2
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_2"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<U>
	CERTIFICATION
</U>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	I, James
	V. Lambert, certify that:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	1.
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	I have reviewed this Annual Report on Form 10-K of GenVec, Inc.;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	2.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Based on my knowledge, this report does not contain any untrue statement of a material fact
	or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements
	were made, not misleading with respect to the period covered by this report;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	3.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Based on my knowledge, the financial statements, and other financial information included
	in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant
	as of, and for, the periods presented in this report;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	4.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The registrant&rsquo;s other certifying officer and I are responsible for establishing and
	maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
	over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	a.)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	designed such disclosure controls and procedures, or caused such disclosure controls and
	procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its
	consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report
	is being prepared;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.75IN; TEXT-INDENT: -0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	b.)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	designed such internal control over financial reporting, or caused such internal control
	over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial
	reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.75IN; TEXT-INDENT: -0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	c.)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures
	and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of
	the period covered by this report based on such evaluation; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.75IN; TEXT-INDENT: -0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	d.)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	disclosed in this report any change in the registrant&rsquo;s internal control over financial
	reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter
	in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s
	internal control over financial reporting; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	5.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent
	evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the Audit Committee of the registrant&rsquo;s
	Board of Directors (or persons performing the equivalent functions):
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	a.)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	all significant deficiencies and material weaknesses in the design or operation of internal
	control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process,
	summarize and report financial information; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.75IN; TEXT-INDENT: -0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	b.)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	any fraud, whether or not material, that involves management or other employees who have
	a significant role in the registrant&rsquo;s internal control over financial reporting.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Date: March 9, 2016
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BORDER-BOTTOM: BLACK 1PX SOLID; WIDTH: 50%">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	/s/ James V. Lambert
</FONT>
</TD>
<TD STYLE="WIDTH: 50%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	James V. Lambert
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Senior Director of Accounting and Finance, Corporate Controller and Treasurer
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(
<I>
	Principal Financial Officer and Principal
	Accounting Officer)
</I>
</FONT>
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage132"></A>
<A NAME="T1600102_EX32-1_HTM"></A>
<EFX_EXHIBIT_32>
<A NAME="FIS_EXHIBIT_32"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	Exhibit 32.1
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_3"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	CERTIFICATION PURSUANT TO 18 U.S.C.
	SECTION 1350,
<BR>
	AS ADOPTED PURSUANT TO
<BR>
	SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In connection
	with the Annual Report of GenVec, Inc. (the &ldquo;Registrant&rdquo;) on Form 10-K as filed with the Securities and Exchange Commission
	on the date hereof (the &ldquo;Report&rdquo;), I, Douglas J. Swirsky, as Chief Executive Officer of the Registrant, hereby certify,
	pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge, that:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(1)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities
	Exchange Act of 1934; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(2)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The information contained in the Report fairly presents, in all material respects, the financial
	condition and results of operations of the Registrant.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	A signed
	original of this written statement required by Section 906 has been provided to the Registrant and will be retained by the Registrant
	and furnished to the Securities and Exchange Commission or its staff upon request.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL; BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Date: March 9, 2016
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BORDER-BOTTOM: BLACK 2PX SOLID; WIDTH: 50%">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	/s/ Douglas J. Swirsky
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Douglas J. Swirsky
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
	President and Chief Executive Officer and Corporate Secretary
</FONT>
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
</EFX_EXHIBIT_32>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage133"></A>
<A NAME="T1600102_EX32-2_HTM"></A>
<EFX_EXHIBIT_32>
<A NAME="FIS_EXHIBIT_32_2"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	Exhibit 32.2
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_4"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	CERTIFICATION PURSUANT TO 18 U.S.C.
	SECTION 1350,
<BR>
	AS ADOPTED PURSUANT TO
<BR>
	SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In connection
	with the Annual Report of GenVec, Inc. (the &ldquo;Registrant&rdquo;) on Form 10-K as filed with the Securities and Exchange Commission
	on the date hereof (the &ldquo;Report&rdquo;), I, James V. Lambert, as Senior Director of Accounting and Finance, Corporate Controller
	and Treasurer of the Registrant, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
	Sarbanes-Oxley Act of 2002, to my knowledge, that:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(1)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities
	Exchange Act of 1934; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(2)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The information contained in the Report fairly presents, in all material respects, the financial
	condition and results of operations of the Registrant.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	A signed
	original of this written statement required by Section 906 has been provided to the Registrant and will be retained by the Registrant
	and furnished to the Securities and Exchange Commission or its staff upon request.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Date: March 9, 2016
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BORDER-BOTTOM: BLACK 1PX SOLID; WIDTH: 50%">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	/s/ James V. Lambert
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	James V. Lambert
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Senior Director of Accounting
	and Finance, Corporate Controller and Treasurer
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	(
<I>
	Principal Financial
	Officer and Principal Accounting Officer
</I>
	)
</FONT>
</P>
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: GAINSBORO 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
</EFX_EXHIBIT_32>

<!-- FOOTER LOGO -->
</BODY>
</HTML>
